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Abstract 
Anthroponotic cutaneous leishmaniasis caused by Leishmania tropica has been 
endemic in Aleppo, Syria for centuries. The first modem description of the disease 
was also done in Aleppo. A surveillance system is in place, and the numbers of 
annual recorded cases have been rising from a few hundred to thousands in the 
late 1980s, to more than 5,000 in most years from 1990, and to more than 10,000 
since 2003. 
A retrospective analysis of routinely collected demographic data was 
performed. The clinical course was examined in a subset of patients. One hundred 
and thirty-two patients were recruited for follow-up study. Parasites were isolated 
from the lesions of these patients before treatment and during the course of 
treatment. Eighty isolates were tested for drug sensitivity in amastigote-
macrophage system and typed to species level. Molecular fingerprinting was 
applied to a subset of isolates. Interviews were held with patients or accompanying 
adults about their knowledge, attitudes and practices regarding prevention, 
diagnosis and treatment. 
Leishmaniasis patients in Aleppo were younger than the general population 
(median age 13 vs. 19 years), and females predominated among adults. Children 
and males were more likely to have lesions on the face. Smear positivity decreased 
with patient age (OR=O.5 in over-forties compared to under-tens). Smear positivity 
peaked at two-month lesion duration (OR=2.2 compared to lesion duration of 
<1 month). A significant proportion of patients, especially adults, did not complete 
their treatment course. 
The isolated parasites were insensitive (median ECso=229 fig Sbv Iml) to 
pentavalent antimony, the drug used in Aleppo, and to paromomycin but were 
sensitive to amphotericin B. No relationship was found between baseline parasite 
in vitro sensitivity and treatment duration. All the typed parasites were L. tropica. 
Parasite schizodemes clustered by place of isolation and by family. 
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Chapter 1. Introduction 
1.1. Leishmaniases: overview and 
epidem iology 
The leishmaniases are a group of parasitic diseases caused by obligate 
intracellular protozoan parasites of the genus Leishmania [Herwaldt, 1999] and 
transmitted by sand flies of the genus Phlebotomus in the Old World and 
Lutzomyia in the New World. Leishmaniases are endemic in 88 countries in 
tropical and subtropical zones of all inhabited continents except Australia. 
[Desjeux, 2001; Blum et al., 2004; World Health Organization, 2004]. 
About 20 species of Leishmania are known to cause disease in man (Table 
1.1). Most of them are originally zoonotic, affecting mainly small rodents that 
act as an animal reservoir. 
Four major eco-epidemiologic entities are recognised: zoonotic and 
anthroponotic visceral leishmaniasis, or kala-azar, and zoonotic and 
anthroponotic cutaneous leishmaniasis [Desjeux, 2001]. 
No reliable data on worldwide leishmaniasis prevalence and incidence exist 
because leishmaniasis frequently occurs in under-served rural areas and is not 
diagnosed; in addition, even diagnosed cases are under-reported because 
leishmaniasis is notifiable in only 33 of the 88 endemic countries. Due to this, its 
occurrence can only be estimated. Conducted surveys always showed higher 
prevalence than thought previously [World Health Organization, 2006]. 
The annual incidence is estimated at about 2 million cases worldwide, 
500,000 for visceral and 1,500,000 for cutaneous forms; overall prevalence is 
about 12 million, with 350 million at risk [Desjeux, 2001]. These estimates are 
based on the number of reported cases, and population at risk was estimated by 
calculating the "relevant population", which was defined as susceptible age 
groups in relevant (urban or rural) epidemiological setting multiplied by 
15 
proportion of country area where leishmaniasis is known to OCcur [Ashford et 
ai., 1992]. These estimates are very approximate and rather old, but these 
figures are cited by all papers, including the most recent ones, with the 
exception of one WHO publication [World Health Organization, 2007] which 
stated the number of cutaneous cases to be one million a year. However, 
because this is an information brochure, no references to support this number 
are mentioned. 
1.1.1. The parasite 
The first accurate description of Leishmania was published in 1898 bv 
Borovsky who described oval bodies filling human cells in sections of 
cutaneous ulcers [Borovsky, 1898]. Borovsky classified them as Protozoa. In 
1903 J. Wright discovered similar organisms in a patient from Armenia and 
suggested naming them Heicosoma tropicum. In 1901 W. Leishman found similar 
organisms in a smear from a spleen of a patient who died from "Dum-dum 
fever"; he published his observations three years later. In 1903 Ch. Donovan 
discovered similar parasites in spleens of kala-azar patients. These organisms 
were initially considered to be trypanosomes but Donovan described them as a 
new species, and in the same year Ross also linked them to kala-azar and 
suggested the name Leishmania donovani. Later Wright suggested the name 
L. tropica for the agent of cutaneous leishmaniasis [Rodjakin and Sukolin, 1999; 
World Health Organization, 2008]. 
Lci~ll1nania exist in two distinct forms: promastigotes, extracellular motile 
oblong organisms with a frontal flagellum that grow in insect gut and culture 
media, and amastigotes, intracellular roundish non-motile form with a short 
flagellum, in the mammal host. There are no reliable morphological differences 
between the promastigotes of different species. However, the amastigotes of 
some species may have morphological differences or characteristic distribution 
within host cells; for instance the amastigotes of L. mexicana are usually situated 
16 
peripherally in infected cells forming a characteristic "garland" [Adler and 
Gunders, 1964]. 
Historically, four overlapping periods of classification can be recognised, 
based on methods available during each period. In the first, the main criteria for 
classification were clinico-epidemiological and morphological. During that 
period the Leishmania of the Old World were initially classified as L. donovani 
that caused visceral leishmaniasis and L. tropica, the agent of localised 
cutaneous leishmaniasis. During the same period serological methods were 
applied to various strains to enable their differentiation. In the next period 
typing was based on iso-enzyme profiles (multilocus enzyme electrophoresis, 
MLEE). Most recently, PeR-based genetic methods were developed. 
In 1913-1915 V.L. Yakimov, while studying leishmaniasis in Turkestan, 
discovered two morphological varieties of the parasite, L. tropica major, usually 
roundish, 5.5x4 f-lm, and L. tropica minor, usually oval, having the shape of rice 
grains, 4x3.25 f-lm. He did not link these varieties to distinct clinical forms. This 
was done in 1940s by P.V. Kozevnikov, N.I. Latyshev and others at the 
Turkmen Dermato-Venerological Institute in Tashkent [Kozevnikov, 1963]. 
Based on clinical and epidemiological data, they described two forms of the 
disease. The first was characterised as wet, with early necrosis, rural, and the 
other as dry, with late ulceration, urban. These were linked to the two varieties 
of L. tropica: L. tropica major and L. tropica minor respectively [Rodjakin and 
Sukolin, 1999], later promoted to species level, L. major and L. tropica based on 
clinical and epidemiological characteristics [Bray et al., 1973; Bray, 1974]. In 
Balkh province, northern Afghanistan, where both forms co-exist, species 
identification for notification purposes is still performed based on size and 
number of intracellular parasites, using micrometer-fitted oculars [Faulde et al., 
2008] (these authors report different reference amastigote sizes: 1.5-2.5 !-lm for 
L. tropica and 4-5 !-lm for L. major; they also mention that the former usually 
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causes high burden of infection, up to 100 parasites per cell, while the latter less 
than 10, usually 2-4, amastigotes per cell}. 
The tendency to name the causative organisms of cutaneous leishmaniasis 
L. tropica persisted at least until the middle of the 20th century: in 1953 F. Biagi 
named the causative agent of localised cutaneous leishmaniasis in Central 
America "L. tropica var. mexicana" [Adler and Gunders, 1964]. 
Serological differentiation of the parasites was used starting from mid-1910s 
applying different techniques available at that time such as complement 
fixation, direct agglutination and lysis, which enabled grouping of the parasites 
into species or species complexes. Early experiments with direct agglUtination 
showed that L. donovani, L. infantum and L. canis were serologically identical [da 
Fonseca, 1933]. Da Fonseca in 1933 used specific Leishmania anti-sera and was 
able to differentiate L. braziliensis, L. tropica, L. donovani, L. infantum and L. canis. 
Later on, tests using sets of monoclonal antibodies made it possible to 
differentiate serotypes within species [Schnur et al., 2004]. 
Isoenzyme characterisation of Leishmania was developed during the 1970s, 
starting from single enzymes [Gardener et al., 1974], then enzyme 
combinations [Chance et al., 1977; Gardener, 1977]. To allow sufficient 
resolution multiple enzyme systems were employed [Kreutzer and Christensen, 
1980]. 
Multilocus enzyme electrophoresis (MLEE) as applied at Universite 
Montpellier is based on electrophoresis of 15 isoenzymes and has been 
performed there since 1981. It allows us to distinguish between species and, 
partially, to group strains at subspecies level. A group of strains displaying the 
same isoenzymatic phenotype is termed "zymodeme". Since 1989 a 
complementary technique, isoelectric focusing, is used [Universite Montpellier 
1]. It has higher resolution but is suitable for six enzymes only [Piarroux et al., 
1994]. MLEE remains the reference technique for Leishmania classification at 
species and sub-species level because during the last 25 years it has been 
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applied to the widest range and greatest number of strains compared to other 
methods [Sch6nian et ai., 2008]. 
At present the reference laboratory that maintains a cryobank of strains is 
the Laboratory of Parasitology and Mycology at Montpellier University. They 
have a searchable catalogue of reference strains on their site. According to 
isoenzyme profile a strain is assigned a MON-number. The numbers are 
assigned sequentially, so close numbers do not imply close isoenzymatic 
profiles. More than 3000 strains falling into more than 260 zymodemes are 
currently listed. 
The catalogue lists seven strains of L. tropica isolated in 1990-1992 and 1997 
in Syria (six from humans and one from a dog) that all belong to MON-76 
group. Syrian L. major strains are MON-26, and L. infantum is MON-I. Manual 
search for L. tropica in neighbouring countries showed that they belong to other 
MON groups: the single isolate from Lebanon (dated 1994) was MON-6; four 
isolates from Iraq (three human isolates of 1965 and one from rat, of 1972) were 
MON-6, MON-7, MON-39 and MON-5; the only listed isolate from Israel, of 
1996, is MON-137. Regrettably, no L. tropica isolates from Turkey are listed; 
those would be of special interest because leishmaniasis due to L. tropica is 
reported from the Turkish provinces of South-eastern Anatolia region and 
Hatay province, which are adjacent to the Syrian Aleppo Governorate. Overall, 
38 strains of L. tropica are listed in the catalogue. They belong to 17 zymodemes. 
From some countries more than one zymodeme is listed but most zymodemes 
occur in one country only, with three exceptions: MON-6 was found in Iraq and 
Lebanon, MON-7 in Iraq, Jordan and Pakistan, and MON-137 in Egypt, Israel 
and Jordan. All MON-76 strains originate in Syria. 
PeR-based molecular typing is based on amplification of nucleic acid 
fragments, then comparing them based either on their size or nucleotide 
sequences. Study of nucleotide polymorphisms began in the early 1970s, and 
phylogenies based on them largely confirmed the taxonomy based on 
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isoenzyme typing, with few exceptions. Genetic methods still suffer from some 
limitations, namely study of heterozygosity and recombination are not fully 
resolved for species that do not have haploid life stages [Schonian et al., 2008]. 
Several methods are applied for characterisation of Leishmania. PCR-RFLP of 
cp8 and gp63, sequencing of ITS 1 and multilocus sequence typing of 
housekeeping genes are suitable for species identification, whereas multilocus 
microsatellite fragment analysis and kinetoplast DNA typing are suitable for 
distinguishing single strains, the former can also be used to infer population 
structure [Schonian et al., 2008]. 
A large study explored genetic relationship between 117 strains of L. tropica 
from multiple Asian and African locations, using 21 microsatellite 
loci [Schwenkenbecher et al., 2006]. Turkish strains from all regions mostly 
belonged to one group, with two strains, from the South-East and Adana, 
forming a distinct group of their own. No strains from Syria were included in 
this study. 
The results of these different methods of classification are broadly consistent 
in defining species complexes and, where applicable, the genetic relations 
between different species. 
1.1.2. Transmission 
Leishmaniasis is transmitted by the bite of an infected female phlebotomine 
sandflies. About 30 species are proven vectors. The Phlebotomus genus is 
divided into 12 subgenera and Lutzomyia into 25 subgenera and species 
groups [Killick-Kendrick, 1999]. 
The ability of a phlebotomine species to act as a vector depends on its co-
existence with reservoir in the same geographic area, feeding preferences and 
susceptibility to infection. In susceptible phlebotomines the parasites attach to 
the epithelium of digestive tract (Leishmania subgenus to the midgut and 
Vianllia subgenus, to hindgut), while in insensitive species the parasites would 
multiply while blood meal is being digested but are voided during 
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defaecation [Killick-Kendrick, 1999]. The structure of parasite 
lipophosphoglycan may play a role in the capacity of Leishmania to establish 
infection in specific vectors [Soares et al., 2004]. However, the vectors 
themselves differ in their Leishmania specificity, some being more "permissive" 
than others, and the attachment of Leishmania to the epithelium in these 
"permissive" vectors is lipophosphoglycan-independent [Myskova et al., 2007]. 
Historically, various insects were implicated in the transmission of 
leishmaniases, with more or less experimental evidence, such as fleas [Sergent 
et al., 1912], lice and bed bugs [Wenyon, 1932], stable flies [Lainson and 
Southgate, 1965]. Moreover, while inducing leishmaniasis in laboratory animals 
or volunteers was possible through injecting them with either emulsion from 
sand flies or with promastigotes obtained from naturally infected sand flies, 
experimental transmission by a bite of a sand fly has been very difficult to 
achieve, which led to the suggestion of other modes of transmission, such as 
crushing or swallowing the insect [Adler, 1929]. However, in 1931 Shortt et al. 
succeeded in transmitting of L. donovani by the bite of Ph. argentipes to 
hamsters [reviewed by Sacks and Kamhawi, 2001], and later, in 1942, also by 
the bite of Ph. argentipes infected from a case of kala-azar, to five healthy 
volunteers [Swaminath et al., 1942]. 
The sand fly seems to be the only plausible natural vector based on 
biological (development of the parasite in the gut), clinical (development of 
sores on exposed parts of the body where sand flies, unlike most other blood-
sucking insects, bite) and epidemiological evidence (the distribution of cases 
follows the distribution of incriminated sand fly species) [Wenyon, 1932; Killick-
Kendrick,1999]. 
1.1.3. Visceral leishmaniasis 
Visceral leishmaniasis has an estimated annual incidence of 500,000 cases 
with about 50,000 fatalities every year but these figures are likely to be an 
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underestimate. It is estimated that between 1984 and 1994 it caused 100,000 
deaths in southern Sudan within a population of 280,000 [Chappuis et al., 2007]. 
Zoonotic visceral leishmaniasis is caused by L. infantum in the Old World 
(Mediterranean region) and in the New World (Latin America), where the 
parasite is called L. infantumlchagasi [Desjeux, 2001; Berman, 2005]. Dogs and 
wild canids act as reservoir and P. perniciosus, P. perfiliewi and P. neglectus are 
among proven vectors [Killick-Kendrick, 1999]. 
Anthroponotic visceral leishmaniasis is caused by L. donovani. It occurs in 
the Indian subcontinent, south-east of Arabian Peninsula and East Africa 
causing severe epidemics [Desjeux, 2001]. P. argentipes is implicated in 
transmission in India and P. orientalis in Arabian Peninsula and East 
Africa [Killick-Kendrick, 1999]. 
1.1.4. Cutaneous leishmaniasis 
The incidence of cutaneous leishmaniases (CL) is estimated at about a 
million cases a year, with 10 million people in 82 countries suffering from it. 
The annual incidence in the Middle East and the Maghrib is estimated at 
350,000 cases [World Health Organization, 2007]. 
Because distribution areas of causative species overlap (Figure 1.1 [World 
Health Organization, 1997]), and parasites are not typed routinely, it is difficult 
to separately estimate the incidence and prevalence of zoonotic and 
anthroponotic forms in the Old World. 
1.1.4.1. Zoonotic cutaneous leishmaniasis 
Zoonotic cutaneous leishmaniasis is caused by L. major (Central and 
Western Asia and North Africa) and L. aethiopica in Ethiopia and 
Kenya [Reithinger ct al., 2007] in the Old World and by L. (Leishmania) mexicana 
and L. (Vianllia) lmciliensis complexes in the New World (Latin America). In the 
Old World the reservoir is small rodents (gerbils of genera Psammomys, Meriones 
and Rl/ol1lbol1Jy~ and the murine Nesokia indica) for L. major and rock hyrax 
(genl'f.1 Proca'l'ia and Heterohyrax) for L. aethiopica [Bray et al., 1973; Negera et al., 
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2008]; and in Latin America, small rodents and big mammals of primary 
forest [Desjeux, 2001] such as sloths, porcupines and armadillos [Gentile et ai., 
1981; Christensen et al., 1982; Yadon et al., 2003]. 
1.1.4.2. Anthroponotic cutaneous leishmaniasis 
Anthroponotic cutaneous leishmaniasis (ACL) occurs in the Old World 
only, and is caused mostly by L. tropica, but also by L. donovani in 
India [Desjeux, 2001; Sharma et al., 2005] It is mostly urban, reflected in old 
classification of leishmaniases into urban (dry) and rural (wet) forms. ACL is 
distributed mostly in Central Asia and Middle East, sometimes overlapping 
areas of zoonotic cutaneous leishmaniasis. In North Africa, the disputable 
species L. killicki causes chronic cutaneous leishmaniasis [Haouas et ai., 2005; 
Kallel et al., 2005; Reithinger et al., 2007; Harrat et al., 2009]. 
The overall incidence is unknown but there are reports about increasing 
incidence of ACL in established foci such as Aleppo in Syria and Kabul in 
Afghanistan [Ashford, Kohestani et al., 1992; Ashford et al., 1993; Neouimine, 
1996; Desjeux, 2001] and emergence of the disease in new foci in 
Algeria [Mihoubi et al., 2008], Jordan [Nimri et al., 2002], Morocco [Rhajaoui et 
al., 2004] and Palestine [AI-Jawabreh et al., 2004]. 
Man is considered to be the only reservoir of L. tropica [Desjeux, 2001; 
Minodier ct al., 2005]; but besides man, domestic and stray dogs [Dereure et al., 
1991] and rats of the genus Rattus [Neouimine, 1996] can become infected. In 
laboratory experiments, rats may infect sand flies even while remaining 
asymptomatic [Svobodova, Votypka et al., 2003]. Although no definite evidence 
exists yet that any species other than man can serve as disease reservoir, this 
possibility should not be excluded [AI-Jawabreh ct ai., 2004], rock hyrax being 
one of suggested candidates based on epidemiological association [Jaffe et ai., 
200'+]. 
ACL is transmitted by Phlebotomus sergellti. Sand flies breed in warm, humid 
environments with decomposing organic matter, such as piles of waste, open 
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sewage ducts [Desjeux, 2001], and in sheds and cellars [Svobodovci, Scidlovci et 
al., 2003]. They are weak fliers, so they rest and feed within a few hundred 
metres of their breeding places [World Health Organization, 1997]. Besides 
humans, they feed on other warm-blooded animals, such as goat, sheep, 
chicken, rat and house mouse [Svobodovci, Scidlovci et al., 2003]. Biting activity 
starts after sunset and continues until dawn. During daytime they rest in dark 
humid places: sheds, rooms, caves, crevices [World Health Organization, 1997]. 
Thus, the most important vector control activities are environmental 
sanitation [Mott et ai., 1990], residual indoor insecticide spraying and using 
ITNs [Davies et al., 2003]. 
1.2. Leishmaniases in Syria 
1.2.1. Geography 
Syria is a country in the Eastern Mediterranean region. It is divided to 14 
major administrative divisions called governorates. Aleppo is the centre of 
Aleppo governorate and is the second largest city (after the capital Damascus), 
located in the north (36° 12' N, 37° 10' E), bordering Turkey (Figure 1.2). 
Population estimate for the city is 1,671,673 (2008) [Wikipedia, 2008] and for the 
governorate, 4,281,000 (2006) [Central Bureau of Statistics, 2007]. 
1.2.2. History 
Cutaneous leishmaniasis has been known in Aleppo since ancient times, 
giving the disease one of its names, Aleppo boil. "One of the first and most 
important clinical descriptions was made in 1756 by Alexander Russell 
following an examination of a Turkish patient" [World Health Organization, 
2005]. He mentioned the local name for the disease, habt as-sineh, which he 
translated as "botch of a year", and attributed it to contaminated water 
sources [Russell, 1756]. 
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1.2.3. Distribution 
In Syria, both anthroponotic and zoonotic (ZCL) forms of leishmaniasis 
occur, of which ACL is responsible for 65%-93% of reported cases (estimated 
by adding up numbers from Aleppo and four adjacent governorates believed to 
be affected by ACL, Figure 1.3 and Figure 1.4). In addition, there are rare cases 
of zoonotic visceral leishmaniasis (ZVL) due to L. infantum (tens of cases 
reported yearly) [Abazid, 2000], see Table 1.2. 
ZCL, due to L. major, occurs in semi-desert areas to the east of Damascus 
and in north-eastern governorates, mainly Hasaka and Deir az-Zawr, where 
several rodent species (Psammomys obesus, Meriones crassus, Nesokia indica) serve 
as reservoirs, and Phlebotomus papatasi is incriminated as the vector. ZVL, with a 
canine reservoir, is confined to several foci in the coastal region (Lattakia and 
Tartous), the north (Aleppo and Idlib) and the south, near the border with 
Jordan [AI-Nahhas et al., 2003]. Ph. tobbi is the implicated vector [Intersectoral 
Committee for Vector Control, 2006]. ACL occurs in the Northern and Coastal 
regions. The putative vector is Ph. scrgcnti [Jalouk ct al., 2007]. 
In 1980s MoH established a reporting system for leishmaniasis with few 
thousand cases reported every year. During 1990s the annual recorded 
incidence was over 11,000 in all but one year (in 1998 it was 8893 cases). During 
2000-2005 the annual recorded incidence was in the range 19,837-29,100, 
then, in 2006 and 2007 decreased to 18,732 and 17,709 respectively [al-Shammas, 
2008]. This can be partly attributed to improvement in reporting, expansion of 
diagnosis and treatment services and active case detection in schools and 
villages but a real increase is possible. It was estimated [Ashford et al., 1993] 
that in early 1990s the passive case detection system in Aleppo recorded and 
treated only 1 patient in 4. There have been no more recent estimates of 
detection rate. 
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1.2.4. Structure of relevant health services 
Syria is divided administratively into 14 governorates. Central executive 
power is represented by the Council of Ministers. 
Medical practice in the Syrian Arab Republic is regulated by the Ministry of 
Health (MoH) in cooperation with relevant professional associations. \1oH 
issues practice licenses to physicians, dentists, pharmacists and nursing staff. 
Medical services are provided through public and private health care 
facilities, in addition to charities. 
Public sector health care facilities belong to one of four ministries: Health, 
Higher Education, Defence or Interior. The former two offer health care to the 
general public, while the latter two cover their staff and staff's family members. 
Public health care facilities of MoH include primary health care (PHC) 
centres, specialised polyclinics, secondary-level hospitals in every governorate 
(one or more) and specialised tertiary hospitals in large cities, such as Damascus 
and Aleppo. There used to be no strict referral system: for example, anyone 
could corne to outpatient clinics in a tertiary hospital and be admitted if deemed 
necessary provided free beds were available, although health district policy did 
exist on paper. Starting from 2007, health district policy was enforced. Every 
family was required to be registered in a PHC centre of their choice. This centre 
would be their first point of encounter with the health system. All referrals to 
specialised clinics or hospitals, except emergencies, can only be issued by the 
PHC centre where the family is registered. 
Ministry of Higher Education runs only tertiary university hospitals in the 
three cities where universities have faculties of medicine (Damascus, Aleppo 
and Lattakia; recently, a faculty of medicine was established in aI-Baath 
University in Horns). These hospitals have outpatient departments and 
emergency departments. There is no formal referral system, and these hospitals 
serve citizens regardless of their place of residence. 
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Public health care facilities currently remain mostly free of charge with few 
exceptions. Free services include diagnosis, treatment, and, for in-patients, also 
bed and three daily meals. If a diagnostic procedure or a drug is not available in 
a PHC centre or a hospital, the patient refers to private-sector laboratories or 
pharmacies. 
Private sector facilities are either small private clinics or, rarely, small 
specialised centres operated by a few physicians with specific area of specialist 
service, in addition to private hospitals which are usually small. Virtually all 
pharmacies are private, as are independent laboratories (those outside health 
care facilities). Fees are usually paid out-of-pocket. 
Charities run small polyclinics with several physicians - general 
practitioners and sometimes part-time specialists, free of charge or charging a 
symbolic fee. They may be equipped with a small lab with basic tests. 
Only health care facilities run by the MoH are obliged to report 
leishmaniasis cases. Other facilities mayor may not do so. 
Import of antimonials is monopolised by the MoH, which distributes them 
to its own facilities and to Ministry of Defence, but not to pharmacies. However, 
drugs may be smuggled in from neighbouring countries, or, probably, leak 
from public facilities, although I am not aware of any cases of the latter. 
Pentostam® and Glucantime® are the two drugs used in MoH system. 
Glucantime (Sanofi-Aventis, France) is the first-line drug for intralesional 
treatment; Pentostam (GlaxoSmithKline, UK) is used either intralesionally, if 
Glucantime fails, or intramuscularly, and its use is normally restricted to 
Leishmaniasis Control Center, but may be distributed to peripheral health 
centres with directions to use it for intralesional treatment instead of 
Glucantime when large stocks with expiry date in the next six to nine months 
exist. Pentostam is deemed more efficient but also more painful when given 
intralesionally. Several years ago MoH imported generic SSG from India (Albert 
David, Kolkata) but received unfavourable reports about its efficiency from the 
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governorates and returned to importing the brand products [Dr. Lama Jalouk, 
personal communication]. 
MoH has two kinds of divisions, both called "directorates": specialised, that 
run their programmes on the country level (e.g. Directorate of Chronic and 
Endemic Diseases responsible, among other things, for leishmaniasis 
surveillance and control programme, etc.) and geographical, by governorate (e.g. 
Aleppo Health Directorate, etc.), which are responsible for running all MoH 
health services and programmes on the governorate level. 
In most governorates, the Directorate for Chronic and Endemic Diseases is 
represented by a specialised "Malaria, Leishmaniasis and Schistosomiasis 
Control Centre". In Aleppo Leishmaniasis Control Center (LCC) used to be 
independent due to the importance of the disease in that governorate. 
Malaria currently occurs in Syria sporadically, and most cases are said to be 
imported, so it does not constitute a major public health problem. The import 
and distribution of antimalarial drugs are also controlled by MoH. The main 
role of antimalarial clinics is to dispense chloroquine based on prescriptions 
from government-run clinics, mostly for its anti-inflammatory properties in 
chronic autoimmune conditions. A similar policy applies to other "dual-use" 
drugs, such as those used in the treatment of tuberculosis. 
1.2.5. Control programme 
Syria has had a surveillance system for malaria since 1950s, which aimed at 
eradicating malaria in accordance with World Health Organization (WHO) 
programme. In 1986 surveillance of leishmaniasis was added to this 
programme. Monthly lists with the names of the patients referring to 
specialised centres were compiled and sent to MoH. In 1994 special forms for 
dat,) collection were introduced; these included patient forms, monthly case 
report forms and daily and monthly vector surveillance forms. Patient and 
monthly report forms included basic epidemiological information. These forms 
h,wt' been used since then until the present. 
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Forms and registries for routine case data collection and reporting, and how 
they are used, are described in more detail in Chapter 2. 
The leishmaniasis control programme in Syria aims to decrease disease 
incidence in endemic areas and to continue surveillance and control activities in 
old and emergent foci by breaking transmission cycle between vector and 
human host [Abazid, 2000]. 
Specialised control centres in governorates implement the control 
programme. It consists of early diagnosis and treatment to self-referring 
leishmaniasis patients, surveys in schools, especially primary schools with 
pupils of ages 6-13 but also in summer student camps (in collaboration with 
Directorate for School Health of Ministry of Education), surveys in newly 
affected villages or areas with sharp increase in incidence, vector surveillance in 
selected houses using overnight paper sheets with castor oil and two campaigns 
a year of residual insecticide spraying in villages and city districts with 
incidence rate greater than 1 % in the previous year. For ZCL, deep ploughing of 
rodent-infested areas may be performed in cooperation with Ministry of 
Agriculture. 
In the army, control measures are performed by the Ministry of Defence 
(MoD) Medical Services Administration. Insecticide spraying, ploughing, case 
detection and treatment are among the activities performed. Reports of the 
activities and case statistics are usually inaccessible. One anecdote reports that 
once the military performed deep ploughing and eradication of chenopods (a 
species of Atriplcx, most probably, the Mediterranean salt-bush Atriplex 
halilllus), known to be the preferred food for the fat sand rat Psammomys 
obcslIs [Aharonson et al., 1969], the main animal reservoir of ZCL in the area of 
Dmair near Damascus [Khiami et al., 1991]. In the next few years MoH noted 
the sharp drop in CL incidence in the area and had difficulty explaining it 
because they had no idea about MoD activities in that area. 
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It seems that above-mentioned measures generally fail in reducing the 
incidence of CL in Syria [Jalouk et al., 2007]. Possible explanations include the 
retroactive nature of spraying campaigns which are based on previous year 
incidence, possible inadequacy in spraying plan, if potential sandfly breeding 
sites are missed, inadequate case detection leaving a sufficient reservoir for 
further spread of infection, etc. 
1.3. The disease 
1.3.1. Clinical classification 
The eco-epidemiologic classification presented above is deliberately 
simplified to serve its purpose. The clinical course of leishmaniases differs 
strikingly depending on causative species and host characteristics. Clinically, 
leishmaniasis is classified into two, visceral (VL) and tegumentary [e.g. 
Azeredo-Coutinho et al., 2007], or three broad categories, where the latter form 
is divided into cutaneous (CL) and mucocutaneous (MCL) leishmaniasis [e.g. 
Herwaldt, 1999]. The visceral form includes viscerotropic forms. 
Cutaneous forms are further subdivided into localised (LCL), disseminated 
(or diffuse, DCL), leishmaniasis recidivans (or recidiva), post-kala-azar dermal 
leishmaniasis (PKDL) [Kenner and Weina, 2007] and chronic (CCL) [Kallel et al., 
2005]. Some authors [Herwaldt, 1999] do not consider chronic and recidivant 
leishmaniasis different forms of the disease. 
Clinical manifestations of infection depend on host characteristics 
(nutritional and immune status), parasite species and virulence, localisation, 
complications and other factors [Rodjakin and Sukolin, 1999]. 
1.3.1.1. Visceral leishmaniasis 
Visceral leishmaniasis is the most severe form of the disease. Overt disease 
is almost universally fatal if left untreated [Herwaldt, 1999; Lira et al., 1999]. It 
manifests by fever (local name for the disease is kala-azar, i.e. "black fever" in 
Hindi), weight loss and enlargement of spleen and liver. 
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Differences in disease epidemiology between the Indian and Mediterranean 
forms were noted before it was known that they are caused by different species 
of Leishmania: in Mediterranean, or infantile, VL most cases (about 90%) in 
endemic areas are less than five years old, whereas in India this age group was 
affected in only 4-30% of cases; in addition, the incidence rate of VL in Italy is 
remarkably lower than in India. Absence of infection in dogs in India, despite 
large numbers examined, was also noted [Adler, 1929]. However, a recent paper 
from Sri Lanka reported isolation of L. donovani from two of 151 pet dogs 
examined in foci of cutaneous leishmaniasis caused by the same parasite. The 
authors considered the available evidence to be insufficient to incriminate dogs 
as reservoir and emphasised the need for further studies [Nawaratna et al., 
2009]. 
L. donovani in the Indian subcontinent, south-east of Arabian Peninsula and 
East Africa is believed to be anthroponotic and may cause severe epidemics. For 
example, MSF Holland reported 100,000 VL deaths in southern Sudan in early 
1990s in a population smaller than one million [Desjeux, 2004]. 
Visceral leishmaniasis caused by L. infantum is zoonotic. It has similar 
clinical manifestations but has a different age group preference. Numbers of 
disease cases are relatively low among inhabitants of endemic areas, and many 
instances of infection remain asymptomatic. In a study in two foci in southern 
Syria where a seroprevalence survey using rK-39 was performed [Al-Nahhas et 
al., 2003] and all children between 6 months and 6 years of age were screened, 
about a quarter (80/345) were seropositive, and of these only ten cases (1 in 8) 
were symptomatic (irregular fever, weight loss and mild, 2-3 cm, 
hepatosplenomegaly). After nine-month follow-up most positive asymptomatic 
children seroconverted to negative, and in four of those who remained positive 
only lymphadenopathy was detected. Bone marrow aspirates were obtained 
from ten asymptomatic cases and amastigotes were detected in all of them, 
although in low numbers compared to symptomatic patients. 
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There are also reports of L. tropica causing "visceralising" disease in 
immunocompetent persons. In a small case series [Magill et ai., 1993] the disease 
had non-specific manifestations and was not usually accompanied bv 
organomegaly, fever or anaemia. 
1.3.1.2. Cutaneous leishmaniasis 
1.3.1.2.1. Localised cutaneous leishmaniasis 
Localised cutaneous leishmaniasis manifests with one or more lesions, 
usually on uncovered body parts. It is mostly associated with L. tropica, L. major 
and L. aethiopica in the Old World but L. donovani and L. infantum can also cause 
localised cutaneous disease; in fact, most of cutaneous leishmaniasis in France 
and Spain, previously attributed to L. tropica, is caused by L. infantum. In recent 
papers cutaneous leishmaniasis due to L. donovani was reported from Sri Lanka 
which was also found to infect dogs [Nawaratna ct a/., 2009], whereas in India 
this parasite could not be isolated from dogs [Adler, 1929]. So, it seems that all 
Old World species can produce cutaneous forms. In the New World all the 
species, except L. infantlllll, produce mostly LCL. 
Lcislllllilllia major infections tend to have a shorter course compared to 
L. tropica, with shorter incubation period, larger and more inflamed lesions, 
earlier ulceration and epithelialisation [Kozevnikov, 1963; Rodjakin and 
Sukolin, 1999]. 
1.3.1.2.2. Disseminated cutaneous leishmaniasis 
Disseminated cutaneous leishmaniasis is caused by L. aethiopica in the Old 
World and L. amilzonensis and L. mcxicana in the New World [Reithinger et ai., 
2007]. 
1.3.1.2.3. Leishmaniasis recidivans 
Follows a healed L. tropica infection which usually manifests as small non-
inflamed satellite lesions that appear around the scar. 
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1.3.1.2.4. Post-kala-azar dermal leishmaniasis 
Post-kala-azar dermal leishmaniasis is a complication of kala-azar caused by 
L. donovani in India and Sudan and follows successfully treated VL. In India 
about 50% of cases suffer from the condition, which typically starts 2-3 years 
post-cure and requires prolonged treatment; in Sudan it affects 5-10% of cases, 
starts 0-6 months post-cure and tends to resolve spontaneously, and only severe 
cases are treated [Zijlstra et al., 2003]. 
1.3.1.2.5. Chronic cutaneous leishmaniasis 
Chronic cutaneous leishmaniasis is usually a complication of ACL caused 
by L. tropica, when a lesion fails to heal within 12-18 months, with or without 
treatment, and satellite lesions appear at its border. Chronic CL is also reported 
from Tunisia as a separate entity where it is caused by L. killicki [Haouas et al., 
2005; Kallel et al., 2005]. Leishmania killicki was characterised as a separate 
species by isoenzyme typing but molecular analyses classify it as 
L. tropica [Schonian et al., 2008]. 
ZCL caused by L. major usually heals in few months, even without 
treatment, and was previously believed not to cause chronic lesions. However, 
wide application of leishmanisation during the Iran-Iraq war permitted 
detection of a few cases that failed to heal normally and remained active for 
several years despite treatment. 
1.3.1.3. Mucocutaneous leishmaniasis 
Mucocutaneous disease is caused by certain New-World species (Table 1.1) 
and is associated with destruction of nasal, oral and pharyngeal mucosa 
resulting in severe mutilation [Desjeux, 2004], social stigma [World Health 
Organization, 2008] and is potentially fatal [Stark, 2008]. It may appear after the 
cutaneous disease has healed or present without evidence of prior cutaneous 
disease. 
Rare cases of involvement of mucous membranes was reported by one 
group from the Old World (Tunisia), due to L. major [e.g. Kharfi et al., 2003; 
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Kharfi et al., 2004]. They noted relatively benign course with no subsequent 
mutilation. However, the lesions were mostly located on the lips or nose, with 
only one case having clearly intra-nasal localisation. 
1.3.1.4. Leishmania/HIV co-infection 
Co-infection with human immunodeficiency virus (HIV) is an additional 
challenge to leishmaniasis control. HIV infection and other immunosuppressive 
states increase the risk for the patients to develop a visceral disease. The main 
risk group in Western Europe is intravenous drug users [Desjeux, 2001]. Up to 
70% of VL cases in Southern Europe are associated with HIV. Overlapping 
areas of HIV and leishmaniasis lead to changes in epidemiology due to disease 
activation in asymptomatic carriers and spread of VL to cities with a potential 
to cause epidemics. Co-infection was reported from 34 countries so far (Figure 
1.5) [World Health Organization, 2008]. 
1.3.2. Pathogenesis 
When an infected female sand fly takes a blood meal, it inoculates 
promastigotes into the skin; the typical number of injected parasites is 10Q03, 
and these are phagocytised by leucocytes. Then the promastigotes undergo 
morphological and metabolic modifications within the macrophages. They 
transform to amastigotes which have a roundish shape with short 
flagellum [Roberts, 2006]. 
The first cells that arrive at the site of infection are polymorphonuclear 
neutrophils. Within them the promastigotes do not change nor multiply. Then 
they can use the apoptotic neutrophils to silently enter their final host, the 
macrophage, where they convert to the amastigote stage [van Zandbergen et al., 
2006]. 
It \vas noted that fresh promastigote cultures are less infective than older 
cultures that contain short metacyclic and non-flagellate forms [Berberian, 1939; 
Ro\\', 1939]. In recent studies it was shown that the inoculum must contain 
~ome apoptotic promastigotes which display the apoptotic "eat me" signal, 
34 
silencing the initial immune response and allowing viable Leishmania to evade 
the defence of the host. Apoptotic promastigotes displayed phosphatidylserine 
on their membrane, and this compound is known to silence phagocyte 
functions and is associated with secretion of transforming growth factor ~ 
(TGF-~) and interleukin (IL) 10, and suppression of tumour necrosis factor a 
(TNF-a), so apoptotic cells do not provoke an immune response [van 
Zandbergen et al., 2006]. 
Amastigotes are enclosed in so-called parasitiphorous vacuoles, which form 
from original phagosome after fusion with lysosomes and endosomes. They 
endure the acidic environment of these vacuoles and are able to feed on vacuole 
contents. Parasites replicate slowly, each replication cycle taking about 
24 hours. [Decuypere, 2007]. 
1.3.3. Role of sandfly inoculum 
Sand fly saliva possesses vasodilatory, immunomodulatory and 
anticoagulant properties which may contribute to evasion of host immune 
response by the parasites and was shown in animal studies to exacerbate 
Leishmania infection [Giunchetti et al., 2008]. Sand fly bites evoke a delayed 
inflammatory response, and the period between the bite and the response 
shortens with repeated exposure [Theodor, 1935]. It was shown that mice 
vaccinated with maxadilan or 15 kDa salivary protein became unresponsive to 
infection with L. major when injected with promastigotes and saliva [Giunchetti 
et ai., 2008], making it a candidate for vaccine development. Another study 
demonstrated that repeated sand fly bites provoked cellular and humoral 
immune response in mice, and the response was specific for the sandfly species 
(Ph. scrgell ti). Cross-reaction with the salivary gland homogenates of Ph. papatasi 
was partial, and there was no cross-reaction with Ph. arabic liS [Drahota et ai., 
2009]. 
A series of shldies demonstrated the role of promastigote secretory gel 
(PSG) in the development of leishmaniasis. Promastigote secretory gel is a gel-
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like substance produced by the promastigotes that blocks the anterior midgut of 
the sandfly [Rogers et al., 2002], and its main component is filamentous 
proteophosphoglycan (fPPG) which is injected during the bloodmeal with the 
promastigotes and has a main role in exacerbating the infection [Rogers et al., 
2004] by enhancing early recruitment of macrophages to the site of infection 
and upregulating the macrophage arginase activity [Rogers et al., 2009]. In 
addition, the PSG plug modifies the behaviour of the sand fly making it more 
likely to return to feeding if interrupted and bite more hosts [Rogers and Bates, 
2007]. 
1.3.4. Immunology (in humans) 
Old-World CL usually cures spontaneously and is believed to confer life-
long immunity [Scott et al., 2004; World Health Organization, 2005]. 
Publications about immune response to L. tropica in humans are extremely 
rare; most research addresses L. major, L. donovani and Latin American species. 
In general terms, the course of the disease is determined by the interaction 
between the parasite species and the host response. The immune response 
ranges from hyperergic reactions with low parasite burden, prominent local 
tissue destruction and strong cell-mediated immunity and delayed-type 
hypersensitivity, exemplified by the chronic cutaneous and mucocutaneous 
disease, to asymptomatic disease, self-healing localised or oligosymptomatic 
visceral infections, to near-complete anergy with high parasite burden, as in 
diffuse cutaneous leishmaniasis, manifest visceral leishmaniasis and post-kala-
azar dermal leishmaniasis [Murray et ai., 2006]. The species usually associated 
with visceral leishmaniasis may also cause cutaneous forms of the disease. 
Thus, L. d0110Valli was reported to cause CL in India [Sharma et al., 2005] and Sri 
Lanka [Siriwardana et ai., 2007; Karunaweera, 2009], most CL cases in Southern 
Europe are caused by L. infalltum, and human cutaneous cases are more 
numerous than visceral ones [Pratlong et ai., 2004]. On the other hand, several 
(\1Sl'S of L. tropiCil causing oligosymptomatic visceral disease in apparently 
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immunocompetent adults were reported [Magill et at., 1993] and one case from 
Iran of classical infantile VL from which L. tropica was isolated [Alborzi et at., 
2006]. 
A longitudinal study in a focus of L. infantum infection in Iran performed 
using leishmanin skin testing and direct agglutination test to measure the 
dynamics of cellular and humoral immunity [Davies and Mazloumi Gavgani, 
1999] suggested that humans may acquire protection against infection with age 
which is independent of exposure to the parasite, probably due to 
immunogenic properties of sand fly saliva. 
In a study of patients with CL due to L. major in Iran, cure was associated 
with proliferation of interferon-y (IFN-y) producing CD4+ cells, while in 
patients with non-healing lesions low levels of IFN-y and high levels of 
interleukin-4 were detected [Ajdary et ai., 2000]. 
1.4. Clinical course of ACL 
After a long incubation period which usually lasts 3-6 months but may 
extend for more than a year, a small papule appears on the location of parasite 
inoculation, usually on an uncovered part of the body, which slowly enlarges 
and reaches 3-6 mm, sometimes up to 20 mm during the course of 3-4 months, 
and becomes a red brownish colour. A characteristic central depression may 
develop, which disappears when scaling starts. Exudate may appear and form a 
crust. The crust falls out exposing an ulcer. The papule usually ulcerates 4-8 
months after appearing but ulceration may be delayed for longer than one year. 
After ulceration it takes about 3 months until epithelialisation starts. 
Epithelialisation is usually complete in 1-2 months, leaving a depressed scar. 
The period from primary papule to scar formation varies from 6 months to 2 
years but is usually between 6 months and one year [Rodjakin and Sukolin, 
1999; World Health Organization, 2005]. 
Two atypical forms are described: (a) chronic (lupoid), usually defined as 
persistence of the lesion for >1.5-2 years, frequently despite treatment; and 
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(b) recurrent leishmaniasis, when new elements appear on or around a healed 
scar, usualIy within 2 years [Marovich et al., 2001]. The former constituted 3%, 
and the latter -6% of patients in Turkey [Cure1 et al., 2002], while in Aleppo the 
lupoid form was reported in >30% [Douba et al., 1997], but the study was based 
in a specialised dermatology referral centre. Some authors [Herwaldt, 1999] do 
not make a distinction between these two entities, which may be justified 
because they cannot be reliably differentiated based on histopathological 
findings, and the clinical history is not always reliable [Douba et al., 1997]. 
Secondary infection may complicate the course of ACL, and often responds 
to topical antibiotics [Alrajhi et al., 2002]. 
Table 1.3 shows a classical comparison between ZCL and ACL [Rodjakin 
and Sukolin, 1999]. 
1.5. Diagnosis 
Primary diagnosis is based on clinical history, characteristic appearance of 
the lesion (for CL) or the systemic signs and symptoms (for VL) upon 
examination, and the epidemiological situation. The diagnosis is usually 
confirmed by visualising the parasites in pathological material. 
1.5.1. Diagnosis of visceral leishmaniasis 
The diagnosis of VL is usually confirmed by microscopical examination of 
spleen or bone marrow aspirates. In addition, the pathological material can be 
cultured to detect promastigotes, and several serological tests were developed, 
such as ELISA, fluorescent antibodies direct agglutination test (DAT) and rK39 
(a rapid dipstick test based on detection of serum IgC antibodies [Singh et al., 
2009] to recombinant K39 antigen based on 39 amino-acid repeat of 
L. clzagasi [Chappuis et al., 2005]). The serological tests may give false-positive 
results in patients who have recovered or had asymptomatic disease [Davies 
and Mazloumi Cavgani, 1999; Al-Nahhas et al., 2003; Teran-Angel et al., 2007]. 
I-Iowt'\'t'r, in a recent report it was shown that rK39 test performed on sputum 
has higher specificity, although marginally lower sensitivity, than the same test 
applied to serum [Singh et al., 2009]. 
1.5.2. Diagnosis of cutaneous leishmaniasis 
The diagnosis of cutaneous leishmaniasis is confirmed by demonstration of 
parasites in pathological material from lesions. This can be done by making slit-
skin smears, punch biopsies or lesion scrapings. Quantity of the parasites in the 
lesions tends to decrease with increasing age of the lesion, [Borovsky, 1898; 
Herwaldt, 1999] making it harder to obtain parasitological confirmation. In 
Aleppo, positivity rates achieved using smears of material obtained from lesion 
scraping using a lancet blade are between 70-80% for lesion durations of 1-9 
months, with best results in lesions of 2-4 month duration. Giemsa-stained 
smears may take as little as 15 minutes to provide a result if done by 
experienced dedicated laboratory staff. Smears are examined microscopically at 
1000x magnification. 
Culture is less sensitive than microscopy [Alrajhi et al., 2002], more 
expensive and time-consuming, and is not routinely used. 
PCR-based diagnosis is promising, offering high sensitivity and specificity 
but is still expensive and sophisticated, and not applied routinely. Leishmanin 
skin testing may be used for screening purposes but not for confirming active 
disease, at least in endemic areas. Serodiagnostic techniques are also of limited 
value in detecting active disease. 
1.6. Treatment 
1.6.1. Antimonial compounds 
Pentavalent antimonials (Sb\) are considered the first-line treatment of 
leishmaniases. Two preparations are available commercially, sodium 
stibogluconate (SSG; e.g., Pentostam) and meglumine antimoniate (MGA; e.g., 
Glucantime). Neither of them is superior; their efficacy depends on antimony 
content (100 mg/ml in Pentostam and 81 mg/ml in Glucantime). The exact 
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mechanism of action of antimonials is only now becoming clear [Croft et al., 
2006]. Treatment is given either locally (intralesional infiltration, i.l.) or 
systemically. Systemic SSG can be given intramuscularly (i.m.) or intravenously 
(i.v.), while MGA intramuscularly only [Blum et al., 2004], in doses of 10-
20 mg Sb v /kg/day for 20 days. Antimonial preparations are toxic, costly, and 
intramuscular and intralesional administration is very painful. 
In the Old World, intralesional therapy (infiltration of upper- and mid-
dermis from multiple sides until the lesion is completely blanched [Uzun et al., 
2004]) has the advantage of low systemic dose, hence less side effects, but 
cannot be applied when lesions are numerous, large or in a difficult location, 
e.g. ears or eyelids. In these cases, or when intralesional treatment fails, 
systemic therapy is given. Reported intralesional treatment regimens vary from 
daily [Tallab et al., 1996] or every other day [Tallab et al., 1996; Alkhawajah et al., 
1997], twice a week [Chiheb et al., 1999; Salmanpour et al., 2001], 
weekly [Mujtaba and Khalid, 1999; Asilian et al., 2003], fortnightly or three 
injections every other day repeated every month until cure [Sharma et al., 2005]; 
the treatment course varies between three [Tallab et al., 1996; Douba et al., 1997; 
Asilian et al., 2003] and up to 20 injections [Uzun et al., 2004]; in Aleppo, Syria, 
up to 24 injections with weekly intervals are given. Treatment may continue 
either for a fixed number of injections or to a certain maximum unless the 
lesions cure earlier. 
1.6.2. Other 
therapy 
pharmacological agents; immune 
A number of other treatments have been investigated, both systemic 
(injectable or oral) and local, given either alone or in combination with 
antimonials. The response to the treatment varies according to the species, so 
investigation of new drugs should be "species-specific"; yet frequently 
treatment studies are performed without defining the species. Clinical trials of 
L. tropica art' rare: one in Syria [Harms ct a!., 1991], one in Turkey [bzgozta~l 
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and Baydar, 1997], and one in Afghanistan [Reithinger, Mohsen et al., 2005] 
were identified. 
Examples of systemic treatment are [Blum et ai., 2004] imidazoles, such as 
itraconazole [Dogra and Saxena, 1996] and fluconazole [Alrajhi et al., 2002]; 
amphotericin B (standard or lipid formulations) [Alvar et ai., 2006]; 
miltefosine [Soto and Berman, 2006]; or immunotherapy [Convit et ai., 2003]. 
As local treatment, different formulations of paromomycin ointment were 
found moderately effective in both forms of Old World CL [EI-Safi et al., 1990; 
Ozgoztasi and Baydar, 1997], and a new topical formulation, WR279,396, a 
hydrophilic ointment with 15% paromomycin and 0.5% gentamicin was tested 
against L. major CL in Tunisia and France with good effect but also with 
surprisingly high effectiveness of the placebo [Ben Salah et al., 2009]. 
Immunomodulation with topical imiquimod was tried without decisive 
advantage [Arevalo et al., 2001; Firooz et al., 2006]. A single patient report 
mentioned successful treatment of L. major CL in an infant using topical 
colloidal solution of amphotericin B [Zvulunov et ai., 2003]. Intralesional 
metronidazole was proposed by one group [AI-Waiz et al., 2004] 
All the treatments mentioned are either toxic (e.g. amphotericin B; lipid 
formulations are less toxic but more expensive) or their efficiency is low or not 
confirmed in larger well-designed trials; many of the conducted trials, even 
those with randomised controlled design, are of low quality, with small 
numbers of patients, inconsistent methods and end-points [Khatami et al., 2007]. 
The same conclusion is supported in a recent Cochrane review of 49 
randomised controlled trials of CL. For L. tropica, the authors made three 
positive statements: there was reasonable evidence that itraconazole 
200 mg/day is better than placebo, intralesional SSG is better than intramuscular 
SSG, and thermotherapy is better than intramuscular SSG [Gonzalez et al., 
2008]. There is an urgent need for new acceptable treatments for all forms of 
leishmaniasis [Alvar et al., 2006; Modabber et al., 2007]. 
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Antimonial compounds, given either intralesionally or parenterally, are the 
first line of treatment in most settings. Pentamidine is used in French Guyana, 
especially for CL caused by L. guyanensis because it is unresponsive to 
antimonials [Minodier and Parola, 2007]. A different approach was 
recommended by Soviet authors [Shuvalova, 2001]: in fresh lesions she 
recommends quinacrine, monomycin (paromomycin), berberine sulphate or 
methenamine, either intralesionally or as ointments or lotions. In advanced 
cases, systemic monomycin or quinacrine is given. Antimonials are reserved for 
severe cases. 
1.6.3. Physical treatments 
Surgical excision, cauterization, cryotherapy and local heat are applied. For 
cryotherapy, liquid nitrogen or dry ice is used. Heat is applied directly (from 
infra-red source) [Rahim and Tatar, 1966] or generated by radio-frequency 
device [Reithinger, Mohsen et al., 2005]. Uncontrolled studies show near 100% 
effectiveness. Controlled studies are rare, and tend to produce less impressive 
results, of effectiveness roughly similar or a little inferior to that of intralesional 
antimonials [Blum et al., 2004]. A few reports on use of ablation \'\'ith C02 laser 
were located, most of them published in 1985-1993, all from USSR, except one 
from Cuba, and a more recent one from Iran [Asilian et al., 2004]. The results 
seem encouraging: for example, out of more than 100 patients treated in the 
USSR in 1980s, no relapses were noted among 82 (76%) patients who could be 
followed up after 7 years [Babajev et al., 1991]. In one Iranian study laser 
treatment was more effective than Glucantime, had less side effects and shorter 
time to cure (1 vs. 3 months) [Asilian et al., 2004]. 
Several studies from Iraq reported very high efficacy of several treatment 
modalities, such as local heating, intralesional hypertonic (7%) saline, 
intralesional [Sharquie et al., 1997] or oral [N ajim et al., 1988; Sharquie et al., 
2001] zinc sulphate, direct current [Sharquie et al., 1998]; but they were either 
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not confirmed in independent studies or the results were unimpressive [e.g. 
Firooz et al., 2005]. 
1.7. Antimonial tolerance 
All the papers describing treatment of CL report varying proportion of 
treatment failures. Although the results cannot be compared due to differences 
in study settings, designs and end-points, it can be stated that no single 
treatment is proven to be highly and uniformly effective. 
Possible reasons for treatment failures are parasite factors, such as \'irulence 
and drug resistance, host factors, such as immunity and nutritional status, poor 
compliance and errors in administration of therapy [Douba et al., 1997; Rodjakin 
and Sukolin, 1999]. Thus, it is desirable to differentiate between drug resistance 
and treatment failure in general, and define the former as increased tolerance of 
the parasite to the studied drug, confirmed using appropriate laboratory 
techniques. 
Most treatment studies concentrate on comparing the effectiveness of 
different treatment options. Only in some publications are failures discussed, 
and even less publications explore the association between clinical treatment 
failures and parasite susceptibility. Most such papers explore the more severe 
forms of leishmaniases, i.e., visceral and mucocutaneous disease; ACL remains 
largely unexplored. 
Determining ill 'l'itro resistance requires using a dividing population of the 
parasite stage found in mammal host [Croft and Brun, 2003], in case of 
Leishmania, amastigotes. A study of treatment failures in kala-azar in India [Lira 
ct al., 1999] found a strong correlation between clinical response and in vitro 
sensitivity of L. dOllovani to sodium stibogluconate in amastigote, but not 
prol11astigote assays. However, Azeredo-Coutinho et al. reported a correlation 
between clinical response and sensitivity to MGA of both amastigote and 
promastigote stages of L. bra:ilicllsis, and a positi\'e correlation between fifty-
percent effective concentration (EC50) values of both stages, although the in vitro 
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sensitivity of promastigotes was about 100 times lower compared to 
amastigotes [Azeredo-Coutinho et al., 2007]. Another study of American 
tegumentary leishmaniasis caused by three species found correlation between 
pre-treatment antimony sensitivity level of intracellular amastigotes and clinical 
outcome, and that sensitivity of the parasites isolated from treatment failures 
was less than pre-treatment strains [Rojas et al., 2006]. 
Culturing of amastigotes requires application of tissue culture techniques, 
such as macrophage-amastigote system, because in usual culture media 
Leishmania transforms to promastigotes, that are far more resistant to 
antimonials in vitro [Croft, 1986]. Until now, only one study assessed drug 
sensitivity of L. tropica and linked it to clinical outcomes [Hadighi et al., 2006]. 
The precise mechanism of action of pentavalent antimonials is not fully 
clarified. It is agreed that SbY is reduced to trivalent antimony, which is the 
active form of the drug, in the macrophages or in the parasites [Croft et al., 
2006]. Most studies were performed on laboratory strains in which resistance 
was artificially induced. Studies showed that resistance involves multiple steps, 
where overproduction of ornithine decarboxylase and y-glutamylcysteine 
synthetase leads to overproduction of trypanothione, which binds to trivalent 
antimony, and the conjugates are either sequestered within an organelle by 
ABC transporter MRPA [Brochu et al., 2003; Carter et al., 2003] or extruded 
from the cell by an efflux pump. In field isolates genes other than described 
may be overexpressed. In addition, loss of AQP1 allele leads to down-
regulation of drug uptake and has been linked to increased resistance to 
antimony [Mukherjee ct al., 2007]. 
1.8. Conclusion 
Leishmaniases affect millions of people, mostly the poorest population 
groups in developing countries. They are classified among neglected tropical 
diseases by the World Health Organization. This neglect was due to diversion 
of efforts to fight major killing diseases: malaria, tuberculosis and AIDS. While 
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visceral and, to a lesser extent, mucocutaneous leishmaniasis received 
considerable attention in the last decade, cutaneous forms of the Old vVorld 
remain largely neglected because they rarely lead to significant disability and 
rarely, if ever, cause death [Reithinger and Coleman, 2007]. 
In the mid-1990s it was noted that intralesional treatment of ACL in Aleppo 
required more injections than in previous years [Douba et al., 1997]. 
The situation with ACL in Aleppo is unique in several ways: first, it is a 
long-standing focus with high incidence; second, a state-run control 
programme has been in place for many years; case detection rate was estimated 
at 25% in 1991 [Ashford et al., 1993]. And last, the incidence has been increasing 
during the last decades, reaching peaks about 30,000 cases per year in Syria and 
exceeding 10,000 cases annually in Aleppo since 2003. 
1.9. Objectives of the study 
To evaluate the effectiveness of current intralesional antimonial treatment of 
ACL in Aleppo governorate and determine whether the response of ACL 
patients is limited by drug sensitivity of the parasite. 
1.9.1. Specific aims 
1) To quantitatively describe the distribution of time-to-cure among ACL 
patients throughout Aleppo governorate, who complete a full course of 
intralesional antimonial treatment. 
2) To test whether time-to-cure is significantly associated with parasite 
sensitivity to antimonials, measured in vitro in amastigote-macrophage 
assay, after adjusting for lesion duration, lesion location, size, number and 
type pre-treatment, as well as the technique of drug administration. 
3) To test whether drug sensitivity decreases during the course of treatment. 
4) To evaluate qualitatively the extent to which selection for drug tolerance 
may be affected by poor treatment compliance (i.e. incomplete courses) and 
poor <ldministration technique. 
-is 
5) To identify social and clinical determinants of treatment-seeking and 
treatrnen t-corn pliance behaviours. 
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1.10. Tables 
Table 1.1. Species of Leishmania that cause disease in man! 
Species Clinical Transmission Other hosts Distribution 
forms (reservoir) 
Old World 
Leishmania aethiopica LCL, DCL zoonotic (rock hyrax)I Ethiopia, Kenya 
L. archibaldi (disputed)2 VL anthroponotic (?) dog Sudan3 
L. donovani VL, LCL, anthroponotic India, Nepal, 
PKDL Bangladesh, Africa, 
SE Asia 
L. killicki (disputed)4 LCL anthroponotic5 North Africa 
L. major LCL (rarely zoonotic: gerbils Central Asia, 
chronic (Psammomys6, Meriones), Middle East, 
and MCL) other rodents (Nesokia N Africa, E Africa 
indicaP 
L. tropica LCL, anthroponotic rock hyrax', Central Asia, 
recidivans dogsS, rats Middle East, 
chronic SE Asia, N Africa 
Old and New World 
L. infantum (chagasi) VL, LCL zoonotic: domestic and Mediterranean 
stray dogs, wild canids6 basin, Central and 
South America 
New World 
L. amazonensis LCL, DCL, zoonotic South America 
MCL 
L. Karnhami LCL zoonotic South America 
L. mexicana LCL, DCL zoonotic Central America, 
Mexico, USA 
Lpifanoi LCL zoonotic South America 
L. venezuelensis LCL zoonotic N Sou th America 
L. (Viannia) braziliensis LCL,MCL zoonotic South America, 
Central America 
L. (V.) colombiensis LCL zoonotic South America 
L. (V.) guayanensis LCL,MCL zoonotic South America 
L. (V.) lainsoni LCL zoonotic South America 
L. (V.) panamensis LCL,MCL zoonotic N South America, 
S Central America 
L. (V.) peruviana LCL zoonotic Peru 
DCL: diffuse cutaneous leishmaniasis; LCL: localised cutaneous leishmamasIs; MCL: mucocutaneous lelshmamasls; 
PKDL: post-kala-azar dermal leishmaniasis; N, S, SE, etc.: north, south, south-east, etc. 
, Based on a table from a published review [Reithinger et al., 2007], amended to add details about old-world species 
according to references below. 
Suggested additional reservoir Uaffe et al., 2004]. 
1 [Negera et al., 2008] '[Kuhls et al., 2005] 3 [Dereure et al., 2003] 4 [Sch6nian et ai., 2008] 5 [Haouas et al., 2005] 
6 [Khiami et al., 1991] 7 [Faulde ct al., 2008; Pourmohammadi et al., 2008] ; [Dereure et al., 1991] 
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Table 1.2. Number of reported ZVL cases in Syria" 
Year No. cases 
1999 55 
2000 37 
2001 30 
2002 38 
2003 36 
2004 19 
2005 18 
2007 12t 
.. [Intersectoral Committee for Vector 
Contro\, 2006] 
[al-Shammas, 2008] 
Table 1.3. Comparison between ACL and ZCL of the Old World". 
ACL ZCL 
incubation long: 2-6 months up to 2 short, usually 2-4 weeks 
years 
initial appearance small papule, brownish or significant acute 
flesh-coloured inflammato~ infiltrate 
development slow 
--.9.uick 
ulceration 3-6 months 1-3 weeks 
lymphangitis rare frequent 
localisation face> lower extremities lower extremities> face 
epithelialisation one year or longer 3-6 months 
seasonality primary disease may primary disease in summer 
present round the year and autumn 
outbreaks rare frequent 
geography urban rural 
parasites in lesion abundant scarce 
.. [Kozevnikov, 1963; Rodjakin and Sukolin, 1999] 
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1.11. Figures 
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Figure 1.1. Distribution of cutaneous leishmaniasis by causati ve 
species in the Old World. 
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Chapter 2. Leishmaniasis in Aleppo 
2.1. Introduction 
2.1.1. leishmaniasis control in Aleppo 
Leishmaniasis diagnosis and treatment in Aleppo is performed at the 
Leishmaniasis Control Center (LCC) and at selected primary health care (PHC) 
centres and health posts in the city of Aleppo and surrounding Aleppo 
countryside (about 18,500 km2), coordinated by LCe. In 2004 there were 30 PHC 
centres diagnosing and treating leishmaniasis, of which 14 (including LCC) 
were in the city and 16 were in surrounding villages (Figure 2.1), plus seven 
health posts that only treated cases diagnosed elsewhere: two in the city and 
five in villages. 
Cutaneous leishmaniasis in Syria is diagnosed clinically and confirmed by 
the detection of amastigotes in a smear from lesion scraping stained with 
Giemsa and examined under immersion. The patients who have lesions from 
which the parasites were detected by this method are termed smear-positive, and 
those in whose smears no amastigotes could be seen, smear-negative. 
The LCC is also responsible for running two campaigns of house-to-house 
insecticide spraying every year, in May and October, in villages and city 
districts where the reported disease incidence in the previous year exceeded 1% 
of the population. 
The LCC is responsible for planning when and where to introduce 
diagnosis and treatment services and puts forward its proposals to Aleppo 
Directorate of Health. When resources permit, a health care worker from the 
PHC centre where diagnosis and treatment services are to be introduced is 
taken for a training course at LCe. Here they are trained in obtaining 
pathological material from the lesion, preparing smears, and performing smear 
micfl)~copy, and are taught to correctly administer intralesional treatment. The 
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training course has no fixed duration but runs until the new worker is deemed 
competent in performing diagnostic and treatment activities. :'\ecessary 
equipment and consumables (microscope, microscope slides, Giemsa stain, 
lancet blades and medicines) are provided by Directorate of Health through 
LCe. 
Health centres differ from health posts in that the former have staff trained 
to administer intralesional treatment, and the latter are visited once a week by 
trained staff either from LCC or from a nearby PHC centre that has trained 
staff. In fact, the term health post can be correct from the point of view of CL 
control, as in other ways they are usual PHC centres. 
Patients with a positive smear made at LCC or a nearby health centre are 
referred to the health post nearest to their home for their treatment. These 
patients are reported from the centre that performed the smear. 
Some health centres may not have staff fully dedicated for treatment and/or 
diagnosis of leishmaniasis. In this case they may restrict leishmaniasis clinic 
time to one or more days a week, usually other than healthy child/vaccination 
days. In addition, not all treating health centres have the necessary equipment 
and skill to diagnose CL. 
Patients with leishmaniasis confirmed by smear examination start 
treatment. If a smear examination result is negative there are a number of 
alternative scenarios: 
1. the patient may be referred to LCC where their original smear is read by 
LCC lab staff, the test may be repeated, and they are examined by a 
physician who is entitled to diagnose leishmaniasis clinically, regardless of 
test results, and to refer the patient back to their PHC to receive treatment; 
2. in some centres there is a dermatologist who is entitled to confirm 
leishmaniasis based on clinical presentation of the lesion, regardless of test 
result, and the patient is treated based on clinical diagnosis (so-called test-
treatment, where the patient is re-assessed after recei"ing a few doses); 
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3. patients with lesions of short duration (less than a month) may be asked to 
come back for another smear after two weeks; or 
4. in the Specialised Centre for Skin Diseases a patient may have their 
leishmaniasis diagnosed clinically and administered a test treatment for a 
few weeks with re-assessment by a dermatologist at each appointment. 
Leishmaniasis patients who self-refer to dermatological outpatient clinics in 
Aleppo University are routinely referred to LCC for diagnosis and further 
management. 
Treatment of leishmaniasis is not compulsory: the patient may choose to 
interrupt their treatment at any time, without informing the health centre, 
which they frequently do. 
In Aleppo the approved treatment schedule was up to three eight-week 
courses of weekly intralesional injections with one-month intervals between 
courses; the patients who, according to the health centre staff judgement, did 
not heal after receiving these three courses are considered treatment failures 
and would be referred to LCC for evaluation and further management. In the 
last years the treatment courses were shortened to six injections, but some 
centres still administer eight-week courses. When the patient is judged to be 
cured, they are advised to attend the centre for review after one month, and 
then at three and six months. 
The Specialised Centre for Skin Diseases mentioned above may also apply 
liquid nitrogen treatment to selected patients, especially those with small 
lesions on trunk or extremities, and who have not responded to intralesional 
antimonials. 
Depending on how busy health centre staff are, they may either ask a new 
patient who had his smear taken to wait until the result is available on the same 
day or come back after an hour or two to start treatment on the same day; or to 
return on the next workday or the same weekday next week. In the latter case 
the patient does not start treatment on the day when the smear was prepared. 
In addition, if a patient presents with a lesion that is complicated by secondary 
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bacterial infection, then antibiotic ointment is prescribed and the patient is 
asked to return after a week when the inflammation has subsided. Secondarv 
infection is considered a contra-indication to start treatment and also to reduce 
the chance of detecting parasites in biological material. 
2.1.1.1. Recording 
Diagnosis and treatment activities are recorded in health centres as follows: 
1. Laboratory register: every patient with suspected leishmaniasis who referred 
to the health centre is recorded. Data fields include: forename, surname, 
father's name, mother's name and surname (women in Syria retain their 
father's surname after marriage), age, sex, place of residence, date of 
referral, number of lesions, lesion duration in months, smear result. The 
data from this type of register are used in preparing monthly reports. Thus, 
all the cases are reported only from the PHC centres that diagnose 
leishmaniasis. 
2. Treatment register: every patient with confirmed leishmaniasis is entered 
when they start treatment. The data fields include forename, father's name 
and surname, age, sex, place of residence, date of diagnosis and dates of 
treatment sessions. There are three groups of six treatment sessions, 
separated by two fields for scheduled one-month treatment interruptions. 
There are also fields marked 'Cure', 'Relapse' and 'Notes'. The date of e,"ery 
treatment session is recorded in the corresponding field of the patient's 
record. From this register one may calculate how many injections each 
patient received, and on what dates. 
3. Daily register: the patients who attend a leishmaniasis clinic for treatment 
every day are recorded. The data fields include full name, treatment 
register ID number, number of lesions injected that day and the sequential 
number of treatment session. This register records the daily number of 
patients and the quantity of drug used eyery day . 
..t. Patiellt trcatlllellt cards: eyery patient undergoing treatment is issued with a 
card which they keep and bring with them every time they come for 
treatment. In addition to personal data, the following is recorded: number 
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and location of lesions, date and result of smear, name of examiner, date of 
each treatment session, scheduled breaks in treatment course after every six 
injections, relapse or cure, referral to another centre. Similar cards are used 
for patients given systemic treatment; since systemic antimonials are given 
daily for three weeks, no lines for treatment interruption are envisaged. If 
one card is insufficient, another card can be stapled to it to record 
additional treatment sessions. At the end of the treatment patient cards are 
to be returned to the health centre, and at the end of every year they are to 
be sent to LCC where they are kept for at least five years. If the card is lost, 
a replacement card is issued, but this only contains personal patient data 
and the date of diagnosis. Dates of previous injections are not always 
recorded. 
A register is used until the book is full, so every book may span more than 
one year or even several years if the annual number of patients is low. 
Registers, when full, are kept at the LCe. One register is in use at anyone time, 
with the exception of treatment registers, as when a new treatment register is 
started, some of the patients recorded in the previous register are still 
undergoing treatment. 
Demographical, clinical and epidemiological data are extracted and 
routinely analysed only from laboratory registers. 
In practice, data are filled in Laboratory and Daily registers promptly; the 
same usually applies to Patient cards unless the patient forgot theirs, in which 
case it would be filled in at the next visit. Injection dates may sometimes not be 
entered in Treatment registers immediately but postponed until the end of the 
day or week (sometimes longer), then transferred from daily registers. 
Cure is rarely recorded at the time of last injection because there is no clear 
definition of cure: it is supposed that a patient should not be considered cured 
until they have finished follow up, which rarely happens. 
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2.1.1.2. Reporting 
Laboratory registers are used to compile monthly recorded incidence 
reports. At the end of every month all the data are copied manually into 
separate sheets after sorting by patient's place of residence, and then taken to 
LCC at the beginning of each month. At LCC the data are entered into a 
computer database. This custom-made MS-Access database contains macros 
that can, more or less reliably, identify duplicate records and generate printed 
summary reports. The practice is relatively new, the database program is 
updated from time to time, and every year a new database file is created. 
Monthly reports are sent to the Directorate of Health which, in tum, sends 
them to the Directorate of Chronic and Endemic Diseases at the Ministrv of 
Health (MoH). LCC also faxes monthly reports directly to the Directorate of 
Chronic and Endemic Diseases. Directorates of Health reports include only 
smear-positive patients; the number of smear-negatives is mentioned separately 
(in Aleppo). Smear-negative patients are not included in annual reports 
compiled by MoH. 
2.2. Objectives 
5. Describe the demographic and clinical characteristics of cutaneous 
leishmaniasis in Aleppo. 
6. Describe the seasonal variation in the number of cases at PHC centres. 
7. Determine whether the response to treatment is influenced by either 
demographic or clinical (lesion number and duration at presentation) 
characteristics of a case. 
S. Determine if response to the treatment is influenced by the health centre 
where treatment is carried out or the month of presentation. 
2.3. Materials and methods 
Four data sources were used in the analysis in this chapter: 
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9. The Main database, based on laboratory registers obtained from LCC which 
contained data on more than 14,000 cases of cutaneous leishmaniasis 
recorded from 19 centres during 2005. 
10. To obtain treatment data, patient treatment cards of cases whose treatment 
started in 2005 were obtained from the LCe. These were matched with the 
Main database, and the treatment data were entered in a table linked to the 
Main database table. Data recorded were: number of treatment sessions, 
dates of first and last recorded injection, date of cure (if recorded in the 
card), scheduled treatment breaks, relapse, referral to another centre. Only 
528 cards from 15 centres were available. 
11. Treatment registers covering the first three months of 2005 were requested 
by the LCC from all centres, but were available from only 13 cenb·es. The 
data concerning about 2000 patients who started treatment in the period 
from January to March 2005 inclusive were entered into an MS Excel 
workbook. The data recorded were patient's name, age, sex, place of 
residence, reporting health centre, number of lesions at presentation, dates 
of injections, total number of injections, date of last injection, and available 
data about cure or relapse. 
12. Statistical Abstract 2006 by Syrian Central Bureau of Statistics [Central 
Bureau of Statistics, 2007] was used. The following data were reported: 
population disb"ibution by age group and sex for Syria and population by 
sex for each governorate. Data from census of 2004 were used for 
comparisons. 
All the databases may have intrinsic biases. Comparing them may give 
insight into some of these biases. 
13. All four data sources incorporate demographic data, permitting performing 
comparisons of distribution by age group and sex; 
14. The three 'leishmaniasis' data sources (numbered 1, 2 and 3 above) 
incorporate baseline data, i.e. lesion duration at presentation and number of 
lesions at presentation, either counts or mean, median, etc. values by age, 
sex, health centre (and lesion duration at presentation by number of 
lesipns). Data on lesion duration are not c1yailable in treatment registers. 
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15. In addition, month of presentation and smear result can be accounted for 
(data sources 1 and 2 because treatment registers only span January to 
March). Since therapy is usually initiated based on smear result, higher 
positivity rate can be expected in Patient cards sample. 
16. between two clinical data sources (2 and 3): clinical data, i.e. relationship 
between baseline variables (age, sex, health centre, number of lesions) and 
treatment duration (mean or median time or number of injections) as 
outcome variables. 
The data in MS Excel spreadsheets were analysed using SPSS version 16). 
Data from MS Access databases were exported to MS Excel first, then analysed 
as above. Graphs were prepared in MS-Excel. 
2.4. Results 
2.4.1. Demography 
The first set of tests was designed to determine whether age and sex 
distribution between general population (that of Syria and Aleppo) is different 
from recorded leishmaniasis population and datasets from treatment registers 
and patient cards. 
The Main dataset contained demographic and clinical presentation data on 
14,368 patients who referred to PHC centres in Aleppo in 2005 and were 
examined by obtaining a smear. The Treatment dataset contained data on the 
number of treatment sessions for the 2145 patients who started their treatment 
from January to March 2005. The patient cards dataset contained demographic 
and clinical presentation data and the treatment sessions for 498 patients who 
started their treatment during 2005 and returned the patient cards upon 
completion of treatment. 
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2.4.1.1. Demography - Results 
2.4.1.1.1. Age distribution 
Raw freq uencies 
Counts of patients at every age were performed. The presence of attractors, 
i.e. values that are consistently higher than expected, was noted, especially in 
the two larger datasets (see Figure 2.2). 
Attractors in our data occur consistently every five years, at multiples of 
five. They probably occur because patients and/or health workers tend to round 
the age (to nearest five years). In the Main dataset they are clear from the age of 
five, while in Treatment dataset they can be suspected from the age of 20 and 
become obvious from 25 years. They were not prominent in Patient Cards 
dataset, probably due to low number of patients of some ages. 
There were statistically significant differences between the median age 
values among the three datasets (shown in Table 2.1): p<O.OOOl (Kruskal-Wallis 
H test). 
Age group comparisons 
Patient age was categorised as in the census that uses five-year age groups 
(Figure 2.3) to allow comparisons. Count distribution tables were produced in 
SPSS. In the Main dataset and Patient cards no patients were recorded as under 
one year of age; probably, ages <1 year were recorded as 1 year. For this reason, 
age group of <1 year was merged with the next group to form 0-4-year-old 
group. This also has the advantage of better comparability because the age 
groups in the census span five years (except the last, 65+, group). 
The age groups followed the classical demographic pyramid in the census, 
whereas in leishmaniasis patients the age group 0-4 years was smaller than the 
next, 5-9 years, age group, and the population in general was younger (Figure 
2.3). 
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Syrian population according to 2004 census: 
Mean and percentile values of age distribution are not stated explicitly in 
the census tables but percentiles can be inferred: the lower quartile is at 9 vears, 
the median is about 19 years, the upper quartile is at 33 or 34 years. This is 
summarised in Table 2.1. 
Age quartiles in leishmaniasis datasets are lower compared to census data. 
In the Treatment dataset, the mean and age quartiles are 1-2 years lower 
compared with the Main dataset (recorded leishmaniasis population) data. This 
shows younger patients are more likely to start treatment. The data in the 
Patient cards dataset seem closer to treatment register statistics than to the Main 
dataset. 
2.4.1.1.2. Sex distribution 
While in Syria and Aleppo governorate there is a slight male predominance 
in the population, among leishmaniasis patients from all datasets females 
predominate (Table 2.2). 
The sex distribution of leishmaniasis cases was similar in the different 
datasets (p= 0.71, Pearson's X2 test). However, it was significantly different from 
the general population in Aleppo: p<O.OOOl for the Main dataset, p=0.015 for 
Treatment registers dataset and p=0.0002 for Patient cards dataset (X2 test). 
To assess the sex distribution by age group, sex was cross-tabulated with 
age groups in the main dataset; in the three younger groups, but not in the 
older ones, the sex ratio was fairly equal and close to that of general population. 
Collapsing age into two age groups: "14 years and younger", and "15 years and 
older", M:F ratio in the younger group was 50.4:49.6. The same ratio was also 
calculated for groups 0-14 years from census data for Syria. It was 50.3:49.7, i.e. 
the same (p=0.91, XC test), while the difference between the two age groups was 
highly significant (p<O.OOOl, Pearson's X2 test). This breakpoint was selected for 
two reasons: first, it represents a breakpoint in census age groups, and thus 
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allows one to calculate the relevant values from census data for comparison; 
second, it is close to the median age in the Main dataset. 
This means the inversion of the sex ratio occurs in the older age group only, 
while in patients of 14 years and younger it does not differ from the general 
population. 
Proportional risk ratio was explored in census age groups. To this end, 
percent of the patients belonging to either sex in each age group was calculated 
(or taken from census data). Census data percentages were used as the 
denominator. Percent of males or females in a given age group in a given 
dataset was divided by the percentage of the corresponding age and sex group 
in the census (Figure 2.4). 
2.4.2. Presentation data of leishmaniasis patients 
2.4.2.1. Aims 
1. To describe presentation variables of leishmaniasis patients in Aleppo 
and explore differences between the three available datasets. 
2. To describe factors which may affect each of the presentation variables. 
2.4.2.2. Methods 
In SPSS, frequencies, mean, median and relevant quantile values of the 
variables were generated. Frequencies were first calculated raw then grouped 
in different ways until the most appropriate grouping was found. Cross-
tabulation or logistic regression was used for categorical variables. 
Presentation variables examined were number of lesions, lesion duration 
and smear result. Explanatory variables were age and sex (for all dependent 
variables), number of lesions (for lesion duration and smear result), lesion 
location (for lesion duration and month of appearance; patients with one lesion 
or those with lesions in one location were analysed) and lesion duration for 
smear result. 
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Lesion duration and smear result data were not available for Treatment 
dataset. 
2.4.2.3. Presentation data - Results 
2.4.2.3.1. The reporting health centres 
The data were available from nineteen health centres in the Main dataset, 
thirteen in Treatment dataset and fifteen in Patient Cards dataset. These centres 
and the number of cases available from each centre in each dataset are listed in 
Appendix 1. 
Table 2.3 displays the distribution of patients by place of residence between 
urban and rural health centres. More than one-quarter of patients in urban 
health centres lived in rural Aleppo. Rural health centres served almost 
exclusively rural residents (99.8%). Overall, about forty percent of all patients 
recorded in 2005 came from rural areas. 
2.4.2.3.2. Distribution of cases by month 
This can be assessed reliably from the Main dataset only, as Treatment 
dataset included only cases starting treatment between January and March 
2005, and patient cards for last months of 2005 were not available for analysis 
because many of them were not returned to LCe. 
Figure 2.5 shows percentages of patients from the Main dataset (squares) 
and Patient Cards (circles) presenting every month. 
Mean monthly percent (dotted line) is 100.;. 12 = 8.3. Months above the 
mean value are December to May inclusive. 
2.4.2.3.3. Number of lesions at presentation 
Frequencies 
About half of patients presented with one lesion, 53.3% in the Main dataset, 
48.9°/c) in the Treatment dataset and 56% in Patient cards dataset, and the 
proportions of patients with two lesions were similar (Figure 2.6). Treatment 
Registers dataset has the lowest proportion of patients with one lesion and, 
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reciprocally, higher proportions of >2 lesions; Patient Cards dataset is vice versa 
(Figure 2.6). The differences between the datasets are statistically significant: 
p=O.OOl, Pearson's X2 test. 
Distribution by age 
The mean and median numbers of lesions in younger and older patients 
were significantly different, with Treatment dataset showing most and Patient 
Cards dataset showing least difference (Table 2.4). 
Distribution by sex 
In all datasets mean values for the number of lesions was marginally but 
consistently higher among females. As for the medians, they were equal to one 
in all groups except females in Treatment dataset, where it was 2. Nevertheless, 
the differences were statistically significant only in the Main and Cards 
datasets, where the median values are seemingly equal (Table 2.5). 
Distribution by month of presentation 
Only the Main dataset was analysed because Patient Cards contain fewer 
subjects towards the end of the year and the Treatment dataset spans only the 
first three months of 2005. Patients presented with more lesions than all-year 
average during the first three and the last three months of 2005. The month of 
appearance was calculated by subtracting the reported lesion duration from 
month of presentation. Numbers higher-than-average for the whole year appear 
from August to November (Figure 2.7). When the patients were categorised into 
two groups according to month of appearance (August to November vs. other 
months), the mean number of lesions was 2.46 and 2.00, and the medians, two 
months and one month, respectively. These differences were statistically 
significant, p<O.OOOl (Mann-Whitney U test). 
Logistic regression 
Number of lesions, grouped into two categories, 1/1 or 2 lesions" and 
1/3 lesions or more", was examined by binary logistic regression in the Main 
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dataset using a univariate model with one explanatory variable at a time, then a 
multivariate model that included all the variables for which significant 
relationship with outcome was demonstrated. The results are presented in 
Table 2.6. 
In both univariate and multivariate analysis all the variables tested had a 
statistically significant impact on the odds ratio. The change in odds ratio 
between univariate and multivariate models was marginal suggesting that the 
factors are independent. 
2.4.2.3.4. Lesion location 
Frequencies 
This analysis was first restricted to patients with one lesion because in 
patients with multiple lesions it would not be possible to distinguish the effects 
of lesion location. These patients represent 53.3% of all recorded leishmaniasis 
patients. The results are shown in Figure 2.8. Most patients presented with 
lesions of the face, followed by upper, then lower extremities. 
Distribution by age and sex 
After preliminary analysis, patients with one or more lesions in one location 
were analysed (n=12,176; 84.7%) and, additionally, all patients, including those 
with multiple lesion locations, were categorised into those who have any 
lesions on face and those who had no lesions on face. The data for the three 
most common lesion locations by sex and age group are shown in Table 2.7 and 
Table 2.8, respectively. 
There were significant differences in lesion locations between age groups 
and sexes in patients with one lesion. To calculate statistical significance, the 
locations in patients with one lesion (n=7650) were categorised as Face and Non-
Face, Hand and Non-Hand, Leg and Non-Leg, and cross-tabulated. All the 
differences were statistically significant, except sex differences for lesion 
location on the lower extremities. 
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Similar results were obtained when patients with one or multiple lesions in 
one location (n=12,176) were compared, and when the patients with multiple 
lesion locations with any lesions on face were compared to those with no 
lesions on face. 
Distribution by reported month of lesion appearance 
In the Main dataset, the date of lesion appearance is calculated by 
subtracting the patient-reported lesion duration from the date of patient referral 
to the centre. Month of reported lesion appearance was extracted, and then the 
cases with lesion durations of 12 months and longer were excluded because 
after long periods the patients tend to round up the duration of their lesions, so 
the data about the month of appearance become unreliable. 
The distribution of the three most common lesion locations (face, upper and 
lower extremities that constitute more than 97% of total) by month of 
appearance was examined in this group. Figure 2.9 shows the percentage 
distribution of the three most common lesion locations for each month (points 
for each month add up to 100%). 
Month of appearance was re-categorised into three categories of four 
months each (January to April, May to August and September to December) 
and cross-tabulated with the three locations. The differences are significant, 
p<O.OOOl (Pearson's X2 test). The proportion of face lesions diminishes in the 
warm months due to the rise of the proportions of other locations. 
Logistic regression 
Lesion location, categorised to face/non-face was examined by binary 
logistic regression in the Main dataset using a univariate model with one 
explanatory variable at a time, then a multivariate model with all the 
explanatory variables included. The results are presented in Table 2.9. The 
changes in odds ratio between univariate and multivariate models were 
marginal suggesting that the factors are rather independent. 
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All the tested variables significantly affected lesion location. Females were 
slightly less likely to have lesions on the face, older patients much less likely 
than younger ones, and, compared to the period between January and April, 
lesions on the face were less likely in the hottest months (May to August) and 
slightly more likely in September to December. 
2.4.2.3.5. Lesion duration at presentation 
Frequencies 
About two-thirds of patients reported lesion duration of 2 months or less, 
and about 90% of 5 months or less. Mean lesion duration was 2.88 and 2.71 in 
the Main and Cards data sets, respectively, and the median lesion duration was 
2 in both datasets (p=0.096, Mann-Whitney U test) and in all the examined 
subgroups. 
The results by subgroup are presented in Table 2.10 and described in the 
text below. 
Distribution by age 
The lesion duration in the older age group (15+) is higher than in the 
younger. Difference in mean values in the Main dataset is estimated 24 days VS. 
less than two weeks in Patient Cards dataset, and both are statistically 
significant: p<O.OOOl for the Main dataset, p=0.025 for Patient Cards dataset 
(Mann-Whitney U test). 
Distribution by sex 
Males seem to report slightly longer durations of lesions than females. The 
difference is no more than one week, not statistically significant: p=0.126 for the 
Main dataset, p=0.305 for Patient Cards dataset (Mann-Whitney U test). 
Distribution hy number of lesions 
Number of lesions was categorised into 2 groups: "1 or 2 lesions" and "three 
or more lesions". 
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The patients with more lesions tended to present slightly later in time, and 
the difference was more pronounced in the Cards dataset (more than half a 
month vs. less than a week in the Main dataset). Both are statistically significant: 
p<O.OOOl for the Main dataset, p=O.OOl for Patient Cards dataset (Mann-Whitney 
U test). 
Distribution by lesion location 
The relationship between the three most common lesion locations (face, 
hand and leg) and lesion duration was examined in patients who had one 
lesion, in patients who had their lesions (one or more) in one location, and all 
the cases after categorising them into those who had at least one lesion on the 
face, regardless of whether they had any other lesions, and those who had no 
lesions on the face. 
In Table 2.11 the mean reported lesion durations for the three most common 
lesion locations are compared. Lesion location on the face was associated with a 
shorter reported lesion duration at presentation compared to other lesion 
locations. The difference is estimated 17-19 days, and is statistically significant. 
Figure 2.12 is a graphical illustration of the distribution of reported lesion 
duration at presentation, relative to all patients in location group (points for 
each location add up to 100%). The patients with facial lesions tend to present 
earlier than those with no lesions on the face. 
Distribution by month of presentation 
Mean lesion duration is higher than the average for the year from March to 
September inclusive (Figure 2.13). Median values are equal to 2 throughout all 
months, yet the differences are significant (p<O.OOOl by Kruskal-Wallis test). 
This represents a three-month shift past month of presentation curve (see page 
64), assuming roughly equal disease cycles (Le. assuming that current 
December can be substituted for last-year December). The data presented are 
for the Main dataset. In the Patient Cards dataset the relationship appeared 
random due to small number of patients, and is not shown. When the patients 
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in the Cards dataset were categorised by month of presentation into two groups 
according to the data from the Main dataset, Le. to those who presented from 
March to September and those who presented in the other months, the mean 
lesion duration at presentation was 2.91 months in the former and 2.26 months 
in the latter group. This difference was not statistically significant, p=O.156 
(Mann-Whitney test). 
The trend in the Main dataset is the gradual increase in lesion duration from 
the start of usual reported appearance of lesions in the end of summer, 
consistent with increasing length of time from transmission season: the patients 
who present in autumn and winter have acquired their lesions during the 
transmission season, before October, so the lesion duration increases. Starting 
from June, the reported lesion duration decreases. This is probably due to 
patients with short lesion durations whose lesions appeared in the next 
transmission season. 
Differences between health centres 
Mean and median lesion duration was calculated by reporting health centre. 
The mean values ranged between 2.2 months for Atareb and 3.9 months for 
Salah aI-Din (Figure 2.14). The median values were equal to 2 months in most 
centres, with the exception of Efrin, Halab al-Jadidah and Salah aI-Din, where 
they were 3 months. 
The centres were categorised into those with short (n=7629) or long (n=6739) 
mean reported lesion duration, with the breakpoint being the mean lesion 
duration for the complete dataset (2.9 months). The mean lesion duration was 
2.4 months in the former group and 3.4 months in the latter. The median was 
2 months in both groups but the differences were statistically significant, 
p<O.OOOl (Mann-Whitney test). 
It was noted that of the four rural centres, three belong to the former 
category, so the centres were also categorised into urban (n=l1,787) and rural 
(n=2,581). The mean lesion duration was 3.0 months in urban centres and 
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2.3 months in rural centres. The median lesion duration was 2 months in both 
but the differences were statistically significant, p<O.OOOl (Mann-Whitney 
U test). 
2.4.2.3.6. Smear result 
Frequencies 
These are only available for Main and Patient Cards datasets, and are 
summarised in Table 2.12. 
Proportion of smear-positive patients is significantly higher in Patient cards 
dataset compared to the Main dataset: p<O.OOOl (Pearson's X2). This is to be 
expected because the positive smear result is the main diagnostic criterion for 
CL in Syria. The Main dataset comprises all the patients who were referred or 
self-referred to health centres and had their smear taken, regardless of whether 
or not they were treated later. Patient cards dataset represents the patients v','ho 
started treatment, thus smear-positive patients are selected into this group. 
Distribution by age 
A clear decline in percentage of positive smear results with increasing age 
was noted in the Main dataset but not in the Cards dataset (Figure 2.15). The 
differences between age groups were statistically significant for the Main 
dataset (p<O.OOOl, Pearson's X2) and not significant for the Cards dataset 
(p=0.297, Pearson's X2). 
The trend was analysed by binary logistic regression with age as continuous 
variable which gave a low but highly significant (p<O.OOOl) B value of 
-0.014 ±0.001, i.e. a 1.4% fall in positivity rate for every additional year of age. 
The data were also analysed according to ten-year age groups. The results 
(Table 2.13) show declining odds ratio with increasing age, and all the 
differences are highly significant. In those aged over forty the odds ratio is 
roughly one-half compared to the youngest age group. 
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The absence of this trend in Patient Card dataset (binary regression: 
B=O.OOI±O.OII, p=0.925) can be explained by the fact that the patients are 
selected for treatment based on positive smear result. 
Differences by sex 
No significant differences between sexes were detected in either dataset. 
Differences by number of lesions 
This was uniform across number of lesions categories in the Main dataset 
and with random fluctuations in the Cards dataset, especially in the groups 
with more lesions that contained few patients each. When divided into two 
groups, of "lor 2 lesions" and "3+ lesions", the results were the same for both. 
Differences by lesion location 
The patients who had any lesions on the face were more likely to have a 
positive smear result compared to those who had no lesions on the face, 80 vs. 
76.4% (p<O.OOOl, Pearson's X2). 
Differences by lesion duration 
In the Main dataset the smear positivity was higher than the total average 
(i.e. that for the whole dataset) in lesions of 2, 3 and 4 months' durations. In the 
Cards dataset the numbers of patients of lesion duration of 5 months fell below 
20, so lesion duration was re-categorised into less-than-one, I, 2, 3, 4 and 5+ 
months. Above-average positivity rates were in lesion durations of up to 3 
months (Figure 2.16). 
The mean and median lesion duration in smear-positive and smear-negative 
patients was explored. The median lesion duration was 2 months in both 
categories of both datasets. The difference between the mean durations was 
about 19 days in the Main dataset (2.74 VS. 3.37 months) and about 38 days (2.59 
l'~. 3.85 months) in the Cards dataset. The differences between the medians 
were statisticall~' significant (p<O.OOl for the Main dataset and 0.004 for the 
Cards dataset, Mann-Whitney U test). 
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The relationship was also analysed by binary regression with less-than-one-
month duration as reference category and six lesion duration categories. The 
odds ratio peaked to more than 2 at 2 month lesion duration then declined to 
about one in the longer-than-five-month category but these differences were not 
statistically significant. 
When lesion durations were divided into three roughly equal groups: "one 
month or less" (n=4175), "two months" (n=5150) and "three months or more" 
(n=5043), the patients who reported lesion duration of 2 months were 
significantly more likely to have a positive smear result (odds ratio = 1.39, 
95% CI = 1.26-1.54, p<O.OOOl) compared to patients with lesion durations of one 
month or less. The patients with the longest reported lesion duration (three 
months or more) were less likely to have positive smear result than patients 
with lesion durations of one month or less: OR = 0.92, 95% CI = 0.84-1.01, 
p=0.085, the difference not statistically significant), and patients with lesion 
durations of two months were significantly more likely to have a positive smear 
result compared to those with lesion durations of three months or more 
(OR = 1.51, 95% CI = 1.37-1.66, p<O.OOOl). 
Differences by health centre 
This was calculated for the Main dataset only (Figure 2.17). Marked 
differences for smear positivity between the centres can be noted, with 
minimum of 58.1% in Salah aI-Din. Numbers of reported cases were high, two 
lowest count of patients were 55 in Haydariyyeh and 96 in Efrin. 
Smear positivity rate was 82.4% in rural health centres vs. 77.0% in urban 
health centres, and this difference is statistically significant, p<O.OOOl (Pearson's 
X2 test). However, this may be confounded by lower mean reported lesion 
duration in rural health centres (see Differences between health centres in 
Lesion duration at presentation, p. 70), so a multivariate analysis including the 
variables that were significant in univariate analysis above (age, lesion duration 
and health centre location) was performed. The results by age group were 
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essentially the same, the maximum difference in odds ratio between univariate 
and multivariate analysis did not exceed 0.01 (Table 2.13). For lesion duration, 
the patients who reported lesion duration of 2 months were significantly more 
likely to have a positive smear result (odds ratio = 1.43, 95% CI = 1.29-1.58, 
p<O.OOOl) compared to patients with lesion durations of one month or less. The 
patients with the longest duration (three months or more) were as likely, 
compared to patients with lesion durations of one month or less, to have 
positive smear result: OR = 1.01, 95% CI = 0.92-1.11, p=0.837). 
Some rural residents might either not have access to CL diagnosis in their 
local PHC centre or be unaware that such diagnosis is available, so they would 
refer to urban health care centres or the LCe. Smear result positivity was 
analysed according to patient's reported place of residence (urban vs. rural), 
and rural residents (n=5,777, or 40.2% of total) had a marginally higher smear 
result positivity rate (78.4%) than urban residents (77.7%), and this difference 
was not statistically significant (p=0.329, Pearson's X2 test). 
2.4.3. Treatment response data 
2.4.3.1. Aims 
The aims of this part of the study were: 
17. To describe the distribution of clinical outcome data and explore the 
differences between the two available datasets. 
18. to explore the relationship between outcome and the demographic and 
presentation explanatory variables. 
Four outcome variables were originally expected: time to cure, relapses, 
number of treatment sessions (injections, or doses) and treatment duration 
calculated as [date of last dose] - [date of first dose]. The latter gives the result 
in days; it was recalculated to weeks by taking integer of [days .;- 7]. Another 
recalculation was done, the integer of [(days+3) .;- 7] to take mid-week points, 
and the latter variable is used in all calculations. 
Relapses could not be reliably estimated in most cases (see the next section), 
leaving two outcome variables: number of doses and treatment duration. 
Outcome variables will be discussed in parallel: for each explanatory variable, 
number of recorded doses, treatment duration and time to cure will be 
reported, the latter for Patient cards only. 
The explanatory variables were categorised when convenient as described 
previously. In addition to the explanatory variables mentioned above, 
differences by treating health centre were explored. 
2.4.3.2. Treatment response data - Results 
2.4.3.2.1. Frequencies 
Cure and Relapse fields 
Cure date is rarely recorded, although it is more likely to be present in the 
Cards sample, probably because it over-represents the patients who were 
considered cured and whose cards were requested back from them. In the 
treatment registers the Cure field is usually left empty. In some cases the word 
Cli rc is recorded without the date, which will be referred to as "Fact of cure", 
and in rare instances, the date of cure. The date of cure was recorded for seven 
patients (0.3°1t») in the Treatment dataset, and for 71 patients the word Cure was 
filled (without the date). In the Cards dataset the date of cure was recorded for 
189 patients (38%). 
Thus, in most instances it is impossible to tell whether or not a patient was 
cured. We can only depend on recorded treatment sessions to calculate the 
number of doses and treatment duration. A selection of 38% of patient cards, 
which are initially biased towards the beginning of the year and by patient self-
selection, are not a reliable source to estimate time to cure; the seven-patient 
(0.3%) selection from treatment registers is probably even less reliable. No 
,malvsis of this variable in Treatment registers will be attempted, but the 189 
patients from Patient cards dataset merit im'estigation despite the likely biases. 
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Relapses were not encountered in patient cards, probably because either 
such patients would still undergo treatment, and total treatment duration 
would be too long to finish within 2005, or because the patients who returned 
their cards would be issued a new one when they refer for treatment of a 
relapse. In Treatment registers 45 counts of relapse exist, two of them include a 
precise date. This variable will not be analysed. 
Variation between primary health care centres 
Proportion of cards of the patients who started their treatment during 2005, 
returned from different health centres by end of April 2006, was estimated by 
dividing the number of available patient cards by the number of reported 
smear-positive patients from the same centres in 2005. The denominator was 
selected as a proxy for patients who started treatment and, hence, had cards 
issued to them. In reality, some smear-positive patients may refuse to start 
treatment, and some smear-negative ones may start treatment based on clinical 
examination only. The results are presented in Figure 2.18. 
Salah aI-Din centre has the highest card-return rate. It is the centre with the 
lowest smear positivity rate, which may mean that considerable proportion of 
patients start treatment despite negative smear results, whose cards are also 
counted, thus increasing the calculated proportion. Twenty-five percent of 
cards from this centre belonged to smear-negative patients, the highest 
proportion among centres from which more than 20 cards was available. 
Nevertheless, this centre still had the highest proportion of cards returned to 
LCC when total number of patients was used as denominator (data not shown). 
Proportion of cards where cure was marked was calculated. Total number 
of available cards was used as denominator. 
Health centres are sorted by the number of available cards, indicated by 
colours and patterns in Figure 2.19 (green, dotted: ~60; blue, diagonal: 30-59; 
yellow, horizontal: 20-29; and pink, checkerboard: <20). Salah aI-Din centre, the 
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one that had the highest proportion of cards returned, has the lowest 
proportion of filling in the date of cure. 
2.4.3.2.2. Description of treatment data 
Number of recorded doses 
The data are summarised in Table 2.14. Two hundred and seventeen 
patients (10.1 %) in the Treatment registers dataset received only one dose, and 
the mode was six doses (228 patients, 10.7%). This reflects the six-dose 
treatment courses adopted in most PHC centres. There is a suggestion of a 
second peak at 8 doses, possibly because some PHC centres used 8-week 
courses. The maximum number of doses recorded in the Treatment registers 
was 24 (Figure 2.20). 
The Patient cards dataset contains about 500 patients. Only eight values 
exceed 20, and only six of them were ~30. This explains the more random 
appearance of the graph. A striking difference from treatment registers is lower 
number of patients receiving few doses and a clear mode at twelve doses, with 
smaller peaks at eight, then six doses. 
The maximum number of recorded injections was 40. This may be because 
when a card is full, another card can be attached to it where additional doses 
are recorded, while in the Treatment registers there is no room to record too 
many doses because every record is represented by one line. 
The median number of recorded doses was six in the Treatment dataset and 
ten in Patient cards. This difference is significant: Mann-Whitney U test, 
p<O.OOOl. 
Duration of treatment 
Treatment durations in Treatment registers distribute along a wider range 
than the number of recorded doses, while in Patient cards the range was only 
slightly wider than number of doses. 
In Treatment registers dataset 224 patients (10.5°n) had duration of a weeks 
(i.c. one injection only). A clear peak occurred at 5 weeks which corresponds to 
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the sixth dose. Low corresponding values in Patient Cards dataset may indicate 
early patient drop-out (Figure 2.21). The median duration of treatment was 
7 weeks in Treatment dataset and 12 weeks in Patient cards, and the difference 
is statistically significant (p<O.OOOl, Mann-Whitney U test). 
In the Patient Cards dataset there was a significant difference in the number 
of recorded doses and treatment duration between the patients with date of 
cure recorded on the card and those whose date of cure was not recorded. The 
median number of recorded doses was 10 and 11 (p=0.019, Mann-Whitney 
U test), and the median treatment duration, 11 and 13 weeks, respectively 
(p=O.OI, Mann-Whitney U test). 
Time to cure 
Time to cure was calculated in weeks in the same way as for treatment 
duration, i.e. date of first injection was subtracted from date of cure, giving 
number of days, then 3 was added to the result to take mid-week points, and 
the integer of the result divided by seven was taken. 
Figure 2.22 shows the raw distribution of weeks until cure, in percent, in the 
subset of patient cards where the date of cure was recorded (n=189). 
This distribution is shifted to the right (the percentile values are higher) 
compared to treatment duration, probably reflecting the cases in which cure 
was diagnosed after a scheduled or non-scheduled break. Only 4 of 189 patients 
have time to cure of six weeks or less, and the median time to cure is 18 weeks. 
2.4.3.2.3. Differences by age 
The difference in the median number of recorded doses and median 
treatment duration between younger and older patients in both datasets is 
equal to one dose or one week, respectively. This difference is statistically 
significant in the Treatment dataset only. In the Patient Cards dataset the 
differences in the number of doses, treatment duration and time to cure 
between older and younger age groups are not statistically significant (Table 
2.15). 
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2.4.3.2.4. Differences by sex 
In the Treatment dataset the median numbers of recorded doses and 
treatment duration is less for males, with difference of one dose or week , 
respectively, is significant. In the cards dataset the median number of recorded 
doses is ten for both sexes but females seem to have longer duration of 
treatment and time to cure (the latter difference being two weeks). However, 
the differences in the tested parameters in Patient Cards dataset were not 
statistically significant (Table 2.16). 
2.4.3.2.5. Differences by number of lesions at presentation 
Number of lesions at presentation was grouped into two categories: "1 or 2 
lesions" and "3 lesions or more". Although the median values were consistently 
higher in the group with three lesions or more in both datasets, the differences 
were not statistically significant, except for the number of recorded doses in 
Patient Cards dataset (Table 2.17). 
2.4.3.2.6. Differences by health centre 
Treatment registers were available from 13 health centres, cards from 
15 centres (four of them <20 cards each) and both registers and cards from 
7 health centres, and of these, two centres had very low number of cards «10). 
For treatment registers the lowest count of patients from a health centre was 
eighty-five. 
The patients from the seven health centres represent 67.6% of the cases in 
the Treatment dataset and 47.8% of the cases in the Patient Cards dataset. 
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Number of doses 
The differences in median number of doses between the two datasets 
(Figure 2.23) are statistically significant for three of the five PHC centres with 
patient numbers >20 in the Patient Cards dataset, p=O.OO1 for Halab al-Jadidah 
and <0.0001 for Bab and LCe, and not significant for T\ayrab (p=O.744) and 
Salah aI-Din (p=0.068), Mann-Whitney U test. The differences between centres 
within each dataset were statistically significant (p<O.OOO1, Kruskal-Wallis test). 
Duration of treatment 
The differences between the median treatment duration between the two 
datasets (Figure 2.24) were significant for LCC and Salah aI-Din centres 
(p<O.OOO1, Mann-Whitney test). The differences between centres within each 
dataset were statistically significant (p<O.OOOl, Kruskal-Wallis test). 
Time to cure 
The distribution is presented in Figure 2.25. The differences between the 
centres are statistically significant, p=0.002 (Kruskal-Wallis H test). 
2.4.3.2.7. Difference by lesion duration at presentation 
Data on lesion duration were not available in the Treatment dataset, so the 
analysis is restricted to Patient Cards. Lesion duration was categorised into 
three groups: one month or less, two months, and three months or longer. The 
categories contained fairly equal numbers of patients. The results are shown in 
Figure 2.26. 
Patients who reported lesion durations of one month or less required more 
doses and had longer treatment duration and time to cure compared to those 
who reported lesion durations of two months or longer. The differences were 
statistically significant for number of doses and treatment duration (p=O.0002, 
Kruskal-Wallis H test) but not for time to cure (p=0.137). 
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The statistical significance for any of the outcome variables did not change 
when lesion duration was compared between one month or less, on one hand, 
and each of the other two durations alone, on the other. 
The differences between lesion durations of two months vs. three months or 
longer were not statistically significant for any of the three outcome variables 
(p=0.369, 0.134 and 0.823, respectively, Mann-Whitney U test). 
2.5. Discussion 
Analysis of the data showed marked differences between the data sources 
used, and differences between the general population and the population of 
leishmaniasis patients in Aleppo as represented by the Main dataset. 
2.5.1. Observed differences 
2.5.1.1. Demographic variables 
It is postulated that differences between datasets are partly due to the 
nature of each dataset: laboratory registers contain all patients with suspected 
leishmaniasis, which means not all of them will have leishmaniasis confirmed 
and start treatment; an entry in the treatment register appears when the patient 
receives their first injection, which implies they had their diagnosis confirmed 
based on smear result or on clinical examination alone and decided to start 
treatment; and, as only cards that were returned by patients are available for 
analysis, this dataset represents patients who completed their treatment (or, at 
least, is biased in this direction compared to treatment registers). This does not 
exclude other possible biases due to non-randomness of both clinical datasets, 
at least because they represent a non-random selection of health centres. 
A typical patient with cutaneous leishmaniasis in Aleppo is a child or 
adolescent with one non-ulcerated lesion who presents within two months after 
the lesion has appeared. 
The median age of leishmaniasis patients is six to eight years lower than 
th,lt of the general population. In addition, there were statistically significant 
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differences between the three datasets (Figure 2.3 ; Table 2.1). This difference 
may be real, consistent with long-standing endemicity of a disease that confers 
some level of immunity; in this case residents are more likely to acquire 
symptomatic or asymptomatic infection and, hence, acquire immunity at 
younger age (probably, with natural subclinical booster inoculations later). But 
the immune response of patients in the younger age group may also contribute 
to these differences, and may be related to prepubertal hormonal background, 
as evidenced by proportional risk ratios of CL patients: while the group below 
14 years of age is characterised by male-to-female ratio similar to that in the 
general population, in the 15+ age group this ratio is inverted (see Sex 
distribution, p.62). On the other hand, a behavioural explanation should be 
considered: it is possible that older patients make the decision to seek diagnosis 
and start treatment themselves, while in case of younger patients, parents take 
the decision; and in older age groups females may be more likely to seek 
treatment for potentially cosmetically disfiguring condition than males, and 
hence, are more likely to put up with painful injections. 
Age distribution of all leishmaniasis patients from our Main dataset is in 
rough agreement with that reported before [Ashford et al., 1993]. However, the 
details cannot always be compared directly due to some differences in division 
into age groups. Ashford et al. (1993) used general population data from UN 
estimates that gave separate percentages for urban and rural population of 
Syria that were seven years old at the time, and their study population was one 
of the districts of Aleppo city, which may explain the observed differences. In 
<;urukova region of Turkey where cutaneous leishmaniasis is also caused by 
L. tropica, the mean age of 1,030 leishmaniasis patients was 22.4 years (in our 
Main dataset, 17.9 years), and M:F ratio, 40.2:59.8, with more pronounced 
female predominance [Uzun et al., 2004]. 
When sex-specific proportional risk ratios (PRR) for each age group were 
calculated, males of younger ages had slightly higher risk than females, and the 
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curves crossed in the age group 20-24 years (Figure 2.4). For both sexes the 
relative risk drops below 1 starting from age group 15-19 years and remains so 
(linked to puberty?), except for females in age group 50-54 years where a 
distinct peak to PRR value marginally greater than one from a background 
about 0.8 is present. The above is true for Main and Treatment registers 
datasets. This finding may be linked to start of menopause, although in this case 
it would be expected to have persisted in older age groups, too. A more 
plausible explanation would be that this peak, together with a smaller one in 
60-64-year-old age group in the Main dataset, may be due to "borrowing" case 
counts from adjacent groups because the former age groups include the values 
of 50 and 60 years, respectively, and these seem to be stronger attractors than 45 
and 55, especially in the Main dataset (Figure 2.2), but this does not explain 
why similar peaks are not observed among males in the same age groups. In 
addition, data about possible attractor values in census data are not available, 
and their presence cannot be ruled out. Available census data show uneven falls 
of percentages between four age groups, from 40-45 to 60-65 (Figure 2.3), which 
may support the hypothesis of "borrowing" counts by stronger attractors, 50 
and 60 years. Assuming equal strength of attraction in census data and 
leishmaniasis datasets, our data must be automatically corrected for this bias, 
and proportional risk ratios must not be affected, so the peaks remain 
unexplained unless we suppose that females of Aleppo are for some reason 
more likely to round up their ages compared to general female population of 
Syria. Looking at age counts in the Main dataset for males and females 
separately after converting them to percentages would allow calculating ratios 
of percentages. Figure 2.27 shows that females are at least twice as likely to 
report ages of 50 and 60 years compared to males, while the same ratio for 55 
and 65 years is not much different from one. This may partly explain the peaks, 
if females in the Main dataset are different from those in Syrian population. 
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A similar trend in proportional risk ratios, which also fell below one in 15-
19 year age group, is published by Ashford et al. (1993). 
2.5.1.2. Clinical presentation 
Statistically significant differences in number of lesions between the three 
datasets were noted, with fewer patients who present with one lesion in the 
Treatment dataset than in the Main dataset. About half of the patients presented 
with one lesion. In Turkey 76% [Uzun et al., 1999] to 80.7% [Uzun et al., 2004] of 
patients present with one lesion. 
There were statistically significant differences in number of lesions between 
age groups. Older patients present with more lesions on average (Table 2.4). 
This may also reflect the attitudes of patients who may be more likely to bring 
their children for treatment than seek treatment for themselves unless 
/I convinced" by higher number of lesions. However, females seem to present 
with higher number of lesions than males, which is unexpected because the 
former are supposed to be more concerned about possible cosmetic 
consequences. 
About two-thirds of patients present in the first two months (64.7% in the 
Main dataset). In contrast, in Turkey the median lesion duration at presentation 
was five months, and the same proportion, 64.7% reported durations of nine 
months or less [Dr. S. Uzun, 2005, personal communication]. This may reflect 
the efficiency of governmental health education programmes in Aleppo or 
better awareness of the population. Older patients and patients with more 
lesions have significantly longer lesion duration. This may be confounded by 
increasing number of lesions with age, which in turn is associated with later 
presentation. Differences in reported lesion duration between sexes were 
slightly longer in males but not statistically significant. 
It does not appear that more lesions form a greater incentive to seek health 
care and this is contrary to what would be expected. Differences may be even 
greater, given that females in these datasets outnumber males and that the 
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former report marginally shorter lesion duration at presentation. On the other 
hand, females tend to have more lesions than males, and thus must shift lesion 
duration in the >2 lesions group (Table 2.10) further down. 
This may signify that the patients fall into two distinct groups with regard 
to health-service seeking behaviour, that can be named 'careful' and 'careless'. 
The former would seek treatment early in the course of the disease and the 
latter would postpone their health centre visit until long lesion duration and if 
numerous lesions convince them to seek diagnosis. The hypothesis would be 
the latter group are less likely to seek treatment at all if they have few lesions. 
The fact that the difference is more pronounced among treated patients (the 
Cards dataset) is in favour of this hypothesis. The 'careful' patients may also 
care more about returning their cards. 
Smear results were positive in 78% of cases, which is close to 82% reported 
from Turkey [Uzun et ai., 2004]. Smear positivity significantly declined with 
increasing age of patient, which may highlight the differences with Turkey 
where the average age of the patients is higher. Smear positivity was 68% in 
lesion durations of less than one month (which probably include a larger 
proportion of non-leishmania I lesions), then rose to more than 75% in lesions of 
1-4 month duration and fell again to below 70% in durations of five months or 
longer. The decline in parasite numbers with increasing lesion duration was 
noted since the first description of the parasite by P. Borovsky in 1898 [Hoare, 
1938]. There were highly significant differences in smear results between health 
centres. These may be due to patient or disease characteristics and/or due to 
differences in staff experience: a 95% positivity rate in one centre can be 
attributed to false-positives. 
In our data the smear positivity declined with increasing age of the patient. 
A putative explanation for this phenomenon might be that the residents of this 
endemic region are regularly exposed to infectious sandfly bites which in many 
cases result in subclinical infections that confer some immunity to the parasite, 
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that increases with age. If, at older age, they are exposed to an infectious bite 
that results in manifest disease, their partial immunity due to earlier exposure 
results in lower parasite burden and decreases the probability of parasite 
detection by microscopy. This may also explain that overall smear positivity in 
Aleppo is lower than that reported from an adjacent region of Turkey despite 
the fact that the study population in Turkey was older and tended to present 
later [Uzun et al., 2004]. 
Our data suggest that smear-negative patients with longer lesion duration 
at presentation are more likely to be treated on the basis of clinical judgement, 
i.e. despite the negative smear result (Figure 2.16). 
2.5.1.3. Health services 
More than one-quarter of patients in urban health centres lived in rural 
Aleppo. This probably reflects unavailability of leishmaniasis diagnosis or 
treatment in certain villages or the fact that some patients may be unaware 
these services exist in their local health centre or prefer urban health centres. 
Rural health centres served almost exclusively rural residents (99.8"0). These 
data come from the period before health distinct policy was enforced (see 
Structure of relevant health services, p. 26). Overall, about forty percent of all 
patients recorded in 2005 came from rural areas. 
2.5.1.4. Response to treatment 
Both number of recorded doses and treatment duration were significantly 
longer in the Patient Cards dataset compared to Treatment registers. Ten 
percent of the patients recorded in the Treatment registers received only one 
dose, which may illustrate early drop-out rate: probably, many of the patients 
who decide to stop treatment do so after the first one or two painful injections, 
and they would not come to the health centre just to return their card. The same 
shift to the right is noted between the datasets in distribution of treatment 
duration. 
86 
In the Treatment registers, treatment durations distribute over a wide range, 
with maximum of 99 weeks, whereas in Patient cards the maximum recorded 
duration was 50 weeks. This may be due to missing out long courses because 
the cards of those patients were less likely to be returned to LCC, or may reflect 
better overall compliance of the patients who returned their cards in the end of 
the treatment, because they were less likely to miss their appointments. 
A clear peak can be distinguished at six doses and five weeks in Treatment 
registers, probably reflecting a kind of "structuring" of health staff and patients' 
perceptions concerning the appropriate time to evaluate the treatment effect in 
the end of the first six-week course. In Patient Cards dataset the mode is twelve 
doses, corresponding to two courses, VS. six in Treatment dataset, which 
highlights the differences between patients in the two datasets. 
In the Patient cards dataset, patients with known cure date differed from 
those whose cure was not recorded, the latter having significantly longer 
treatment duration and number of recorded doses. This may be due to 
difference of health staff attitudes: patients with slower treatment progress are 
probably less readily rated as cured. The statistical significance of these 
differences also means the results obtained in the subgroup of patients with 
known date of cure cannot be reliably generalised neither to all the patients 
who returned their cards nor to other datasets. 
The median treatment duration, number of recorded doses and time to cure 
was shorter by one (week or dose) in the older, 15+ years, age group, but this 
difference was statistically significant in the Treatment dataset only (p<O.OOOl, 
Mann-Whitney U test). This may reflect that younger patients are brought to 
the centre by adults, and it is more difficult for them to decide to drop out and 
enforce their decision, but a biological explanation might also be plausible. In a 
study of American cutaneous leishmaniasis in Peru it was shown that young 
age was a significant risk factor for treatment failure [Llanos-Cuentas et al., 
2008]. If the fact of returning the card can be used as a proxy for completion of 
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treatment, adults seem less likely to complete their treatment course than 
children, and if the Patient cards dataset tends to over-represent compliant 
patients regardless of age, this may explain the lack of statistical significance. 
However, the Patient cards dataset is smaller, and consequently has less 
statistical power to detect significant differences. 
Females tended to require more doses and longer treatment duration than 
males, and the differences were significant in Treatment dataset only. On the 
other hand, the median time to cure in females was two weeks shorter than in 
males. Although not statistically significant, it is possible that, due to small 
sample size, the significance could not be detected. If they are significant "in 
reality" (Le. were the sample size larger), shorter time to cure in females is 
contrary to the data on recorded doses and treatment duration, and must be 
explained by some other factor, e.g. that the females are more compliant, thus 
more likely to come for treatment appointments on time, and males, if they 
come at all, miss more appointments on average, probably because they are 
more likely to have occupational obligations. This is supported by the 
observation that female-to-male ratio in this subset is nearly 60:40, higher even 
than in total patient cards sample. 
Number of lesions at presentation did not significantly affect the treatment 
course, although patients with three lesions or more had consistently higher 
median values for number of recorded doses, treatment duration and time to 
cure. The only significant difference was the number of recorded doses in the 
Patient cards dataset (Table 2.17). 
The differences in clinical outcomes were significantly different between 
health centres by Kruskal-Wallis test. 
The number of recorded doses and treatment duration, but not time to cure, 
were significantly lower in patients with longer lesion duration at presentation. 
This may either reflect the role of acquired immunity or the natural course of 
the disease. 
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2.5.2. Notes on data sources 
Treatment registers and patient cards were not sufficiently reliable sources 
of data because, first, both were available only from a minority of health centres 
(see Differences by health centre, page 79) and, second, because "Cure" field 
was empty in most instances. This is most probably due to absence of clear 
definition of cure: staff are taught that cure should not be diagnosed until the 
patient has finished their follow-up period. During my work in health centres I 
noticed that at the end of the treatment not all patients are told to come back for 
follow up after one month; usually they were told to come back if they notice 
anything unusual with their treated lesion. Nevertheless, in many instances 
patients finishing their treatment were not recorded as cured in treatment 
registers; they also were asked to keep their patient cards "just in case". In 
addition, the field title ("Cure") in treatment registers may be ambiguous: it is 
not clear if it requires a tick mark, the word "cured" (or "yes"), date of 
provisionary cure (when patient is judged not to require further treatment) or 
date of definite cure after completion of the three scheduled follow-up visits. 
This may explain both the very low rate of recording date of cure and of 
returning patient cards. In addition, because these data are not analysed 
routinely, the staff get no feedback about the missing, incomplete or incorrect 
data, so have little incentive to improve data quality. In addition, there are 
currently no facilities for classifying and storing patient cards in health centres. 
In LCC received patient cards are pooled without classification and stored in 
cardboard boxes. 
Possible biases of data from treatment registers and patient cards make 
them unsuitable for generalising the results to Aleppo CL population. Yet 
despite these defects, and partially thanks to them, these differences mav 
provide some insights into underlying causes. 
Figure 2.2 shows raw age distribution in datasets. Notable peaks in case 
counts of ages divisible by 10 and 5 suggest that patients (and/or staff) tend to 
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round patient's age to the nearest 5 and the nearest 10 years. Another 
theoretically possible explanation is that patients are not asked about their age, 
and health centre staff record their own rounded estimates; but in reality staff 
do ask about the patients' age. This illustrates possible inaccuracies in patients' 
reporting of other information about themselves, e.g. lesion duration. But raw 
distribution of lesion durations showed only one attractor value: at 12 months. 
Other contributing factors may be decrease of smear positivity rate with age 
(Figure 2.15), which, in turn may be confounded by the fact that older patients 
tend to report longer lesion duration at presentation, which is also associated 
with decline in positivity rate (Table 2.10). More sophisticated statistical 
analysis of available data may reveal relative importance of above-mentioned 
factors. 
Another explanation for younger age of CL patients may lie in differences in 
treatment-seeking behaviour: younger patients are usually brought to health 
centres by parents or other related adults; it is the latter who take decision both 
for seeking health care and treatment on behalf of children. It can be speculated 
that the same adults may pay less attention to their own minor ailments. This 
hypothesis cannot be tested using available data, although some indirect 
evidence may be interpreted in its favour: for example, differences in number of 
treatment sessions between treatment registers and patient cards, Table 2.14, 
may indicate that adults are more likely to prematurely stop treatment; on the 
other hand, mean number of treatment sessions is similar between both age 
groups in Patient cards dataset (0.1 doses) unlike Treatment registers (where 
the difference is close to one dose), which may indicate that compliant patients 
in both age groups need about the same number of doses until discharge; and 
there are even smaller differences between age groups in the Patient cards 
dataset with regard to duration of treatment. 
Differences between centres in the number of recorded doses (Figure 2.23) 
are striking, and the ratio between Treatment and Patient cards datasets varies 
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widely, being largest at LCC, indicating low card return rate. This may be 
explained, however, by the policy applied in 2005, when diagnosed patients 
were given the first injection immediately, issued a card and referred to a health 
centre near their home. And Nayrab health centre is unique because of higher-
than-one ratio between mean numbers of doses. 
This may indicate differences in practices between health centres or 
differences in patient characteristics. Differences in time to cure cannot be 
analysed reliably due to low numbers of cards available from each (maximum 
32 cards, Figure 2.25), although it is tempting to note that al-Jalaa health centre 
requires more than five weeks less than average to cure its patients. 
Time to cure was longer by 2-3 weeks than average for patients with lesion 
duration at presentation of one month, while it was slightly less than average 
for those who reported lesion durations of 2 or more months at presentation. 
This may be an indicator of developing immunity in the course of the disease. 
Data from three different sources about the 2005 population of cutaneous 
leishmaniasis patients in Aleppo were compared. Several interesting patterns 
were noted. But due to incompleteness of this data the significance of observed 
differences cannot be known. This applies especially to details of clinical course 
of CL in Aleppo: time to cure cannot be reliably estimated. Patient cards with 
marked cure date might provide the best estimate but the available sample is 
clearly biased. This would justify a more robust data collection and analysis. 
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2.6. Tables 
Mean 
Table 2.1. Age, mean values and quartiles: Syrian population 
(census 2004), and main dataset, treatment registers, patient cards 
and patients with known cure date (2005). 
Census Main Treatment Patient cards Known cure date 
unknown 17.94 16.48 16.62 17.42 
25th percentile 9 6 5 6 7 
Median 19 13 11 12 12 
75th percentile 33 25 23 22 23 
Table 2.2. Sex distribution in Syria and Aleppo according to 2004 
census, and in the data sets of 2005 leishmaniasis patients. 
Syria Aleppo Main Treatment Patient cards Known cure date 
Males 
Females 
51.1 51.5 47.7 48.9 43.2 -to.7 
48.9 48.5 52.3 51.1 56.8 59.3 
Table 2.3. Distribution of patients by place of residence between 
urban and rural health centres (Main dataset). 
Patients residence 
Centre location Urban Rural Total 
Urban 
Rural 
Total 
Dataset 
8587 (72.9%) 3200 (27.1 %) 11787 (100%) 
4 (0.2%) 2577 (99.8%) 2581 (100%) 
8591 (59.8%) 5777 (40.2%) 14368 (100%) 
Table 2.4. Mean and median number of lesions in two age groups in 
the three data sets. 
Mean Median Mann-Whitney U 
Ar,;c r,;roup 0-14 15+ 0-14 15+ 
Main 1.9 2.5 1 2 p<O.OOOl 
Treatment 2.0 2.8 1 2 p<O.OOOI 
Cards 1.9 2.2 1 2 p = 0.015 
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Dataset 
Main 
Treatment 
Cards 
Variables 
Sex 
Age group 
Lesion noted 
Table 2.5. Mean and median number of lesions by sex in the three 
datasets. 
Mean Median Mann-Whitney U 
Sex M F M F 
2.18 2.31 1 1 p=O.0004 
2.26 2.39 1 2 i p=O.251 
1.93 2.08 1 1 p=O.045 
Table 2.6. Regression analysis of factors that affect number of 
lesions (one or two vs. three or more). 
Univariate analysis Multivariate anal sis 
CL CL 
Category* OR lower upper p OR lower upper 
Female 1.180 1.094 1.273 <0.0001 1.140 1.056 1.231 
p 
0.001 
15+ tfears 1.678 1.556 1.810 <0.0001 1.677 1.553 1.810 <0.0001 
Dec - July 0.611 0.565 0.659 <0.0001 0.608 0.562 0.657 <0.0001 
* The reference categories were assigned as follows: sex, male; age group, 0-14 years; calculated month 
of lesion appearance ("lesion noted"): August to November. OR, odds ratio. 
OR, odds ratio; eL, 95% confidence limits. 
Table 2.7. Lesion locations by sex. One lesion section: patients with 
one lesion. The One location section: patients whose lesions were 
confined to one location, whether solitary or multiple. The 
percentages add up to less than 100% for each sex because other 
locations are excluded. Any lesions on face section shows the data 
for the complete dataset, comparing patients who had any lesions 
on face with those whose lesions were in other locations. 
Male Female p <X2) 
Lesion location One lesion (n=7,650) 1 lesion 
Face 44.8% 41.9% 0.01 
Hand 34.3% 39.6% <0.0001 
Leg 16.3% 16.7% 0.652 
% of total 95.4% 98.2% 
One location (11=12,176) 
Face 44.7% 38.0% <0.0001 
Hand 35.9% 45.0% <0.0001 
Leg 16.1% 15.6% 0.481 
o~ of total 96.7% 98.6% 
Any lesions on face (n=14,36S) 
Face 46.8% 40.4% <0.0001 
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Table 2.8. Lesion locations by age group. The One lesion section: 
patients with one lesion. The One location section: patients whose 
lesions were confined to one location, whether solitary or multiple. 
The percentages add up to less than 100% for each age group 
because other locations are excluded. Any lesions on face section 
shows the data for the complete dataset, comparing patients who 
had any lesions on face with those whose lesions were in other 
locations. 
Age group 0-14 years 15+years 
-.£ <Xl) 
Lesion location One lesion (n=7,650) 
Face 
Hand 
Leg 
% of total 
Face 
Hand 
Leg 
% of total 
Face 
55.9% 24.8% 
25.0% 54.8% 
15.3% 18.3% 
96.2% 97.9% 
One location (n=12,176) 
57.9% 19.6% 
24.3% 61.8% 
14.9% 17.1% 
97.1% 98.5% 
Any lesions on face (n=14,366) 
59.4% 23.7% 
Table 2.9. Regression analysis of factors that affect lesion location 
(face vs. non-face). 
<0.0001 
<0.0001 
0.0005 
<0.0001 
<0.0001 
0.0008 
<0.0001 
Univariate analysis Multivariate anal sis 
CL CL 
Variables Category* OR lower ,:!££er p OR lower upper p 
Sex Female 0.769 0.720 0.822 <0.0001 0.812 0.756 0.872 <0.0001 
Age group 15+]Lears 0.213 0.198 0.229 <0.0001 0.217 0.202 0.234 <0.0001 
Lesion noted May-Aug 0.579 0.527 0.636 <0.0001 0.609 0.552 0.673 <0.0001 
Sep - Dec 1.131 1.050 1.218 0.001 1.135 1.048 1.229 0.002 
* The reference categories were assigned as follows: sex, male; age group, 0-14 years; calculated month 
of lesion appearance ("Lesion noted"): January to March. 
OR, odds ratio; eL, 95% confidence limits. 
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Age 
Sex 
Number of 
lesions 
Table 2.10. Mean lesion duration at presentation (in months) in the 
subgroups by age, sex and number of lesions. The median values 
are 2 months in all the subgroups. 
Mean lesion duration at presentation (months) 
Main p value* Cards p value* 
0-14 2.60 
<0.0001 2.51 
15+ 3.22 3.01 
0.025 
M 2.91 0.126 2.93 0.305 
F 2.85 2.54 
1 or 2 2.85 
<0.0001 2.54 0.001 
3+ 2.94 3.28 
,. Mann-Whitney U test. 
Table 2.11. Mean reported lesion duration at presentation (months) 
by lesion location in patients with solitary or multiple lesions in 
one of the three most common locations, compared to those with 
lesions in other locations. The last two columns compare patients 
with any lesions on face with those who had no lesions on face. The 
median values were equal to 2 months in all cells, p<O.OOOl (Mann-
Whitney test) for all comparisons. Yes and No refer to the lesion 
locations in rows. 
One lesion One lesion Any lesion(s) 
or more on face 
Lesion location lfes no yes no lfes 110 
Face 2.51 3.15 2.51 3.11 2.56 3.12 
Hand 3.11 2.74 3.07 2.73 
Leg 3.21 2.81 3.19 2.81 
Table 2.12. Smear results in the Main dataset and Patient cards. 
Smear result 
Dataset Pos Neg 
Main 78.0% 22.0% 
Patient Cards 90.6% 9.4% 
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Table 2.13. Odds ratios (OR) of smear positivity in five age groups. 
The youngest age group serves as the reference category. 
Univariate ana!ysis Multivariate anal, sis 
CL CL 
A&e~oup* n OR lower upper ~ OR lower uHer P 
0-9 5446 1.000 <0.0001 1.000 <0.0001 
10-19 4043 0.752 0.679 0.832 <0.0001 0.749 0.677 0.830 <0.0001 
20-29 1991 0.666 0.588 0.753 <0.0001 0.676 0.597 0.766 <0.0001 
30-39 1202 0.656 0.565 0.761 <0.0001 0.657 0.566 0.763 <0.0001 
40+ 1684 0.505 0.445 0.572 <0.0001 0.503 0.444 0.571 <0.0001 
* The age group 0-9 years IS the reference category, the corresponding p value IS for the overall 
regression model. The multivariate analysis model included lesion duration at presentation and 
health centre location (urban vs. rural). 
OR, odds ratio; CL, 95% confidence limits. 
Table 2.14. Comparison between recorded doses, treatment duration 
and time to cure in the Treatment register (n=2145) and Patients 
cards (n=498) datasets. Treatment duration and time to cure are in 
weeks. Time-to-cure data were available for 189 patients. 
Recorded doses Treatment duration Time to cure 
Dataset Treatment Cards Treatment Cards 
Mean 6.80 11.61 10.02 15.40 
Percentile: 
10 1 5 0 5 
25 3 7 3 8 
median 6 10 7 12 
75 9 15 14 23 
90 12 20 22 30 
Maximum 24 40 99 50 
Table 2.15. Median values by age group of the number of recorded 
doses and duration of treatment in Treatment and Patient Cards 
datasets, and time to cure in the Patient Cards dataset. Treatment 
duration and time to cure are in weeks. 
Age ro~ p* 
0-14 15+ 
Recorded Treatment 7 6 
doses Cards 10 11 
Treatment Treatment 8 7 
duration Cards 12 12 
Time to cure Cards 19 17 
* Mann-Whitney U test 
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Cards 
19.58 
9 
12 
18 
27 
32 
50 
<0.0001 
0.667 
<0.0001 
0.696 
0.198 
Table 2.16. Differences between sexes in the number of recorded 
doses, treatment duration and time to cure. 
Sex po. 
M F 
Recorded doses Treatment 6 7 
Cards 10 10 
Treatment Treatment 7 8 
duration Cards 11.5 13 
Time to cure Cards 19 17 
* Mann-Whitney U test 
Table 2.17. Differences in recorded doses, treatment duration and 
time to cure according to number of lesions at presentation. 
Lesions at presentation po. 
lor 2 3 or more 
Treatment 6 7 Recorded doses 
Cards 10 12 
Treatment Treatment 7 8 
duration Cards 12 14.5 
Time to cure Cards 17 19 
* Mann-Whitney U test 
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0.0002 
0.919 
<0.0001 
0.690 
0.522 
0.333 
0.026 
0.778 
0.180 
0.290 
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Figure 2.1 . Schematic map of health centres that treat lei shmaniasis 
patients in Aleppo city and coutryside as of 2004. Locations of 
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Chapter 3. Clinical course of 
leishmaniasis in Aleppo 
3.1. Introduction 
Cutaneous leishmaniasis (CL) has been endemic in Aleppo for centuries. 
The first known recognisable description of the disease and its clinical course, 
under the name mal d'Aleppo, was published in 1756 by Alexander Russell who 
lived in Aleppo for thirteen years [Russell, 1856]. He noted that the disease was 
not restricted to the city of Aleppo, " ... being almost as common at Antab, and all 
the other villages on the banks of the rivers Sejour and eoick, as at this place; 
which favours the opinion of it being occasioned by the \\"Llter." He also 
mentioned that "[t]he natives call it Habbt il senne, or Botch of n year, from the 
supposed time of its duration." This vernacular name is still common until 
present in Aleppo; outside Aleppo in Syria it is known as "habbet Halab", or the 
sore of Aleppo [Elgood, 1934]. 
In 1929, T. Canaan wrote: "The disease in Aleppo is so common as to be 
proverbial amongst the Arabs of Syria and Palestine" [Canaan, 1929]. Several 
years later the same (about Syria and Lebanon) was mentioned by 
Hovnanian [Hovnanian et al., 1937] who described an outbreak of cutaneous 
leishmaniasis in Aleppo in a community of refugees with disease prevalence of 
43%. 
Cutaneous leishmaniasis in Aleppo is caused by Leishmania tropica, and the 
putative vector is Phlebotomus sergenti [Ashford et al., 1993]. Leishmania tropica is 
generally believed to be anthroponotic [Desjeux, 2001]. As reviewed in 
Chapter 1 and Table 1.3, L. tropica infection tends to run a longer course 
compared to L. major, and is more likely to cause chronic disease or relapse after 
apparent cure [Herwaldt, 1999]. No other causatiw agents nor leishmaniasis 
forms were identified in Aleppo Governorate to date, although a few cases of 
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infantile visceral leishmaniasis are recorded in small foci in adjacent coastal 
(Lattakia and Tartous) and Idlib governorates. The forms encountered in Syria 
are also reviewed in more detail in Chapter 1. 
It is believed that insecticide spraying as part of malaria control efforts in 
1950s lead to a concomitant fall in leishmaniasis cases in Syria Ualouk et al., 
2007]. During the following years only a few hundred cases were reported from 
Aleppo, but from 1985 there was a considerable rise in the reported incidence of 
leishmaniasis that could not be fully attributed to improved case detection and 
reporting [Ashford et at., 1993]. Three peaks over 8,000 cases occurred in 1991, 
1994 and 2001, and more than 11,000 cases in 2003-2005, despite two campaigns 
of insecticide spraying every year. 
This huge number of cases in a large city could not be managed by one 
specialised control centre. For this reason, leishmaniasis diagnosis and control 
facilities were introduced into an increasing number of primary health care 
(PHC) centres. Due to logistic constrains, not all of these have laboratory 
diagnostic facilities but a member of staff was trained to administer 
intralesional injections to the patients from the catchment area of the PHC 
centre, who were diagnosed elsewhere: either at the main Leishmaniasis 
Control Centre (LCC) or in a nearby PHC centre where CL diagnostic facilities 
are available. 
Cutaneous leishmaniasis in Syria is diagnosed clinically and confirmed by 
the detection of amastigotes in a Giemsa-stained smear from lesion scraping 
examined under immersion. The patients who have lesions from which the 
parasites were detected by this method are termed smear-positive, and those in 
whose smears no amastigotes could be seen, smear-negative. For the purpose of 
this study, we also cultured biological material from the lesions. The patients 
from which promastigotes were detected in the culture medium will be termed 
culture-positive and those in whose cultures promastigotes could not be 
detected, culture-negative. 
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Our attempt to examine the demographic and clinical characteristics of 
leishmaniasis patients in Aleppo based on routinely collected data, as well as 
the relationship between them and the treatment course, is described in 
Chapter 2, where the weaknesses of each dataset is discussed. Thus, we aimed 
at examining the same relationships in a sample of patients which is smaller but 
followed up more closely. 
The study proposal and data collection instruments were reviewed and 
approved by the Ethical Committees at LSHTM and Syrian Ministry of Health. 
3.2. Materials and methods 
Patient recruitment, examination and follow up was performed by one 
investigator. This imposed certain limitations on the work schedule. Cutaneous 
leishmaniasis is treated in Aleppo by intralesional injections of Glucantime:B' 
(meglumine antimoniate) once a week, so that patients who receive an injection 
on a certain weekday would normally receive their next injections on the same 
weekday. 
Given this, during the work-week up to five health centres could be covered 
but it was decided to leave one day free for the laboratory work necessary for 
culturing the clinical isolates (see Chapter 4). For this reason, four health centres 
needed to be selected as study sites. 
3.2.1. Sample size 
Because no information was available on variation in time to cure, variation 
in drug sensitivity of Leishmania tropica or the association between treatment 
duration and parasite sensitivity, rather arbitrary assumptions had to be made. 
Since neither clinical nor drug sensitivity characteristics were known, the 
calculations were made to detect possible relationships between Leishmania 
drug sensitivity and clinical outcome. For the purpose of simplification, the 
sensitivity was categorised into tolerance and intolerance, the division between 
the t\\l) to be made either by median sensitivity as determined by the fifty-
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percent effective concentration (ECso) or, in case of bimodal distribution, 
according to the range of numbers in each group; and the clinical response into 
cure or non-cure at a set time point close to median treatment duration. Cure is 
defined in the section 3.2.5. Baseline and follow-up data below. The median 
treatment duration was expected to be roughly equal to one treatment course of 
six or eight doses. This duration was based on personal communications with 
Dr. Lama Jalouk (Syria) and Dr. Soner Uzun (Turkey). 
Assuming that proportion of laboratory parasite tolerance in treatment 
failures equals 40% and in treatment successes 5%, Epilnfo (version 6, CDC, 
Atlanta, Georgia, USA) sample size calculator suggested two equal groups of 27 
patients each. Assuming baseline culture positivity rate to be around 
25% [Alrajhi et al., 2002], about two hundred patients should be recruited. 
However, our baseline culture success rate approached 70% which allowed us 
to decrease the minimum sample size. 
3.2.2. Selection of PHC centres for the study 
To cover different study areas, two centres from the countryside and two 
from the city were to be selected. These centres were to be located in non-
adjacent areas. 
The number of patients reported by the health centres of Aleppo were 
examined (Appendix 2). Since it could be expected that an unknown proportion 
of patients might refuse to participate in the study, and of those who agree to 
participate an unknown proportion would drop out, the centres for the current 
study were selected that report large number of leishmaniasis patients. 
However, some PHC centres would diagnose CL in patients from outside 
their catchment area, and then refer these patients to a PHC centre that treats 
CL ne,lr the patients' place of residence. These patients would be reported by 
the PHC centre that performed the diagnostic smear. For this reason, the centres 
that only have treatment, but not diagnostic, facilities, report no patients. 
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The centres that reported the highest numbers of patients were contacted 
and visited to obtain a clearer idea of the actual number of patients treated 
there, and the centres that mainly diagnosed and treated patients from their 
own catchment area, i.e. where the patients were more likely to continue 
treatment in the same PHC centre, were preferred. In the city, one of the 
candidate centres was closed for refurbishment, and another centre served a 
population which included a considerable proportion of immigrants from 
nearby villages who were likely to leave for their villages for several weeks 
during harvest seasons. In the countryside, Hritan centre, in fact, diagnosed 
cases from several nearby villages and referred them to local health centres for 
treatment, and these cases constituted about half of the reported patients. 
Finally, the two centres selected in the city were Yousef al-Azmeh (in the 
north-east) and the Specialised Centre for Skin Diseases in Hamadaniyyeh 
(south-west), and in the countryside, PHC centres of Atareb (a town about 
30 km to the WSW of Aleppo with population about 20,000) and Kafr Hamra (a 
village 7.5 km NW of Aleppo with a population about 9,000). The latter location 
was considered an emerging focus of CL, and treatment, but not diagnostic, 
facilities were introduced into its PHC centre in that year - a member of staff 
was trained to administer intralesional treatment for patients diagnosed 
elsewhere but no laboratory was equipped and no one of staff was trained to 
prepare and read smears. In the latter centre we introduced diagnostic services: 
once a week, during our visit, smears were prepared from the lesions of all the 
patients that sought diagnosis, and these smears were then taken to LCC where 
they were examined microscopically, and the results were reported to Kafr 
Hamra PHC so the patients might start treatment without having to leave their 
village for diagnosis. The population was informed about the availability of 
diagnosis on a certain weekday by announcements made from minarets. 
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3.2.3. Patient eligibility 
The patients were eligible for the study if they agreed to participate, had not 
more than five lesions, had not received antimonial treatment for this instance 
of disease (i.e. patients with history of previous cured CL, whether treated or 
not, would be included if they were not treated for their current CL) and health 
centre staff deemed them eligible for intralesional treatment in this health 
centre. In addition, it was required that parasites be demonstrated in lesion 
smears and/or by culture, so the patients with negative smear results were 
considered conditionally eligible until culture results became available. If the 
culture became positive, the patient was contacted and invited to start 
treatment. If the staff made a decision to start treatment of a smear-negati\"e 
patient on clinical grounds, the patient would be followed up" If during this 
provisional follow-up the patient became ineligible, they were excluded. For 
example, one patient who had five lesions and was negative by smear was 
contacted after her culture became positive, and when she came she presented 
four new lesions for a total of nine, and was excluded from the study. 
3.2.4. Recruitment and consent 
The purpose of the study and the expected procedures were explained to 
every patient or, in case of children, to their parent or accompanying adult, and 
any additional questions answered. It was also explained that the patient's 
decision would not affect in any way the quality of care, and that the patient is 
free to withdraw from the study at any time. The consent form also included 
points concerning the photographic images obtained in the course of treatment, 
and the patients had a chance to accept or refuse photography altogether or of 
certain lesions, and could accept or refuse possible specific uses of photographs, 
such as other research uses, teaching, publication in medical periodicals or 
publishing on the internet, provided the images would not allow the 
identification of the patient. Informed consent was obtained and the form 
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signed by literate adult patient or adult guardian (Appendices 3 and 4). If the 
patient or guardian were illiterate, the consent form was signed by two 
members of PHC centre staff who witnessed the consent. 
The aim was to invite every new eligible patient to participate in the study. 
However, when the patients were too numerous during the peak season, those 
who came while another new patient was being interviewed, and the interview 
was unlikely to be finished soon, these candidates were not invited, so that 
minimum disruption was caused to patients and health centre staff. The 
maximum reasonable number of patients that could be recruited on a single day 
would not usually exceed six. 
3.2.5. Baseline and follow-up data 
After obtaining consent from the patient or accompanying adult, basic 
demographic, education and clinical presentation data were recorded in a 
specially designed questionnaire (Appendices 5 and 6). In addition, patient's 
telephone numbers were obtained. The adult patients or the adult 
accompanying minors were also questioned about their knowledge, attitudes 
and practices with regard to the disease (presented in Chapter 5). 
Patients who missed an appointment or did not tum up until about noon 
were contacted by telephone. If they could not make today's appointment, they 
were asked to come in the next week. 
The patient's lesion was measured at baseline, then before every injection 
during the course of treatment. Measurements were performed with a pair of 
dividers and a ruler. Two measurements were made for each lesion: the length 
(the longest diameter) and the width (the longest perpendicular to the length) of 
the outer palpable border of the lesion. If there was any redness surrounding 
the palpable lesion, this was considered beyond the lesion borders. The lesion 
was photographed with a digital camera (an eight-megapixel Sony DSC \\'-100), 
with a ruler v,ith patient ID and date of visit visible in the frame. 
122 
For every injection, an attempt was made to assess the quality of drug 
administration. 
Several authors agree that the drug should be injected (1) into upper and 
mid-dermis (2) from different sides of the lesion (3) using a fine-bore (insulin) 
needle; (4) new needle must be used for each injection; (3) complete blanching 
of the lesion must be achieved; (6) necrotised tissues should not be 
injected [Dowlati, 1996; Alkhawajah et al., 1997; Gurei et al., 2000; Ministry of 
Health (Syria), 2003; Blum et al., 2004]. 
In practice, the above-mentioned points are emphasised in Aleppo, except 
using a new needle for each injection: when the patient needs more than one 
injection, they are all performed with the same needle, unless the syringe needs 
to be refilled: a used needle is not introduced into the drug vial or ampoule, 
which serves more than one patient. 
Each of the five points was assessed, whenever possible, on a binary yes/no 
(1/0) scale, and a binary five-digit number was recorded in a special field for 
each treatment session. 
For non-ulcerated lesions, the cure was defined as disappearance of the 
infiltrate, so that the lesion cannot be detected by palpation. For ulcers, the 
additional condition was complete re-epithelialisation of the ulcer surface. In all 
cases, the lesion must be judged as cured by the health centre staff who are 
actually responsible for patient management. Date of cure was the first date on 
which the patient was seen as cured. This might happen either during a 
treatment course or after a scheduled or non-scheduled treatment break. 
3.2.6. Data entry 
The data were entered into EpiData version 3.1 (The EpiData Association, 
Odense, Denmark) by two persons. The data from the questionnaires were 
dictated aloud by one person (Dr. J. Abazid, a dermatologist), and repeated 
aloud while being entered by the other (myself). The first person checked the 
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data while they were entered, then the next piece of data was dictated. EpiData 
files were exported to Microsoft Excel workbook format, readable by SPSS. 
3.3. Results 
3.3.1. Sample description 
One-hundred thirty-two patients were enrolled in the study. Of these, 
twenty-five patients had lesions from which no parasites had been seen on 
smear or grown on culture (defined as negative both by smear and culture), and 
were excluded, leaving 107 patients in the sample. Of these, 81 patients had 
lesions from which parasites had been seen on smear and grown on culture 
(defined as positive by smear and culture), six positive by smear only and 
twenty by culture only. For patient inclusion purposes any culture with 
detectable promastigotes was counted, including those contaminated with 
bacteria, yeasts or moulds, that were later destroyed and discarded. 
Demographic and clinical presentation characteristics of the patients 
included in and those excluded from the study are presented in Table 3.1. 
Included patients had significantly fewer lesions (mean, 2.13 us. 2.68, median 2 
us. 3, p=0.031, Mann-Whitney U test), were more likely to be males (56.1 % us. 
28%, p=O.Oll, Pearson's Xc), more likely to have lesions on the face (53.3% vs. 
20%, p=0.003, Pearson's X2) and less likely to have lesions on the lower 
extremities (16.8% us. 30.6%, p=0.032, Pearson's X2). The differences in age, 
reported lesion duration at presentation, lesion locations on the upper 
extremities, trunk, ears or neck, lesion type (papule us. ulcer) and the location of 
the primary health centre (urban ;:'5. rural) were not statistically significant. 
Forty-five patients (34.1 %) presented with one lesion. 
The analysis that follows will be restricted to the patients that met our 
inclusion criteria, unless stated otherwise. 
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3.3.2. Demography 
Patients' ages ranged between less than a year to seventy years. Due to 
relatively small number of patients, year-by-year description of age distribution 
was not feasible because most ages occurred only once or twice, and the 
maximum frequency was eight (for three-, nine- and ten-year-olds). The 
patients were divided into two groups: 0-14 and 15+ year old. 
The age was significantly higher in the urban health centre patients 
compared to rural, but was not different between sexes (Table 3.2). 
The proportion of males was higher in urban compared to rural centres but 
the difference was not statistically significant (62.0% VS. 50.9%, p=0.247, 
Pearson's X2). 
The patients in Kafr Hamra centre were significantly younger than those in 
the other study locations (median age 7 VS. 14 years, p=0.0002, Mann-Whitney 
U test). The differences between the other centres were not significant (p=O.232, 
Kruskal-Wallis test). 
3.3.3. Clinical presentation 
3.3.3.1. Lesion location 
More than half of the 107 eligible patients (57, or 53.3%) had lesions on the 
face, and fifty-five patients (51.4%) on the upper extremities. Lesions on the 
lower extremities were encountered in eighteen (16.8%) patients, and on the 
neck, ears and trunk in seven, five and three patients, respectively. 
Lesion locations were not statistically different between sexes nor between 
health centres (urban vs. rural). For age groups, the younger age group was 
significantly more likely to have lesions on the face (67.6% I'S. 28.2%, p<O.OOOl, 
Pearson's Xc) and less likely to have lesions on the upper extremities (38.2% vs. 
74.4(~), p=0.0003, Pearson's X2). For the other locations, the differences were not 
statistically significant (Table 3.3). 
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3.3.3.2. Number of lesions 
The mean number of lesions in our sample was 2.13, and the median, 2. The 
differences in numbers of lesions between sexes, younger and older patients or 
health centre locations were not statistically significant. 
3.3.3.3. Lesion duration at presentation 
The mean lesion duration in our sample was 2.74 months, and the median 
two months. The only statistically significant difference was between males and 
females, with the males reporting a shorter lesion duration than females (mean 
2.51 VS. 3.04, median 2 vs. 3, p=O.Oll, Mann-Whitney U test). 1\:0 significant 
differences by age, lesion location, number of lesions or health centre location 
were detected (Table 3.4). 
3.3.3.4. Smear result 
Since the positivity of smear or culture was one of our inclusion criteria, this 
analysis includes the recruited patients that were later excluded from the study 
due to negative smear and culture. 
Mean and median values of continuous variables (age, number of lesions 
Zlnd reported lesion duration at presentation) in smear-positive and smear-
negative patients were calculated and the significance of the differences 
examined using Mann-Whitney U test. Categorical variables (sex, health centre 
location and lesion location on the face us. no lesions on the face) were cross-
tabulated and the significance of the differences examined using Pearson's Xc. 
No differences were statistically significant. 
When the health centres were analysed separately, the smears were positive 
in 22/24 patients (91.7%) in Atareb, 13/16 patients (81.2%) at the Specialised 
Centre for Skin Diseases, 27/50 patients (54%) in Kafr Hamra and 26/42 patients 
(61.9%) in Yousef al-Azmeh, and these differences were statistically significant 
(p=0.006, Pearson's Xc). The patients diagnosed at Kafr Hamra centre were 
significantly less likely to have a positive smear result compared to other 
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centres, although their smears were read by dedicated laboratory staff at the 
Leishmaniasis Control Center (p=0.016, Pearson's X2). 
Lesion duration at presentation was shown in Chapter 2 to affect smear 
result, with highest positivity rates in lesion duration of two months. So lesion 
durations were categorised into three categories, of durations of one month or 
shorter, two months and three months or longer, and analysed by binary 
logistic regression with the lesions of one month or shorter selected as the 
reference category. The lesions of two months' duration were significantly more 
likely to r~sult in positive smears (odds ratio 2.91,95% confidence interval 1.04-
8.15, p=0.041) compared to those of shorter durations, and lesions of three 
months or longer did not differ significantly from the reference category (odds 
ratio 1.11, 95% confidence interval 0.48-2.57, p=0.808). 
3.3.3.5. Culture result 
This section includes all the patients who were recruited, both those who 
were included in the final analysis and those who were excluded due to 
negative smear and culture results. 
The analysis was conducted as for the smear result above. The results are 
presented in Table 3.5. The only significant association was lesion location on 
the face: the culture was positive in 87.1 % of patients who had any lesions on 
the face vs. 65.7% of patients who had no lesions on the face (p=0.004, Pearson's 
X2). 
Again, the Kafr Hamra health centre provided significantly less positive 
cultures, 66% vs. 81.7% in other centres (p=0.041, Pearson's X2). The differences 
between the other health centres were not statistically significant (p=O.184, 
Pearson's X2). 
Analysing the relationship between lesion duration at presentation and 
culture result by logistic regression did not show statistically significant 
differences. Compared to the reference category with lesion durations of one 
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month or less, the patients with lesions of two month duration had odds ratio of 
positive result of 1.08 (95% CI 0.402-2.89, p=0.879). 
The relationship between laboratory results and lesion type (papule <'s. 
ulcer) could not be analysed because biological material was obtained from 
ulcers in only five cases, and of these two were positive by smear and three by 
culture, and only one patient was positive by both methods. 
3.3.3.6. History of previous cutaneous leishmaniasis 
Nine patients reported previous leishmaniasis which was treated in eight of 
them. The only untreated patient was a seventy-year-old lady who had 
leishmaniasis in childhood that cured spontaneously. Previous leishmaniasis 
occurred in the treated patients one to five years before the index lesions, and in 
one of them the new lesion appeared one month after she finished the treatment 
for the previous instance. 
The patients who had previous leishmaniasis did not differ significantly 
from those who presented with the first instance of the disease with regard to 
age, lesion duration or treatment but the number of lesions was significantly 
higher in patients who reported no previous leishmaniasis (Table 3.6). 
3.3.4. Clinical course 
3.3.4.1. Description of the sample 
Treatment duration and time to cure were calculated in the same way as in 
Chapter 2: treatment duration was obtained by subtracting the date of first 
treatment session from the date of the last treatment session. This gave the 
number of days of treatment. To convert to weeks, three was added to the 
result, then it was divided by seven and the integer was taken as number of 
weeks. Time to cure was calculated in a similar way, with the difference that the 
date of first treatment session was subtracted from the date when the cure was 
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diagnosed. This variable was available only for the patients who finished their 
follow-up until they were told by the health centre staff they were cured. 
One hundred and seven patients met inclusion criteria. For these patients, 
the number of treatment sessions, treatment duration and time to cure is 
analysed. 
Of these patients, nine (8.4%) did not start treatment (zero visits), and were 
excluded from further statistical analysis, so treatment duration and number of 
visits data were available for 98 patients. 
Data on date of cure (and, hence, on time-to-cure) were available for fifty 
(46.7%) patients. 
3.3.4.2. Description of clinical variables 
For all patients who started treatment mean, median and mode for the 
number of treatment sessions, treatment duration and time to cure were 
calculated. In addition, for patients whose time to cure was known, the period 
between the last injection and the diagnosis of cure was calculated. This period 
will be referred to as convalescence. The latter three variables are expressed in 
weeks. 
The number of treatment sessions and treatment duration were available for 
98 patients, and time to cure and convalescence for fifty patients. The results are 
presented in Table 3.7. 
The patients whose date of cure was known were compared to those v"ho 
were lost to follow-up, and the results are presented in Table 3.8. The former are 
termed coll/plete follow-up and the latter, incomplete follow-up. The patients with 
incomplete follow-up were significantly older (median, 15 l'S. 9 years), had 
fewer lesions, attended significantly less treatment sessions and had 
significantly shorter duration of treatment. The differences in lesion duration at 
presentation, sex composition and lesion location (any lesions on the face us. no 
lesions on the face) were not statistically significant. 
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3.3.4.3. Differences by age and sex 
Mean and median values for the number of treatment sessions, treatment 
duration and time to cure were calculated and the medians compared between 
age groups (0-14 years and 15+ years) and sexes by Mann-Whitney U test. The 
results are presented in Table 3.9. Younger patients had more treatment 
sessions, longer treatment duration and time to cure and shorter convalescence 
compared to the older patients, and the differences were statistically significant 
(p=O.OOO1, 0.01, 0.037 and 0.027, respectively). Females had more treatment 
sessions, longer treatment duration and time to cure and shorter convalescence 
compared to males, but the differences were not statistically significant. 
3.3.4.4. Differences by lesion location 
This was analysed for all patients where those who had any lesions on the 
face were compared with those who had no lesions on the face, then for patients 
with one lesion, where location on the face was compared with other locations. 
The results are presented in Table 3.10. 
In both groups the patients with lesions on the face received significantly 
more injections and their treatment duration was significantly longer. Time to 
cure was not significantly different. The convalescence period was shorter in 
those who had lesions on the face, but this was significant in all patients but not 
in patients with one lesion. 
3.3.4.5. Differences by health centre 
The differences between health centres in the number of treatment sessions 
and treatment duration were not statistically significant. However, the values 
for time to cure and convalescence were significantly different, with patients at 
Hamadaniyyeh (Specialised Centre for Skin Diseases) having the shortest 
median time to cure and Kafr Hamra the shortest convalescence period. 
Patients treated at Atareb had the longest \"alues both for time to cure and 
cOlwalescence. The results are presented in Table 3.11. 
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3.3.4.6. Differences by number of lesions 
The number of lesions was categorised into lJ one or two lesions" and IJthree 
lesions or morelJ in the same way as in Chapter 2. This resulted in two groups 
of 69 and 29 patients for the first two outcomes and 39 and 11 patients for the 
last two outcomes, and the differences between them were not statistically 
significant: the median number of treatment sessions in patients with one or 
two lesions was nine vs. six in those with three lesions or more (p=0.173, :"Iann-
Whitney U test), treatment duration 12 vs. 10 weeks (p=0.185), time to cure, 22 
vs. 23 weeks (p=0.707) and convalescence, 4 vs. 5 weeks (p=0.101). 
3.3.4.7. Differences by lesion duration 
Lesion duration was grouped into three categories as in Chapter 2, lJup to 
one month", "two months" and IJthree months or longerlJ , then to two 
categories, IJtwo months or shorter" and IJthree months or longer". Both 
groupings did not reveal any statistically significant effects on the outcome 
variables tested (Table 3.12) 
3.3.4.8. Multivariate analysis 
The variables which showed p values below 0.1 in the analyses above were 
entered into a multivariate logistic regression model. Outcomes were grouped 
into binary categories divided by the median value. For every explanatory 
variable univariate regression was compared to the multivariate model. The 
results are reported by outcome. 
3.3.4.8.1. Number of treatment sessions (visits) 
The results for the number of treatment sessions are presented in Table 3.13. 
The explan'1tory variables entered in the model were age group (0-14 and 15+ 
\"ears), lesion location (any lesions on the face "S. no lesions on the face) and 
folll)\\'-up status (patients who were followed up until cure "S. those who were 
lost to folll)\,' up before cure was formally diagnosed). The reference groups 
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were the younger age group, patients who had no lesions on the face and 
patients with incomplete follow-up. In addition, health centres were entered in 
the model, with Yousef Azmeh centre selected as reference group. 
Compared to univariate analysis, the odds ratios were considerably deflated 
(became closer to 1) and remained statistically significant for lesion location on 
the face and follow-up status, but not for age and health centres. This shows 
that lesion location and follow-up status do confound each other, but 
nevertheless each of them significantly affects the number of treatment sessions, 
and that the differences attributed to age in univariate analysis become not 
significant when possible confounders are taken into account. In the univariate 
model two centres significantly differed from the reference centre, but in the 
multivariate model the differences were no longer statistically significant, 
which suggests that the apparent differences in the number of treatment 
sessions between them could be explained by variations in sample 
characteristics. 
3.3.4.8.2. Treatment duration 
The results for treatment duration are presented in Table 3.H. The 
explanatory variables and the reference groups were the same as for the 
number of treatment sessions. In univariate analysis only the Hamadaniyyeh 
health centre was significantly different from the reference centre. In 
multivariate analysis the odds ratios for age, lesion location and follow-up 
status were considerably deflated, and those for the health centres considerably 
inflated, but only the differences by age group and lesion location remained 
statistically significant. This suggests these two variables are associated, and 
that they may explain the differences in follow-up status and between health 
centres. 
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3.3.4.8.3. Time to cure 
Only two variables were associated with statistically significant differences 
in time to cure divided into two categories by the median value in univariate 
analysis (p<O.l): age and lesion duration at presentation. The results are 
presented in Table 3.15. Compared to univariate analysis, the odds ratio was 
marginally inflated for age group when corrected for lesion duration. The odds 
ratio for lesion duration was considerably inflated for lesion duration and 
became statistically significant (p value was 0.08 in univariate analysis and 
decreased to 0.045) indicating that, although the two variables confound each 
other, yet both are probably significant predictors of time to cure. 
3.4. Discussion 
The age distribution of our sample was closer to Treatment and Patient 
Cards datasets than to the leishmaniasis population of 2005 (the Main dataset in 
Chapter 2). However, unlike the three datasets examined in Chapter 2, in our 
sample males predominated. The mean number of lesions in our sample was 
2.13 VS. 2.17 in the leishmaniasis population. The smear result was positive in 
81.3% of cases vs. 78% in leishmaniasis population. Thus, our sample is fairly 
representative of the population, except for the sex distribution. 
The patients included in the study differed from the excluded ones in their 
number of lesions (less in our sample), sex (more males in the sample) and 
lesion location (more lesions on the face and less on the lower extremities). 
Lesion locations were not significantly different between urban and rural 
health centres or by sex, but younger patients were more likely to have lesions 
on the face and less likely to have lesions on the upper extremities. The same 
trend \V as noted in the leishmaniasis population for the age groups, and the 
differences between sexes, while statistically significant due to larger sample 
size, were not strikingly different. 
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While the differences in the number of lesions by age and sex were not 
significant in the sample, the same trend as in the population was observed 
with fewer lesions in males and the younger age group. 
Lesion duration at presentation did not differ significantly between age 
groups, and the same trend as in the population was observed, with younger 
patients tending to present earlier. However, in our sample the females had 
significantly longer lesion durations in contrast with the population. This 
variable can be compared with the data from Turkey [5. Uzun, personal 
communication, 2005], where the median reported lesion duration at 
presentation was six months, which may reflect better awareness of the people 
in Aleppo of the disease, probably due to its high incidence, long history and 
health education efforts. 
No significant relationships between the smear result and other possible 
explanatory variables were detected in our patients. 
The mode for the number of treatment sessions was six, and for treatment 
duration five weeks. This corresponds to one standard treatment course and 
means that most patients stop treatment after one course of injections, either 
because they are cured or because they feel they need no more treatment. The 
mode value for time to cure may also be consistent with this, as after six 
injections the patients are asked to return after one month, or five weeks, for 
examination. However, the mode for convalescence was one week, which 
suggests that most frequently the cure is diagnosed in the middle of the course 
when the patient comes for their next injection and are told they are cured. 
The patients who completed follow up were significantly younger than 
those who did not. This may be due to the fact that children may have no choice 
over whether to stop the treatment because they are brought to the health 
centre by adults, whereas the adult patients are more likely to decide to decline 
further treatment. This is further illustrated by less treatment sessions and 
shorter treatment duration in older patients. However, for the patients with 
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complete follow up, younger patients had significantly longer time to cure 
despite shorter convalescence. This suggests children tend to respond to 
intralesional antimonials less well. 
The patients who completed follow up had significantly fewer lesions. This 
may be due to the fact that more lesions mean more injections in every session 
and, consequently, more pain. And, as expected, the patients with incomplete 
follow up had significantly less treatment sessions and shorter treatment 
duration. 
Lesion location on the face was associated with significantly more injections 
and longer treatment duration. However, the differences in time to cure among 
patients who completed follow up were not statistically significant. This 
favours the hypothesis that lesion location on the face is a cause of more 
concern and an incentive to complete treatment and make sure the lesion is 
cured but the possibility that the lesions on the face need more treatment 
sessions or that health centre staff tend to treat them for longer periods cannot 
be excluded. 
Multivariate analysis confirmed that age is a significant independent 
predictor of our outcome variables for all patients. Lesion location on the face 
was a significant independent predictor of number of treatment sessions and 
treatment duration but not time to cure. Follow up status was a significant 
independent predictor of number of treatment sessions only, and longer lesion 
duration at presentation was independently associated with shorter time to 
cure. 
Our method of measuring the length and width of the lesions is not 
convenient for assessing the treatment course. The lesions typically enlarged 
upon treatment, then their dimensions remained relatively stable, but the lesion 
itself gradually became more flat (a dimension not measured in our study) until 
the infiltrate became no longer detectable by palpation. 
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Due to its relatively benign course, the Old World cutaneous leishmaniasis 
is a largely neglected disease. In most studies the causative agent is either not 
reported or is assumed based on previous results of epidemiological 
investigations. In addition, due to lack of consensus, the end-point of the 
studies vary considerably, making comparisons even more difficult [Gonzalez 
et ai., 2008]. Very few studies were available for comparison, which differed in 
their aims and design. We review here the ones that were concerned with 
localised cutaneous L. tropica infection, where the causative organism was either 
typed or where it was known to be the only causative organism in the study 
area (namely, the Mediterranean and South-Eastern Anatolian Regions of 
Turkey, which are adjacent to Aleppo Governorate, and Kabul, Afghanistan) 
and which studied intralesional antimonial compounds either exclusively or as 
one of the study arms. In the current study, a selection of isolates obtained in 
Aleppo during fieldwork was typed, and all belonged to L. tropica. More details 
are reported in Chapter 4. 
One study in Aleppo [Harms et ai., 1991], one in Afghanistan [Reithinger, 
Mohsen et ai., 2005], two from Iran [Hadighi et ai., 2006; Sadeghian et al., 2007] 
and two from Turkey [Gurel et al., 2000; Uzun et al., 2004] are reviewed. 
The demographic and presentation variables are compared to the group of 
patients that met our inclusion criteria. 
Our patient sample has the lowest mean age among those reported: 16.3 
years VS. 21 by Harms, 22.4 by Sadeghian and 22.4 by Uzun. Reithinger reported 
the median age (13 years), which is also greater than in our sample (11 years). 
This may indicate longer endemicity of the disease in Aleppo if the 
development of immunity is assumed. 
The number of lesions in our sample was greater than that reported by 
other authors: in our sample the mean number of lesions was 2.1, while 
Sadeghian reported 1.5, Uzun, 1.4 and Gurel, 1.4. In our sample 38% of patients 
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presented with one lesion, while the proportion was 63% in the sample of 
Hadighi and 81 % and 80% in the studies of Uzun and Curel, respectively. 
The median lesion duration at presentation was reported by Reithinger 
(2005) and Uzun (personal communication), and it was six months in both 
studies, compared to two months in our sample. Sadeghi an reported a mean 
lesion duration of four weeks. In our sample the mean lesion duration was 2.7 
months. 
Eighty-eight percent of our patients presented with non-ulcerative lesions, 
and 94% of all lesions were non-ulcerative. Both Hadighi and Uzun reported 
71 % of non-ulcerative lesions. In the case of Uzun, this might be due to longer 
average lesion duration at presentation, a variable not reported by Hadighi. 
Sadeghian reported no ulcers among his patients which might be due to 
unusually short lesion durations in his sample. 
Some studies reported baseline lesion size as maximum lesion diameter. In 
our sample the mean and median lesion diameter was 9.1 mm and 7 mm, 
respectively. Reithinger reported median value of 12 mm, sadeghian, a mean of 
14.7 mm, Uzun, a mean of 13.6 mm and Harms, a median of 15 mm, and it was 
usually stated that the measurements were made to the infiltrate, not the 
surrounding redness, so the data are comparable. Our sample showed the 
smallest baseline lesion size. This may be related to earlier presentation of our 
patients, although the patients of Sadeghian presented with considerably 
shorter lesion durations yet had larger lesions. 
Most studies reported proportion of patients that were cured at a fixed 
point of time rather than time to cure. Similar proportions could be calculated 
for our patients in most cases. For this purpose, the patients who completed 
follow-up were selected. Reithinger reported 50% cure at 75 days and 75% cure 
at 100 days. Only 22% and 40% of patients were cured at these time points, 
respectively, in our sample. Hadighi and Sadeghian reported percent of cure at 
six months, 90% by the former and 57% by the latter. In our sample 74% of 
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patients were cured at week 26. Interestingly, Sadeghi an reported two measures 
of cure: proportion of patients cured and proportion of lesions cured, and both 
were in perfect agreement. Harms reported 76% cure rate after ten weeks, 
compared to 18% in our sample. Finally, Curel reported 85% cure rate both 
after thirty and ninety days. In our sample only one patient (2%) was cured at 
five weeks and 32% at thirteen weeks, the closest point to ninety days. Uzun 
reported mean and median number of injections in their study, which were 
equal to 8.5 and 7, respectively. In our study the corresponding values among 
patients with complete follow up was 9.5 and 8, respectively. Thus, our 
numbers were consistently higher than those reported by other authors. 
However, these data cannot be compared directly due to important differences 
in treatment regimens. Most studies used regimens of four or five doses given 
in weekly intervals (in case of Reithinger, every five or seven days), Uzun in 
Turkey used continuous course of weekly injections until cure for a maximum 
of twenty weeks. In Aleppo, injections are given weekly in courses of six, and 
after each course there is a one-month (in practice, five-week) break. It is not 
infrequent that in the end of the course the lesion is not fully cured. In such 
cases the patients may be asked to come back after another month for 
evaluation and possible continuation of treatment or formal discharge. For this 
reason our time to cure variable may be longer than actual time to cure, and this 
is illustrated by the delay between the last injection and diagnosis of cure, that 
we termed 'convalescence', which was about a month on average (with mean of 
5 weeks and median of 4 weeks). However, the mode value was one week, 
which means many patients were told they were cured when they turned up for 
their next injection during a treatment course. 
In summary, the characteristics of cutaneous leishmaniasis in Aleppo 
appear different from other settings. Possible explanations for these differences 
may lie in the causative organism, host population characteristics and in the 
history of the disease, as Aleppo is a well-known long-standing focus of 
138 
anthroponotic cutaneous leishmaniasis, and there is a relatively strong, 
comprehensive and well-managed programme of leishmaniasis control which is 
based primarily on the treatment of passively-detected cases. 
A considerable proportion of patients do not complete the treatment until 
they are formally told they are cured. Pentavalent antimonials are capable of 
selecting resistant parasites in experimental models [Grogl et ai., 1989; Lucumi 
et ai., 1998], The parasites do not disappear from the lesions promptly but can 
still be detected in some patients undergoing treatment. It can be speculated 
that in the lesions of patients who prematurely stop the treatment the parasites 
will multiply again, and these patients will serve as potential source of infection 
by less antimony-sensitive parasites. There are reports of isolation of less 
sensitive parasites from patients with treatment failure or subcurative treatment 
with antimonials [Grogl et ai., 1992; Rojas et ai., 2006]. 
Since the humans are believed to be the only source of anthroponotic 
cutaneous leishmaniasis infection, treatment-selected antimony-resistant 
parasites may be transmitted to other people and cause infections with 
insensitive parasites (often termed by clinicians 'primary resistance'). 
Thus, it is worthwhile to explore the sensitivity of Leishmania to antimonial 
preparations in Aleppo and whether any relationships can be found between 
parasite sensitivity and clinical outcome of the disease. We attempted to isolate 
the parasite from leishmaniasis patients in Aleppo before and during the course 
of treatment. This is described in the next chapter. 
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3.5. Tables 
Table 3.1. Demographic and clinical presentation characteristics of 
the patients included in (n=107) and excluded from (n=25) the study. 
Variable Included Excluded 
mean median mean median 
Age, years 16.28 11 18.76 12 
Number of lesions 2.13 2 2.68 3 
Lesion duration, months 2.74 2 2.42 2 
Sex, % males 56.1 28.0 
Lesions on face, % of patients 53.3 20.0 
Lesions on hand, % of patients 51.4 60.0 
Lesions on leg, % of patients 16.8 30.6 
Lesions on trunk, % of patients 2.8 4.0 
Lesions on ears, % of patients 4.7 4.0 
Lesions on neck, % of patients 6.5 0.0 
Centre location, % rural 53.7 66.7 
Ulcers, number/total (%) 13/107 (12.1) 2/25 (8) 
p 
0.379' 
0.031" 
0.471' 
O.OlIt 
0.003t 
0.438t 
0.032t 
0.753t 
0.884t 
O.189t 
0.247t 
0.556t 
• Mann-Whitney U test; t Pearson's X2. For lesion locations the sums add to more than 100% 
because some patients had lesions in more than one location. 
males 
females 
urban 
rural 
Table 3.2. Mean and median age (years) comparisons: males vs. 
females and rural vs. urban health centres. 
n mean median 
60 14.32 10 
47 18.79 12 
50 18.56 13.5 
57 14.28 9.0 
. Mann-Whitney U test; n, number of patients in each group. 
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p' 
0.290 
0.047 
Table 3.3. Lesion location by sex, age group and health centre 
location. The values in the cells are percentages of patients in each 
category having lesions in the corresponding location. 
Location males females ~' 0-14 15+ p' urban 
Face 53.3 53.2 0.988 67.6 28.2 <0.0001 52.0 
Hand 46.7 57.4 0.268 38.2 74.4 0.0003 56.0 
Leg 16.7 17.0 0.961 13.2 23.1 0.190 24.0 
Trunk 1.7 4.3 0.421 2.9 2.6 0.909 2.0 
Ears 5.0 4.3 0.856 7.4 0.0 0.083 6.0 
Neck 5.0 8.5 0.466 7.4 5.1 0.654 8.0 
* Pearson's X2. 
Table 3.4. Reported lesion duration at presentation by sex, age, 
lesion location, number of lesions and health centre location. 
n mean median 
males 59 2.51 2 
females 46 3.04 3 
0-14 68 2.53 2 
15+ 37 3.14 2 
lesions on face 56 2.50 2 
no lesions on face 49 3.02 2 
1 or 2 lesions 72 2.75 2 
3 lesions or more 33 2.73 2 
urban 49 3.02 2 
rural 56 2.50 2 
'Mann-Whitney U test; n, number of patients in each group. 
Table 3.5. Relationship between culture result and age, number of 
lesions, lesion duration at presentation, sex, lesion location and 
health centre location. The differences between health centres are 
reported in the text. 
Culture Positive Negative 
mean median mean median 
~ge, years 16.04 10 18.97 14 
Number of lesions 2.15 2 2.50 2 
Lesion duration, months 2.81 2 2.29 2 
Sex, % males 55.0 37.5 
Lesions on face, % of patients 54.0 25.0 
Centre location, % rural 54.0 62.5 
, Mann-Whitney U test; t Pearson's X2. 
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rural p' 
54.--1 0.805 
--17 A 0.373 
10.5 0.063 
3.5 0.637 
3.5 0.542 
5.3 0.568 
~' 
0.011 
0.234 
0.199 
0.910 
0.407 
p 
0.228' 
0.199' 
0.217 
0.085t 
0.004t 
0.399t 
Table 3.6. Comparison between the patients with (n=9) and without 
(n=98) history of previous leishmaniasis. 
Previous leishmaniasis No Yes 
mean median mean median 
Age, years 15.89 10 20.56 12 
Number of lesions 2.19 2 1.44 1 
Lesion duration, months 2.77 2 2.38 1.5 
Treatment duration, weeks 14.18 12 13.12 9.5 
. Mann-Whitney U test. 
Table 3.7. Mean, median and mode values for treatment sessions, 
treatment duration, time to cure and convalescence. The first two 
variables were available for 98 patients, the latter two for 50 
patients. The latter three variables are expressed in weeks. 
p'" 
0.283 
0.027 
0.506 
0.886 
Variable mean median mode 
Treatment sessions 9.5 8 
Treatment duration 14.1 12 
Time to cure 21 22.5 
Convalescence 5 4 
Table 3.8. Comparison of demographic and clinical characteristics of 
patients with complete and incomplete follow up. 
Follow up 
incomplete complete 
mean median mean median 
Age (years) 21.4 15 12.0 9 
Number of lesions 2.4 2 1.9 2 
Lesion duration (months) 2.6 2 2.8 2 
Treatment sessions 7.9 6 10.9 10 
Treatment duration 12.0 8 15.9 15 
(weeks) 
Sex (% males) 60 54.7 
Lesion location (% face) 46.7 60.4 
. Mann-Whitney U test. t Pearson's X2. 
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6 
5 
10 
1 
p 
0.029' 
0.044' 
0.509' 
0.001' 
0.015' 
0.598+ 
0.175+ 
Table 3.9. Mean and median values for treatment sessions 
treatment duration, time to cure and convalescence by age grou~ 
and sex. 
Age group 
0-14 15+ 
mean median mean median 
Treatment sessions 11.0 10 7.1 8 
Treatment duration 16.4 17 10.2 7 
Time to cure 22.5 25 16.9 13 
Convalescence 4.6 3 6.2 5 
Sex 
M F 
mean median mean median 
Treatment sessions 8.8 7 10.5 10 
Treatment duration 13.4 10.5 15.1 12.5 
Time to cure 19.8 18 22.5 25 
Convalescence 5.3 4 <i.7 4 
Mann-WhItney U test 
Table 3.10. Mean and median values for treatment sessions, 
treatment duration, time to cure and convalescence by lesion 
location in all patients (any lesions on face vs. no lesions on face) 
and in patients with one lesion (n=37 for number of sessions and 
treatment duration, n=20 for time to cure and convalescence; face vs. 
other locations). 
All patients 
any lesions on face no lesions on face 
mean median mean median 
Treatment sessions 11.3 12 7.4 6 
Treatment duration 17.2 19 lOA 9 
Time to cure 21.2 23 20.8 22 
Convalescence 3.9 3 6.8 5 
Patients with one lesion 
on face in other locations 
mean median mean median 
Treatment sessions 11.5 10 6.4 6 
Treatment duration 18.0 22 9.7 8.5 
Time to cure 21.9 25.5 18.3 17 
Convalescence 3.3 2.5 7.3 5.5 
. Mann-Whitney U test. t Exact significance is reported due to small numbers of patients. 
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p' 
0.0001 
0.01 
0.037 
0.027 
~. 
0.85 
0.390 
0.195 
0.493 
p. 
0.0001 
0.0002 
0.726 
0.019 
E· 
O.003t 
0.029t 
OA73' 
0.157t 
Table 3.11. Mean and median values for treatment sessions 
treatment duration, time to cure and convalescence by health centre.' 
Health centre 
Atareb Kafr Hamra Hamadaniweh Youse! Azmeh 
mean medt mean medt mean medt mean medt 
Treatment s.essions 9.2 7 10.5 10 6.7 6 10.3 10 
Treatment duration 14.6 11 13.5 12 9.1 6 16.7 17.S 
Time to cure 28.9 29 16.8 15 13.75 11.S 22.5 24.5 
Convalescence 9.8 8 3.1 1.5 5.5 5 4.3 
• Kruskal-Walhs test. t medIan. 
Table 3.12. Mean and median values for treatment sessions, 
treatment duration, time to cure and convalescence by lesion 
duration at presentation. 
Lesion duration (months) 
lor 2 3+ 
mean median mean median 
Treatment sessions 9.4 8 9.9 10 
Treatment duration 14.4 12 14.0 12 
Time to cure 23.8 25 18.7 18 
Convalescence 6.0 5 4.1 .f 
~1 2 3+ 
mean median mean median mean median 
Treatment sessions 9.1 8 9.7 8 9.9 10 
Treatment duration 14.4 12 14.4 14 14.0 12 
Time to cure 20.8 23 26.6 26 18.7 18 
Convalescence 5.0 3.5 6.9 5 4.1 .f 
• Mann-Whitney U test. t Kruskal-Wallis test. 
Table 3.13. Multivariate regression model for the number of 
treatment sessions split into binary variable by the median value (S7 
VS. 8+). Younger age group, no lesions on the face, patients with 
incomplete follow-up and Yousef Azmeh health centre were the 
reference categories. 
4 
univariate multivariate 
Variable OR p OR 
Age group «14 VS. 15+) 0.18 (0.07-0.43) <0.001 0.44 (0.15-1.33) 
Lesion location (face) 6.81 (2.80-16.57) <0.001 5.10 (1.73-15.03) 
Follow-up status 3.81 (1.64-8.83) 0.002 3.16 (1.12-8.89) 
Health centre 
Atareb 0.71 (0.24-2.09) 0.538 1.51 (0.40-5.70) 
Hamadalliyyeh 0.18 (0.04-0.76) 0.019 0.29 (0.06-1.41) 
Kafr Hamra 3.42 (1.04-11.32) 0.044 3.05 (0.77-12.12) 
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p' 
0.052 
0.052 
0.009 
<0.001 
p' 
0.759 
0.795 
0.064 
0.298 
pI 
0.875 
0.965 
0.080 
0.345 
p 
0.146 
0.003 
0.029 
0.542 
0.123 
0.114 
Variable 
Table 3.14. Multivariate regression model for treatment duration 
split into binary variable by the median value (:Sll vs. 12+ weeks). 
Younger age group, no lesions on the face, patients with incomplete 
follow-up and Yousef Azmeh health centre were the reference 
categories. 
univariate multivariate 
OR (95% CD p OR (95% cn 
Age group ($14 vs. 15+) 0.24 (0.01-0.57) 0.001 0.33 (0.12-0.95) 
Lesion location (face) 4.69 (1.99-11.02) <0.001 3.41 (1.28-9.06) 
Follow-up status 2.29 (1.02-5.15) 0.046 1.79 (0.70--4.59) 
Health centre 
Atareb 0.48 (0.16-1.44) 0.19 0.79 (0.22-2.78) 
Hamadaniyyeh 0.18 (0.05-0.67) 0.011 0.25 (0.57-1.11) 
Kafr Hamra 0.56 (0.20-1.61) 0.285 0.34 (0.10-1.12) 
Table 3.15. Multivariate regression model for time to cure split into 
binary variable by the median value (:S22 vs. 23+ weeks). Younger 
age group and lesion duration of two months or less were the 
reference categories. 
univariate multivariate 
Variable OR (95% cn p OR (95% cn 
Age group «14 vs. 15+) 0.21 (0.05-0.87) 0.032 0.18 (0.04-0.91) 
Lesion duration ($2 vs. 0.36 (0.11-1.16) 0.08 0.27 (0.07-0.97) 
3+) 
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p 
0.039 
0.014 
0.226 
0.707 
0.068 
0.075 
p 
0.038 
0.045 
3.6. Figures 
Figure 3.1. The road signs on the entrance of the rural localities . 
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Chapter 4. Parasite sensitivity to 
antimonial drugs 
4.1. Introduction 
4.1.1. Background 
As mentioned in the Conclusion to Chapter 1, in mid-1990s it was noted that 
cutaneous leishmaniasis in Aleppo required more intralesional injections to 
achieve cure than in previous years [Douba et ai., 1997]. The authors 
hypothesised that the lack of response they observed might have been due to 
several factors: selection of tolerant strains of parasites, inadequacy of 
intralesional treatment alone, technical errors in administration, failure to 
follow treatment protocol by medically unqualified persons in the informal 
sector or lack of patient compliance. The authors argue these factors would lead 
to partial immunity and to an increase in chronic lesions and, as a consequence, 
to an increase of human reservoir, and might also serve as an explanation for 
the increase in reported incidence of the disease. The authors were not able to 
conduct assays of parasite drug sensitivity due to lack of facilities and 
recommended that such assays be conducted in the future. 
In this text sel1sitiuity refers to inhibition of Leishmania isolates by the drugs 
in in vitro tests. 
Treatment outcome depends on several factors related to the pathogen, the 
host and the treatment. 
• Treatment factors may be drug-related or physician-related. 
• Pathogen factors include innate or acquired tolerance to the treatment 
and virulence of the infecting strain(s). 
• Host factors include immune response which might be adequate, 
suppressed or inefficient, or pathologically uncontrolled [Murray et ai., 
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2006]; treatment compliance is another important factor [Douba et ai., 
1997]. 
Drug-related factors are related to drug characteristics such as 
pharmacokinetics and quality. 
Physician-dependent factors include dosage, frequency, mode of 
administration, including possible technical errors in administration. 
Anthroponotic infections have a higher potential of developing tolerance to 
anti-infectious agents due to drug pressure during treatment compared to 
zoonoses [Bryceson, 2001], unless animals are treated with the same drugs as 
humans [Dujardin et al., 2008]. This is because in zoonoses humans are "dead-
end" hosts, and drugs do not affect parasite's reproductive success because the 
parasite is not returned to the transmission cycle [Woolhouse et ai., 2002]. 
Therefore, it is important to explore whether the treatment used in Aleppo, 
where the disease is believed to be anthroponotic [Ashford et ai., 1993], leads to 
selection of less sensitive parasites. Development of Leishmania drug tolerance 
during treatment has not been explored extensively. While development of 
secondary tolerance (the one that develops during treatment) was 
demonstrated in a Colombian study in four of twenty patients with leishman-
iasis caused by the Viannia subspecies of Leishmania [Rojas et al., 2006], in a 
larger study of 185 clinical isolates from Iran, mostly belonging to L. tropica, 
only primary tolerance (when the isolates are initially tolerant to the drug) was 
found [Hadighi et al., 2007]. 
4.1.2. Drug sensitivity determination 
Sensitivity of Leishmania to drugs can be determined using 
promastigotes [Azeredo-Coutinho et al., 2007], intracellular 
amastigotes [Berman et al., 1982; Neal and Croft, 1984], axenic amastigotes [EI 
Fadili et al., 2005] or animal models [Escobar et al., 2001; Sacks and Noben-
Trauth, 2002], and measurement of sensitivity may be by counting infected 
H8 
macrophages and/or parasites, radiolabelling or measurement using 
luciferase [Berman and Gallalee, 1985; Hadighi et al., 2006]. 
Promastigotes are far less sensitive to pentavalent antimony preparations 
than amastigotes [Azeredo-Coutinho et al., 2007]. This mayor may not apply to 
other drugs (see "Overview of the drugs" below). For this reason, and because 
the amastigotes in the vertebrates are located intracellularly, determining in 
vitro sensitivity requires using a dividing population of the parasite stage found 
in mammal host [Croft and Brun, 2003]. A few studies explored the correlation 
between the sensitivity of promastigotes and amastigotes on one hand, and 
treatment outcome, on the other. While a study of treatment failures in kala-
azar in India [Lira et al., 1999] found a strong correlation between clinical 
response and in vitro sensitivity of L. donovani to sodium stibogluconate in 
amastigote, but not promastigote, assays, another study from Brazil found a 
positive correlation between drug sensitivities of L. braziliensis isolates in both 
stages, which also correlated with the clinical outcome (although promastigotes 
required drug concentrations higher by about two orders of magnitude 
compared to amastigotes) [Azeredo-Coutinho et al., 2007], which might indicate 
that in different species of Leishmania there mayor may not be correlation 
between sensitivities of the two parasite stages. However, both studies were 
done on small samples of patients (26 in the former and 19 in the latter). 
The protocols for determining in vitro amastigote sensitivity to Sbv vary 
widely with regard to length of incubation and exposure, number of duplicates 
for each drug concentration, number of concentrations used and drug dilutions 
in the series (Table 4.1). 
4.1.3. Typing of Leishmania 
The methods of Leishmania classification and typing are reviewed in greater 
detail in Chapter 1. In this chapter, the specific methods used for typing of the 
study strains are presented later (Leishmania typing, p. 168). 
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Several methods are applied for molecular characterisation of Leishmania. 
PCR-RFLP of cp8 and gp63, sequencing of ITS1 and multilocus sequence typing 
of housekeeping genes are suitable for species identification, whereas 
multilocus microsatellite fragment analysis and kinetoplast O:\'A typing are 
suitable for distinguishing single strains, the former can also be used to infer 
population structure [Schonian et ai., 2008]. 
4.1.4. Overview of the drugs 
This brief overview is concerned with the drugs used in the assays. For each 
drug the available data on indications, sensitivity of different species of 
Leishmania (promastigotes and amastigotes) and pharmacokinetics are 
reviewed. This section is mainly based on Dollery's and Martindale reference 
books [Dollery and Boobis, 1991; Sweetman, 2002], unless stated otherwise. 
4.1.4.1. Pentavalent antimony 
Sodium stibogluconate (SSG) is a gluconate of antimonic acid. It is a mixture 
of ionic antimony compounds with ill-defined composition that has Sb\ content 
not below 30% and not above 34%, usually with less than two atoms of sodium 
per atom of antimony. The commercial solution of SSG contains 100 mg Sbv/ml, 
of meglumine antimoniate (MGA), 81 mg Sbv/m!. The two drugs are considered 
equivalent if the dose is calculated based on antimony content. 
SSG and MGA are primarily used for treatment of leishmaniases. They are 
administered intramuscularly or intravenously at a dose of 20 mg/kg/day with 
no upper limit for at least twenty days. This dosage is used in Syria to treat 
cutaneous leishmaniasis (CL) that cannot be treated with intralesional 
injections. 
Intralesional treatment is used to treat CL in the Old World. Treatment 
protocols vary, examples are: three injections on alternate days every month, 
repeated as necessary in India [Sharma et al., 2005]; three injections a week for a 
total of ten injections or weekly injections in continuous course until cure in 
Turkey [Ok et al., 20021; weekh· injections given in up to three six-week or eight-
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week courses with one-month intervals between the courses in Syria, and a 
fortnightly regimen was successfully tested in Pakistan [Mujtaba and Khalid, 
1999]. A substantial proportion of CL treatment research is poorly 
designed [Khatami et al., 2007; Gonzalez et al., 2008]. 
Sensitivities of different species to Sbv vary widely. Old-World "cutaneous" 
species seem to be less sensitive in amastigote-macrophage tests (most values 
>20 I-lg Sbv/ml) compared to New-World species and L. donovani (most values 
<10 I-lg Sbv/ml) [Neal et al., 1995]. In one study comparing the sensitivities of 
promastigotes and amastigotes of Latin American species to SbV the sensitivity 
of promastigotes was lower by approximately two orders of magnitude, and 
there was positive correlation between the two [Azeredo-Coutinho et al., 2007]. 
Pentavalent antimony compounds have poor gastrointestinal absorption. 
After intravenous administration, the initial distribution phase is followed by 
quick biexponential renal elimination. Elimination half-life of the initial phase is 
about 1.7 hours and that of the terminal phase about 33 hours. Peak 
concentration occurred one hour after administration of 50-100 mg Sbv was 10-
151-lg Sbv/ml. About 80% of antimony is recovered in the urine after 6 hours, 
and up to 94% in 24 hours. 
In one study [Chulay et al., 1988] that examined pharmacokinetics after 
intramuscular administration of 10 mg Sbv/kg, patients were treated for thirty 
days with either SSG or MGA, and the pharmacokinetics of both drugs were 
remarkably similar. The peak concentration of about 10 I-lg Sbv/ml was reported 
after two hours. Initial absorption phase was characterised by a half-life of 
0.85 hours and initial-phase elimination half-life was two hours. The mean half-
life of the slow elimination phase was 76 hours. The authors attributed the slow 
elimination phase to partial conversion of Sbv to Sbill. A slow increase of trough 
concentrations during the course of treatment was noted. 
One study measured antimony pharmacokinetics in blood and normal and 
affected skin of leishmaniasis patients. After intramuscular injection of SSG 
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equivalent to 600 mg Sbv, the maximum concentration in blood (8.81 fig Sbv/ml) 
was achieved after about an hour and a half, and in skin lesions, 5.2 fig Sb \/ml 
after 2.1 hours [al Jaser et al., 1995]. TIUs dose corresponds to the low-dosage 
treatment protocol of 10 mg Sbv/kg body weight, which may be suitable for 
L. major because it is generally sensitive to antimony. However, the World 
Health Organization (WHO) recommended a dose of 20 mg Sbv/kg body weight 
for parenteral treatment with no maximum dose. Earlier, WHO recommended 
that the dose should not exceed 850 mg Sbv [Alvar et al., 1997]. 
Pharmacokinetics in children (aged between three and six years) were 
compared to adults in one study in patients with cutaneous leishmaniasis [Cruz 
et al., 2007]. The patients were given MGA at 20 mg Sbv/kg intramuscularly for 
20 days. In addition, one group of children received 30 mg Sbv/kg on the last 
day. Drug exposure was assessed by the area under the 24-hour time-
concentration curve (AUCo.24h) in plasma. The values in children were lower by 
42% due to significantly higher (by 75%) weight-adjusted clearance. After a 
dose of 30 mg Sbv/kg in one group of children, drug exposure reached 86% 
(corresponding to 48% increase compared to the standard, 20 mg Sbv/kg, dose), 
and peak serum concentration 113% of adult values. 
No studies were identified that examine the kinetics of tissue concentration 
of drugs following intralesional administration. These would be more relevant 
to the Syrian setting, as intralesional treatment with Glucantime is used as first-
line treatment in Syria. 
4.1.4.2. Amphotericin B 
Amphotericin B is an antifungal polyene antibiotic administered 
intravenously as an antifungal or antiprotozoan treatment or applied locally for 
superficial fungal infections in immunocompetent patients. 
In one study [Escobar et al., 2002], sensitivity to amphotericin B of 
promastigotes and amastigotes of reference strains of different species of 
Leishmania was determined using amastigote-macrophage assay. Promastigotes 
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were on average as sensitive to amphotericin B as amastigotes, and ECso values 
for L. tropica reference strain intracellular amastigotes were 0.05 and 0.09 f.lM in 
two experiments. In the second experiment infection levels in control wells 
were rather low (46%). For the other species tested the ECso values for 
intracellular amastigotes were in the range between 0.036 (L. donovani) and 
0.14 f.lM (L. mexicana), and for promastigotes, between 0.003 (L. donovani) and 
0.27 f.lM (L. mexicana). 
Amphotericin B is available in several formulations. The colloidal 
("conventional", deoxycholate) formulation achieves plasma concentrations 
between 0.5 and 4 f.lg/ml, and on maintenance doses of 400-600 f.lglkg is usually 
around 0.5 f.lg/ml. Half-life is about 24 hours. The metabolic pathways are 
unknown. About 40% is recovered unchanged in the urine. The drug binds with 
plasma proteins (90-97%). 
Conventional amphotericin B is associated with nephrotoxicity that occurs 
in almost all patients. Glomerular and tubular damage is observed. The 
nephrotoxicity becomes irreversible in 15% of patients who received a total 
dose of 30 mg/kg and in 80% after a total dose of 75 mg/kg [Davidson and Croft, 
1993]. 
Non-conventional formulations (lipid-associated) provide higher plasma 
and several times lower renal concentrations, and have better safety profile than 
conventional formulations [Lachaud et al., 2009] but their use is limited in most 
settings by their high cost [Ameen, 2007], which may be offset by shorter 
hospital stays in Israel [Solomon et al., 2007] and Europe but no other endemic 
region [Murray et al., 2006]. They have a major advantage in visceral 
leishmaniasis because the liposomes are cleared by phagocytising mononuclear 
cells, and the drug accumulates in reticuloendothelial system, thus targeting 
L. donovani. Total doses of up to 15 mglkg are not usually associated with 
nephrotoxicity. The drug should not be exposed to temperatures below O°C or 
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above 25°C, as this causes changes to the liposomes and may increase toxicity 
or decrease efficacy [Bern et ai., 2006]. 
In a short report [Bau et ai., 2003] it was suggested that heating conventional 
amphotericin B to 70°C for 20 minutes leads to superaggregation and several-
fold decrease of in vitro and in vivo toxicity and an increase of antileishmanial 
activity in mice, and that clinical trials be conducted. However, no further 
development of this suggestion could be traced. 
The bioavailability after oral administration is less than 5%, which permits 
topical use for the treatment or prevention of fungal infections of the oral cavity 
and gastrointestinal tract with negligible toxicity [Meis and Verweij, 2001]. 
A recent study of a novel formulation of amphotericin B for oral 
administration [Wasan et ai., 2009], conducted on mice infected with L. donoc'al1i, 
reported promising results: the formulation given twice daily for five days at 10 
or 20 mg/kg led to near-complete (>99%) suppression of parasite load in the 
liver. No toxicity data were reported. 
4.1.4.3. Miltefosine 
Miltefosine belongs to the alkylphosphocholine group of phospholipid 
analogues [Croft et ai., 2003]. It was originally developed as an anti-cancer drug 
but showed marked toxicity below therapeutic doses. Six-percent miltefosine 
solution was evaluated as topical application for skin metastases of breast 
cancer with limited efficacy [Terwogt et ai., 1999; Leonard et ai., 2001] and tried 
in skin lymphoma and melanoma. A single-case report was published about 
successful treatment with the same solution of skin metastases of epidermoid 
carcinoma [Mahieu-Renard et al., 2005]. 
Miltefosine is the only oral preparation with demonstrated efficacy in the 
treatment of visceral leishmaniasis and Latin American cutaneous leishman-
iasis [Berman et al., 2006]. A study on mice suggested topical application of the 
6% solution might be a promising approach for cutaneous 
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leishmaniasis [Schmidt-Ott et al., 1999] but a trial in humans had discouraging 
results [So L. Croft, personal communication]. 
In the study mentioned above [Escobar et al., 2002], sensitivity to miltefosine 
of promastigotes and amastigotes of different species of Leishmania was 
determined using the amastigote-macrophage assay. Promastigotes were more 
sensitive to miltefosine than amastigotes, and EGo values for L. tropica reference 
strain amastigotes were 5.82 and 10.83 ~ in two experiments. 
Pharmacokinetics of miltefosine were not studied extensively. In a relatively 
large trial cutaneous leishmaniasis due to L. major acquired in northern 
Afghanistan in 31 Dutch military personnel was treated with 150 mg 
miltefosine daily for 28 days, and the median plasma concentration in the last 
week of treatment was -31 mg/ml (-75 mM), with a terminal elimination half-
life of 30.9 days [Dorlo et al., 2008]. The drug could be detected in plasma 
samples taken five to six months after the end of treatment, and the authors 
suggested the presence of subtherapeutic concentrations may contribute to 
selection of resistant parasites and emphasised the importance of measures to 
prevent the risk of teratogenic effect. The patients in this study either did not 
benefit from Pentostam and cryotherapy or had extensive disease. The outcome 
of miltefosine treatment was not reported. 
4.1.4.4. Paromomycin 
Paromomycin (aminosidine) is an aminoglycoside antibiotic that shares 
many features with other aminoglycosides but is active against several protozoa 
(Leishmania, Entamoeba histolytica, Cryptosporidium spp.) and tapeworms. 
Oral absorption of paromomycin is low. It is administered intramuscularly 
for systemic treatment of visceral leishmaniasis [Sundar et al., 2007]. It was 
recommended for the treatment of cutaneous leishmaniasis in the form of 
intralesional injections or topical formulations in the USSR [Shuvalova, 2001], 
and is used in methylbenzethonium chloride ointment in Israel [EI-On et al., 
1992; Davidson et al., 2009]. 
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Tests in amastigote-macrophage model showed marked differences 
between species, the most sensitive (ECs0<5 flM) being L. major, L. tropica and 
L. panamensis. The ECso of L. amazonensis was beyond the highest testing 
concentration. Leishmania donovani strains were mostly sensitive with EGo 
values between 6.1-43.S flM, with the exception of one strain (DDS) with 
ECsO> 150 flM. 
Pharmacokinetics of paromomycin were studied by Kanyok et al. in 1997 in 
healthy American volunteers [Kanyok et al., 1997]. Two doses, 12 or 15 mglkg 
intramuscularly, were tested. The mean peak plasma concentration was 
22.4 flg/ml (approximately 36 flM) and occurred after a mean of 1.34 hours (the 
differences of these parameters between the dosing groups were not statistically 
significant). Fifty percent of the dose was recovered in the urine in the first four 
hours, and plasma levels after 24 hours were undetectable in all but two 
subjects. 
During the Phase III trial in India, it was shown that peak serum level of the 
drug after intramuscular administration of 11 mg paromomycin base per 
kilogram body weight was about 20 flg/ml (about 33 flM), and occurred one 
hour post-injection [Sundar et al., 2007]. 
4.1.4.5. Trivalent antimony 
Trivalent antimony compounds, such as tartar emetic, were used to treat 
leishmaniasis and schistosomiasis in the early part of 20th century but were 
associated with significant toxicity and were superseded by safer therapies 
when these became available. 
Trivalent antimony compounds are poorly absorbed after oral 
administration. They were used orally as emetics and expectorants. 
The toxicity of trivalent antimony compounds is probably related to their 
slower excretion. They were administered intravenously. If injected locally or 
extravasated they cause severe pain due to tissue damage. They have greater 
affinity to cell than plasma proteins, and tend to accumulate during treatment, 
156 
and are slowly excreted, mainly in the urine, during several months thereafter. 
Prolonged treatment may lead to subacute poisoning. 
Parenteral administration was almost universally associated with 
electrocardiographic changes, frequently with bradycardia, hypotension or 
arrhythmias, and occasionally resulted in sudden death. 
One study examined the excretion of pentavalent and trivalent antimony 
preparations in hamsters and human volunteers [Goodwin and Page, 1943]. 
After an intravenous dose of 50 mg of stibamine glucoside, blood concentration 
of antimony at one hour post-injection was 1.6 mg Sblll/lOO ml (16 mg SbIIl/litre, 
or 16 I-lg/ml) and 0.8 mg Sblll/100 ml at 3 hours. 
4.2. Materials and methods 
Recruitment and follow up of patients are described in detail in Chapter 3. 
In this chapter, the details of parasitological work are described. 
4.2.1. Parasite isolation and culture 
The Leishmaniasis Control Center of Aleppo kindly provided a separate 
room for the research laboratory. This room was equipped with locally made 
incubators (F. Jarad Company, Mhardah, Hama Governorate, Syria) and an air 
conditioner (this option was cheaper that buying a refrigerated incubator), a 
desk, a fridge/freezer with a separate freezer compartment and, later, a locally 
manufactured bespoke class 2 biosafety hood (Hisham Janat, Aleppo, Syria). An 
inverted microscope (Carl Zeiss, German Democratic Republic) was kindly lent 
by the Department of Microbiology at Damascus Universitv Facultv of 
Medicine. 
Alcohol burners were purchased and kept in the four study health centres. 
Ethanol (95%) was purchased from a state pharmacy in one-litre bottles as 
necessarv. The ethanol was used without dilution both to refill the burners and 
for skin disinfection prior to obtaining biological material from patients. 
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Undiluted household chlorine bleach (Clorox, Saudi Arabia) was used for 
disinfecting contaminated tools before discarding them. 
Culture media were prepared in batches, as necessary, at the London School 
of Hygiene and Tropical Medicine (LSHTM) and sent by express mail. Agar 
slopes supplemented with rabbit blood and penicillin, streptomycin and 
gentamycin were prepared in Nunclon tubes (Nunc, Denmark), 2 ml in each. 
M199 (Sigma) [Coderre et al., 1983] (Appendix 7) was distributed into IS-ml 
centrifuge tubes. Upon receiving the media they were transferred to the 
refrigerator. NNN agar tubes were kept in the refrigerator and the liquid 
medium, except one or two tubes, in the freezer. The necessary materials were 
carried in a bag, with cold boxes during the summer. 
The routine protocol for obtaining biological material for analysis, as 
recommended by the Syrian MoH, was followed. About 2 ml of the liquid 
medium was added to the agar slope over the burner flame immediately before 
inoculation, the cap was replaced promptly on both tubes, and the agar tube 
labelled with patient ID, passage number (the initial inoculation was considered 
Passage 0) and the date of isolation. The lesion was wiped with a piece of 
cottonwool soaked in ethanol, left to dry, then scraped with the tip of a sterile 
disposable lancet blade until the tissue liquid appeared. This drop was touched 
with a sterile disposable Pasteur pipette (pastette), transferred into the tube, 
and the cap replaced promptly, all done over the flame. The rest of the 
biological material was used to prepare a smear, the analysis recommended by 
MoH. 
Until the end of working hours the tubes with cultures were kept at room 
temperature. On the way back to the lab at LCC the tubes were kept in a bag or, 
during winter, in an internal pocket. 
In the lab the tubes were transferred to a 26°C incubator, situated in the air-
conditioned lab. In case of a power cut, upon resuming of power supply the air 
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conditioner would switch on automatically, so room temperature would not 
usually exceed 24°C in the hot season. 
The tubes were examined under an inverted microscope at 10x6.3 (the 
maximum available magnification) at least once a week for active 
promastigotes. Within 2-3 weeks after isolation the samples, whether positive 
or negative, were subpassaged into the same biphasic medium, unless 
contaminated. Negative samples were re-examined until they became at least 
40 days old, and samples that did not convert to positive during this period, as 
well as all contaminated samples, were discarded with LCC laboratory waste 
after every tube was opened and topped up full with either undiluted chlorine 
bleach or 95% ethanol, then the cap replaced tightly. 
4.2.2. Transport and cryopreservation 
The cultures that were positive, not contaminated and were subpassaged, 
were prepared for sending to LSHTM for preservation. The tubes with cultures 
were wrapped in parafilm, then into a diaper and sent by express mail. It was 
aimed to send different passages of the same isolate separately (Figure .t.l). The 
parcels were usually sent on Sunday (a workday in Syria) and were normally 
delivered to the School Reception on Wednesday or Thursday morning. 
In London, the cultures were placed in a refrigerated incubator at 26°C 
overnight to settle, then transferred to flasks with 10 ml of M199 (Sigma) with 
20% heat-inactivated foetal calf serum (HIFCS), and the passage number would 
increase by one. After achieving an acceptable concentration of active 
promastigotes in the medium, the cultures were centrifuged, the pellet 
resuspended in ..J- ml of M199 with 20% HIFCS and 8-10% dimethyl sulfoxide 
(DMSO), distributed to properly labelled I-ml cryovials, frozen slowly in a 
-80°C freezer for 2..J- hours, then transferred to liquid nitrogen. Each isolate was 
frozen in triplicate or quadruplicate, ha\'ing a passage number of 1 for original 
isolates (labelled at isolation "Passage G") or 2 for the isolates subpassaged in 
Aleppo. 
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4.2.3. Reviving frozen isolates 
Frozen cultures were removed from liquid nitrogen and unfrozen quickly in 
a 34°C incubator, then each culture was inoculated into two flasks containing 
10 ml of M199 with 20% HIFCS. These cultures were marked with the same 
passage number as the frozen isolate (e.g. "Passage 1 from liquid nitrogen"). After 
achieving successful growth, normally in 4-7 days, the cultures were sub-
passaged into larger flasks containing 20 ml of the same medium. One of these 
flasks was used for sensitivity assays, the other for back-up freezing, and 
cultures in the small flasks were used for preparing pellets for typing and, if 
necessary, fingerprinting. 
4.2.4. Amastigote-macrophage assay 
4.2.4.1. Drugs 
The following drugs were used in the assays: 
19. Sodium stibogluconate (SSG; Pentostam™, GlaxoSmithKline, UK), kindly 
supplied by the manufacturer in the form of powder with 31.3% 
pentavalent antimony content. This preparation has been used as a gold 
standard for pentavalent antimonials. 
20. Glucantime™, commercial formulation (Sanofi-A\'entis, France), from batch 
711 manufactured October 2004 that was in use in primary health care 
centres in Aleppo during the study period, kindly pnn-ided by Leishman-
iasis Control Center of Aleppo. It contains 300 mg of meglumine 
antimoniate per miIlilitre with pentavalent antimony content of 81 mg/m!. 
21. Amphotericin B (AmB, Fungizone, Bristol-.t>.lyers Squibb, UK): shown to be 
almost uniformh- effective against L. dOllomni infection, even at low 
doses [Davidson and Croft, 1993]. 
22. Triyalent antimony (SblIl ) preparation (potassium antimony(III) oxide 
tartrate hemihydrate, Fluka Chemika, Buchs, Switzerland): no longer used 
in the treatment of leishmaniasis. Generally accepted to be the active form 
of antimony against Leislzma1zin: pentavalent antimony is reduced to 
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trivalent form inside the cells [Goodwin and Page, 1943; Brochu et al., 2003; 
Mukherjee et al., 2007]. 
23. Miltefosine (Zentaris, Frankfurt, Germany): the first oral antileishmanial 
drug with demonstrated efficiency against \'isceral leishmaniasis in 
India [Sundar et al., 2002], possible efficacy against cutaneous leishmaniasis 
caused by L. braziliensis in Bolivia [Soto et ai., 2008] and a recent report of 
two cases suggested it might be a promising candidate for the treatment of 
cutaneous leishmaniasis due to L. tropica [Killingley et al., 2009]. A clinical 
trial comparing miltefosine to Glucantime for L. tropica infection is being 
conducted in Iran [Killingley et ai., 2009]. 
24. Paromomycin (PM; paromomycin sulphate, Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany): this drug was used for the systemic, local (ointments) 
or intralesional treatment of leishmaniasis in the Soviet Union [Shuvalo\'a, 
2001], and is used in the form of ointments in Israel [Shani-Adir et al., 2005]. 
4.2.4.2. General description 
The protocol used at LSHTM [Yardley et al., 2005; Yardley ct al., 2006] for 
parasite drug sensitivity determination was followed. Certain parameters may 
differ between Leishmania species, so different combinations were tested before 
the actual experiments began, as described in "Assay optimisation" below. 
Female CD1 mice (Charles River Ltd., UK) were injected intra peritoneally 
with 2 ml of sterile 2% starch solution. After 24 hours the exudate containing 
macrophages was harvested by peritoneal lavage into cold RPMI-1640 with 
penicillin and streptomycin. The fluid was withdrawn and dispensed into 50-ml 
conical centrifuge tube(s). The tubes were kept on ice while in transport. On 
arrival the suspension was spun down at 1500-2000 rpm for 10 minutes in a 
centrifuge cooled to 4°C, the supernatant discarded and the pellet resuspended 
in 10 ml of cold RPMI-1640. Cells were counted in a Neubauer haemocytometer. 
The suspension was diluted to 5x105 macrophages/ml, then distributed into 
wells mounted on 16-well glass slides (Nunc, Rochester, NY), using Eppendorf 
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multidosers and syringes, 100 !-AI in each well (equivalent to 50,000 macrophages 
per well). This day is considered Day 0 of the experiment. 
Eight slides were used for each full assay. The first two slides were controls, 
with four wells used in each. The other six slides were used for assaying serial 
dilutions of drugs, each drug in four concentrations, each concentration in 
quadruplicate (Figure 4.2). 
After 48 hours (Day 2) the cell cultures were infected with a suspension of 
Leishmania promastigotes. 
After 24-hour incubation, one control slide was stopped: the medium 
removed, the wells detached, the slide fixed with absolute methanol for one 
minute and stained with 10% Giemsa solution for ten minutes. 
In the other slides the medium was removed using sterile disposable 
pastettes, then 150 !-AI of medium was added into each drug assay well and 
200 !-AI into five-day untreated control wells. 
Drug solutions were prepared in 24-well tissue culture plates with four 
serial dilutions of each drug, in four-fold the desired concentrations. 50 !-AI of 
solution was added to each well to give the desired concentration in the total 
200 !-AI volume. 
On Day 5 the medium was replaced and fresh drug dilutions added, as 
above, and on Day 7, i.e. after a five-day exposure to the drug, the experiment 
was stopped as described above for the control slide. 
The slides were examined microscopically at x1000 with immersion. In each 
well 100 macrophages were counted, and the percentage of infected 
macrophages was recorded. 
The percentage inhibition was calculated according to the following 
formula: 
%inhib = inflesr - infcrr' xl 00 
infcrr' 
where: 
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%inhib is percentage inhibition, 
inflesl is percentage infection in the test well, 
infc1r' is the mean percentage infection in the four 5-day control wells. 
The data on percentage inhibition in every well were entered into a Prism 
(version 4.2 for Windows, GraphPad Software, Inc.) template, and the 3000 
effective concentration (ECso) was calculated. 
4.2.4.3. Assay optimisation 
4.2.4.3.1. Parasite-to-macrophage ratio 
The assay was conducted using one reference strain of L. tropica (MHOM/ 
SU/74/K27, abbreviated here as K27) and two field isolates, A021/p and K100/p. 
The macrophages were infected in four ratios: 3:1, 5:1, 7:1 and 10:1. Different 
slides were stopped after 24, 48 and 72 hours and 5 days post-infection. The aim 
was to obtain an infection level of 70% or more after 2.f hours rising to 80% or 
more after five days. 
One of the field strains gave very high infection levels (>91 % after 24 hours 
and >94% after five days) at all parasite-to-macrophage ratios, the other, at 5:1 
or more. The reference strain K27 was contaminated, so only the 24-hour slide 
was available to evaluation. It failed to reach 70% infection level even at the 10:1 
ratio. Later on, reduction of parasite-to-macrophage ratios to 3:1 was tried again 
with different drug concentrations (sec "Drug concentration range"), resulting 
in low infection levels in two of the three strains tested. 
4.2.4.3.2. Washing 
In addition, selected slides were washed with plain cold RPMI-1640 24 or 48 
hours post-infection to remove excess promastigotes. Washing did not improve 
the number of promastigotes in the final slides, so it was not employed in 
further experiments with one exception: we tried to remove the actiyely 
swimming promastigotes that were clearly visible under the inverted 
microscope before stopping one slide after the end of the experiment. The wells 
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were repeatedly washed with cold phosphate-buffered solution (PBS) and re-
examined under inverted microscope after each wash. Each wash was 
performed by pushing PBS several times then aspirating and discarding it. The 
density of promastigotes became lower only after six to seven washes, and after 
fixing and staining the slide it became obvious that most macrophages were 
washed away as well. 
4.2.4.3.3. Drug concentration range 
About twenty field isolates were then tested using standard drug doses 
with three-fold dilutions, each dose in quadruplicate. The concentrations of 
antimony preparations were calculated according to antimony content, while 
for the other drugs molar concentrations of the compound were used. 
SSG and Glucantime were used at 80, 27, 9 and 3 I-lg Sbv/ml; SbIll at 30, 10, 
3.3 and 1.1 I-lg SbIll/ml [Yardley et ai., 2006]; AmB, at 2, 0.66, 0.22 and 0.07 !-lM; 
miltefosine, 30, 10, 3.3 and 1.1 !-lM; and paromomycin at 50, 16.7, 5.55 and 
1.85 I-lM. 
The microscopical examination revealed that all the isolates tested had EGo 
values for SSG (and Glucantime) and Sbill higher than the highest drug 
concentration used (80 and 30 I-lg/ml, respectively), with high parasite burdens 
but were all very sensitive to AmB (several isolates showing EGo values below 
0.07 I-lM, the lowest concentration used). 
The following experiment used a maximum of 120 I-lg Sbv/ml against three 
isolates at two parasite-to-macrophage ratios, 3:1 and 5:1. The top concentration 
of AmB was reduced to 1 I-lM. The concentration of Sbill remained unchanged 
because higher concentrations cause toxicity to macrophages. The results did 
not change significantly: all the tested isolates had EGo values higher than 
120 I-lg Sbv/ml, and at 3:1 infection ratio only one isolate exceeded 80% infection 
in untreated control wells. The range of EGo values for AmB lay between the 
two lowest concentrations for two of the three samples, so in subsequent 
experiments the maximum dose of AmB was further decreased to 0.5 !-lM. 
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The next experiment was designed to test for drug response at Sb' 
concentrations up to 500 f..tg/ml. In order to cover the lower part of the range, 
five-fold dilutions were used: 500, 100, 20 and 4 f..tg Sb'/ml. 
4.2.4.3.4. Drug exposure period 
In addition, an attempt was made to increase the drug exposure period, so 
the same experiment was run in triplicate: one arm for five days' exposure 
(standard duration), and the other two arms for seven and ten days. In the latter 
two arms the medium was replaced and fresh drugs added on the fifth day of 
exposure, and in the ten-day arm, also on the seventh day of exposure. 
Of the three samples tested one had slight bacterial contamination in the 
five-day arm which became heavy in the 7- and 10-day arms, hence could not 
be evaluated, and had an ECso value greater than 500 f..tg/ml at five days. 
Another isolate had an ECso value greater than 500 f..tg Sb'/ml in all the three 
arms, and the last one showed ECso values of 114, 224 and 137 f..tg Sb'/ml at 5, '7 
and 10 days, respectively. It was concluded that, 1) the top concentration of 
500 f..tg/ml might also be too low; and, 2) increasing the duration of the 
experiment beyond five days is unlikely to provide any additional information. 
4.2.4.3.5. Final calibration of Sb v concentrations 
The next experiment was conducted with an additional top concentration of 
2500 f..tg Sb'/ml (2.5 mg). The five isolates tested in this experiment showed ECso 
values that ranged between 121 and 239 f..tg Sbv/ml for SSG and between 468 
and 2288 f..tg Sbv/ml for Glucantime, so the new maximum of 2500 f..tg/ml was 
considered unnecessary for SSG. Because it seemed that Glucantime had lower 
activity, for it the top concentration was kept at 2500 and the minimum at 
20 f..tg Sb '/ml. 
4.2.4.3.6. ECso calculations: infected macrophages vs. parasite 
burden 
For fin:' isolates an attempt was made to determine ECso values by counting 
the number of parasites in each macrophage (parasite burden). The number of 
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parasites inside 25 infected or uninfected macrophages in each well (4 wells per 
concentration) were counted. The results differed considerably from the 
classical method. ECso values obtained by parasite burden were considerably 
lower than those by proportion of infected macrophages, and the difference 
ranged between 3.6 and more than 30 times. The results are presented in Table 
4.2 (for SSG) and Table 4.3 (for Glucantime). However, in this study, 
determining drug sensitivity by parasite burden for all isolates was not a 
feasible option due to time constraints. 
In many slides, in addition to intracellular amastigotes, different amounts of 
promastigotes were present. In this case, only the macrophages that contained 
any amastigotes were counted as positive (infected). Sometimes the 
promastigotes would considerably obscure the picture making counting 
extremely difficult. The macrophage was counted as positive only if at least one 
amastigote could be discerned among the promastigotes. The macrophages that 
contained promastigotes only, but no amastigotes, were considered negative. 
In one of the experiments two days passed between spreading out the 
macrophages and infecting them. All the isolates tested in that experiment 
looked remarkably clear, i.e. without promastigotes. It was decided to infect the 
macrophages after 48 hours of incubation. 
4.2.4.4. Validation: Inter-experiment variability (AmB) 
4.2.4.4.1. Experiments with different drug doses 
Three isolates were tested for Am8 sensitivity twice, using different 
protocols: the first protocol with maximum dose of 2 f-LM (high dose) before 
concentration calibration was finished, and the second, with maximum dose of 
500 nM (low dose) that was finally used in all the isolates. The results are 
shown in Table 4.7. 
4.2.4.4.2. Experiments with different isolates from the same patient 
For seven patients the results of sensitivity testing for AmB were available 
from different isolates obtained in the course of treatment with antimonial 
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drugs, tested in different experiments. Assuming that treatment with 
antimonials does not affect the sensitivity to AmB, these were compared to 
assess inter-experiment variability. The last row shows the results for the same 
isolate (K112/p) tested twice using the same protocol but in two different 
experiments (Table 4.8). 
4.2.4.5. The drug sensitivity assay: the final conditions 
All the isolates for which the results will be reported were tested in the 
conditions described below, with the exception of Table 4.7 that displays the 
impact of drug concentration range on the sensitivity values obtained. All the 
clinical isolates were tested within seven passages from clinical isolation. 
The procedures for macrophage induction and harvesting remained as 
described above. The same applies to preparation of cell cultures for the 
experiments. Briefly, mice were induced with starch, and the macrophages 
harvested after 24 hours, centrifuged, resuspended in RPMI-1640 plus 10% 
HIFCS, counted, diluted to 5x10S cells/ml, plated out in 16-well cell culture 
slides and incubated at 34°C in 5% C02/air mixture throughout the experiment. 
This day is the Day 0 of the experiment. 
Macrophages were infected after 48 hours (on Day 2) at 5:1 parasite-to-
macrophage ratio, incubated for 24 hours and drugged (on Day 3) as described 
above. The drug concentrations finally used in full experiments with a parasite-
to-macrophage ratio of 5:1 are outlined in Table ~.4. 
The medium was replaced after two days (on Day 5), and fresh drugs 
added. After further three days (Day 8) the experiment was stopped, the slides 
fixed with methanol and stained with Giemsa stain as described above. 
4.2.4.5.1. Full and Essential assays 
Full assays that included all the tested drugs were applied to the isolates 
obtained before treatment. 
In "essential" experiments only the first three drugs in Table ~A - SSG, 
Gluc,mtime and ArnB - were used. These included the follow-up isolates 
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obtained during the course of treatment and repeated assays of pre-treatment 
isolates (i.e. the isolates that were tested at low doses of Sb\ in the calibration 
process using all the drugs). This was done due to time constraints. 
Amphotericin B was used as a positive control because it was uniformly 
effective in clearing the macrophages at the doses tested. Miltefosine and 
paromomycin were included in the assays to test possible alternatives to SbY 
treatment. 
4.2.4.6. Priorities - selection of isolates for testing 
Due to the large number of clinical isolates (about 150 from acute leishman-
iasis patients and 37 from chronic or relapsed patients), priorities for testing 
were set. According to the aims of the present study, these were as follows: 
1. The strains from patients for whom serial (pre-treatment and follow-
up) isolates were available; 
2. The strains from patients with successful pre-treatment isolates, if the 
patients were followed up clinically for at least six weeks; 
3. The strains from chronic or relapsed patients. 
Due to time restrictions, the isolates from patients for whom follow-up data 
were incomplete or who did not start treatment were not tested. Only a dozen 
of isolates from chronic/relapsed patients was tested during assay calibration 
period with low doses of Sb\ and these tests were not repeated with high 
concentrations. Thus, only the isolates from the first two categories were tested. 
4.2.5. Leishmania typing 
4.2.5.1. Typing to species level 
The isolates eligible for drug assays (n=40) and seven isolates from chronic 
or relapsing patients were typed to species level. The typing was performed at 
LSHTM by Dr. Isabel Mauricio by microsatellite analysis of the ribosomal D~ A 
internal transcribed spacer [Mauricio I't al., 2004; Kuhls et al., 2005]. The results 
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were compared to the profiles of reference strains of L. donovani (YiHOM/I\:/80 
/DD8), L. major (MHOM/SU/73/5-ASKH), and L. tropica (MHOM/SU/197.f/K27). 
In addition, ten of the above-mentioned isolates were subtyped using 
multilocus sequence typing (MLST) for five enzymes [Yiauricio et al., 2006]. 
4.2.5.2. Fingerprinting 
A selection of clinical isolates was sent to Dr. Israel Cruz of Instituto de Salud 
Carlos III (Madrid, Spain) who kindly agreed to perform fingerprinting. The 
isolates were selected for typing if they belonged to patients from whom serial 
isolates were available or if patients were members of one family. 
Fingerprinting was performed using digestion with two enzymes, RsaI and 
HaeIII for kinetoplast DNA (kDNA) and cysteine proteinase B antigen-
encoding gene (cpb), respectively. These enzymes were shown to give the 
highest polymorphism [Botilde et al., 2006]. The samples were also 
fingerprinted using DraIII. The procedures used are outlined in Appendix 8. 
4.2.5.3. Sample preparation 
Pellets for typing were prepared either from live promastigote cultures or 
from cryopreserved aliquots. The culture or aliquot was transferred to a 15-ml 
centrifuge tube and topped up with cold PBS to 13-15 ml, centrifuged at 
2000 rpm for 10 minutes, the supernatant discarded, the pellet resuspended in 
13-15 ml PBS and centrifuged again as above. The pellets were kept in the 
freezer at -80°C until typing. 
Prior to sending the samples to Spain for fingerprinting, the pellets were 
thawed shaken to mobilise them and 1 ml of 70"~() ethanol added to each. After , 
this, the samples were sent by express mail. 
All the samples were of sufficient size to perform the necessary tests. 
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4.3. Results 
4.3.1. Drug sensitivity 
Eighty isolates from patients with acute cutaneous leishmaniasis were 
successfully tested (i.e. with acceptable infection ratios in untreated controls 
and no or insignificant contamination) with high doses of antimony and one 
isolate from a patient with chronic lesions. For all these isolates the sensitivity to 
SSG was determined by percentage of infected macrophages. The results of 
testing using parasite burden are reported in Table 4.5 but not included in 
further statistical analyses, as that would mean having two different values for 
the same isolate. 
Sensitivity to Glucantime was determined for sixteen isolates, to 
amphotericin B, for 67 isolates, and to miltefosine and paromomycin, for eleven 
isolates. For miltefosine and paromomycin the isolates were selected based on 
good readability of SSG slides. Most of these readable slides were also sensitive 
to SSG, so the selection is non-random. 
The results of sensitivity testing are summarised in Table 4.6. All the isolates 
were sensitive to amphotericin B. For all the other drugs, some isolates were 
insensitive, i.e. showed inhibition of growth of less than 50% at the highest 
concentration used in the assay for that drug. All the isolates tested for 
paromomycin were insensitive to the drug (ECso> 50 !-1M). Range, mean and 
quartile values for the isolates for which the ECso values lay within the range of 
test concentrations of every drug are given in Table 4.6. 
4.3.1.1. Sensitivity to SSG and Glucantime 
ECso values for SSG and Glucantime, including the results obtained using 
parasite burden, were plotted, after converting to common logarithms (10glO) of 
the ECso values (Figure 40.3), and analysed by linear regression. Adjusted 
Rc=O.721, p=O.OOOl, showing a highly significant positive correlation between 
the sensitivities to these pentavalent antimony drugs. 
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4.3.1.2. Relationship between sensitivity to SSG and other 
drugs 
No relation between sensitivity to SSG and that to AmB or miltefosine was 
detected. Sensitivity to SSG was classified as either "sensitive" or "insensitive" 
by selecting the breakpoints in two ways: the isolates with ECo>500 f.lg Sbv/ml 
vs. those with ECso~500 f.lg Sbv/ml and the isolates with sensitivity below or 
equal to the median value (229 f.lg Sbv/ml) and those with ECso higher than the 
median, including the isolates with ECso>500 f.lg Sbv/ml. The median 
sensitivities to AmB for each of the comparisons were compared by Mann-
Whitney test, resulting in p=O.170 in the former comparison and 0.787 in the 
latter, both not statistically significant. 
For miltefosine, the results of only nine isolates were available, all 
corresponding to the isolates with sensitivities to SSG of ~500 f.lg SbY/ml, and 
only one isolate corresponded to the group of sensitivities to SSG above the 
median, and for this reason the two groups, one of which consisted of only one 
isolate, could not be compared (Table 4.6). 
All the isolates tested for paromomycin gave ECso values beyond the range 
of test concentrations (Table 4.6). 
4.3.1.3. Exposure to antimonial treatment and sensitivity to SSG 
Fifty-two serial isolates from 23 patients were available. For the remaining 
28 patients one isolate was available from each patient. The isolates were 
classified to exposed and unexposed groups, the former comprising the isolates 
obtained before treatment and the latter during the course of treatment. 
No significant differences in the median sensitivity to SSG were found 
between the two groups: p=0.141, Mann-Whitney test, when all the isolates 
were analysed and p=0.21 when the analysis was restricted to patients with 
serial samples. Exposure to treatment and nominal sensitivity (below vs. above 
the median) were cross-tabulated, p=O.l1 by Pearson's X" test. 
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4.3.2. Parasite typing 
4.3.2.1. Typing to species level 
All the parasites typed to species level belonged to Leishmania tropica. 
Subtyping using MSL T showed that all but one belonged to the common 
heterozygous group, and one isolate was homozygous. 
4.3.2.2. Fingerprinting 
Seventy-two isolates from 35 patients were fingerprinted using three 
restriction enzymes: DraIII, HaeIII and RsaI. According to DraIII, all the isolates 
belonged to one group. Fingerprinting using HaeIII and RsaI grouped the 
isolates into 29 schizodemes with perfect agreement between both methods. 
Twenty-one isolates were available from fourteen patients belonging to six 
families. 
• As a rule, the isolates from one patient belonged to the same schizodeme 
(SchD). 
• In four families comprising nine patients, the schizodeme was common 
for each family. 
• In the fifth family the grandmother had SchD S14, and grandson, 516 at 
baseline (the homozygous one, KI27/p) and 512 before the 4th dose. 
• In the last family (3 members), one member with 2 sequential isolates 
had SchD S15 sharing it with an unrelated patient; another member, 511; 
and the third member with pre-treatment isolates from two lesions, 510 
and 512. 
• Unrelated people might share the same schizodeme, but the sharing 
always happened within the same health centre catchment area (see 
Chapter 3). 
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4.3.3. Drug sensitivity and treatment course 
Parasite sensitivity was categorised into "sensitive" and "insensitive" in two 
ways: first, all the parasites that had SSG ECo values within the test 
concentration range, i.e. up to 500 f.!g SbY/m!, were considered sensitive, and 
those with values beyond the testing range, insensitive (Table 4.9). Second, all 
the parasites that had SSG ECso values within the testing range were divided 
into sensitive and insensitive by the median value, 229 f.!g SbY/ml, and this was 
taken as a breakpoint, but the sample still contained the isolates that had SSG 
ECso values beyond the testing range (Table 4.10). The median values for the 
number of injections, treatment duration and time to cure were compared 
between the patients whose isolates were "sensitive" and "insensitive" 
parasites at baseline. 
The differences between the groups were not statistically significant in the 
first comparison (below 500 vs. over 500 f.!g SbY/ml). In the second comparison 
(up to 229 vs. >229 f.!g SbY/ml) the patients with less sensitive isolates had 
significantly less visits and shorter treatment duration. The differences in time 
to cure were not statistically significant. 
4.4. Discussion 
The most striking finding was the very low in vitro sensitivity of our isolates 
to SSG. In a similar study performed in Iran [Hadighi et aI., 2006], where the 
causative organisms were L. major and L. tropica, the maximum EC;ll value 
reported was 51 f.!g Sb \/ml, which is below the 1st quartile in our dataset. That 
study differed from ours in the length of drug exposure (six days ['5. five days) 
and in much shorter length of incubation of macrophages with parasites (two 
hours U5. 24 hours). The authors used 4:1 parasite-to-macrophage ratio and 
supplemented the culture medium with 15%, rather than 10%, of foetal calf 
serum. The authors mentioned that they determined Eel' both by percentage of 
infected macrophages and number of parasites per infected cell but did not 
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mention either whether the results between the two methods were similar nor 
which method was used for reporting sensitivity values. It is hard to say with 
confidence whether these differences in the testing protocol can explain the 
differences in results. This is the only study linking the in vitro sensitivity of 
field isolates of L. tropica with clinical outcome that could be identified. 
There was a strong positive correlation between the sensitivities of our 
strains to Pentostam and Glucantime, which is to be expected, as the two drugs 
have the same active substance, pentavalent antimony. 
All the isolates tested were highly sensitive to AmB and insensitive to 
paromomycin within the drug concentration range used in this study. 
Nine of 11 isolates for which the sensitivity to miltefosine was determined 
were sensitive to the drug. The same isolates were also sensitive to SSG. 
In a study of L. tropica drug sensitivity in Iran [Hadighi et ai., 2007] eight 
isolates (four sensitive and four insensitive to Glucantime) were tested for in 
vitro sensitivity to amphotericin B, miltefosine and paromomycin. All the 
isolates tested were sensitive in vitro both to miltefosine (ECso=l flM) and 
paromomycin (ECso=5 flM), and two of the isolates that were insensitive to 
Glucantime had high AmB ECso values (17 and 26 flM). 
No correlation was found in our sample between the isolate sensitivity to 
SSG and that to AmB. 
The relationship between the sensitivities to SSG and miltefosine or 
paromomycin could not be established because the latter was uniformly 
insensitive and for the former only one isolate with low sensitivity to SSG was 
available. 
A recent study of nineteen clinical isolates of L. donovani from areas of high 
and low antimony sensitivity [Kumar et ai., 2009] revealed that the isolates from 
areas with low antimony sensitivity were less sensitive to amphotericin B and 
miltefosine in vitro, suggesting the potential for development of cross-resistance 
to these drugs. This study also reported a weak correlation between the 
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sensitivity of promastigotes and amastigotes to AmB and a strong correlation 
between the sensitivities of these two parasite stages to miltefosine. 
The lack of significant difference between the isolates obtained before or 
after treatment is in agreement with the results of a similar study of L. tropica 
from Iran [Hadighi et al., 2007], but another group working with New World 
species (L. braziliensis, L. guayanensis and L. panamensis) found that several 
isolates obtained from poorly responding patients during the course of 
treatment became less sensitive to antimony in vitro compared to baseline 
isolates [Rojas et al., 2006]. These authors used a human promonocytic cell line 
(U-937) in their assays, 20:1 parasite-to-macrophage ratio and 72-hour drug 
exposure. 
The results of parasite typing showed that all the isolates tested are 
L. tropica, confirming the aetiology of leishmaniasis in Aleppo. 
Fingerprinting of selected isolates showed that in most cases the organism 
isolates from the same patient during the course of treatment is the same, and 
that the parasites isolated from members of one family usually belong to the 
same strain, with a few exceptions in both cases. The strain with the same 
fingerprint may affect unrelated patients but in our selection the patients with 
the same strain would corne from a catchment area of the same PHC centre. 
This is in accordance with the "patchy" distribution of leishmaniasis due to 
short flight range of phlebotomines. 
We failed to find a meaningful correlation between pre-treatment parasite in 
vitro sensitivity and treatment outcome. Moreover, when the isolates were 
classified into "sensitive" and "insensitive" using the median sensitivity of the 
numbers within testing concentration range, it seemed that the patients from 
whom less sensitive parasites were isolated before treatment had significantly 
shorter treatment duration and required fewer injections. The studies that 
addressed the relationship between baseline Leishmania sensitivity and 
treatment outcome are few. In the above-mentioned Iranian study [Hadighi et 
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al., 2006] a strong correlation between pre-treatment parasite sensitivity and 
clinical outcome was reported: the ECso values for the parasites from 
responding patients was below 10 f-lg Sbv/mI, whereas from non-responders it 
was over 10 f-lg Sbv/ml. But another study, from Peru [Yardley et al., 2006], 
found no correlation between baseline antimony sensitivity of the clinical 
isolates and clinical outcome. Definitions of treatment success are not uniform. 
In the Iranian study the treatment success was complete re-epithelialisation 
with no relapse within 6 months of follow up. In the latter study two measures 
were used: 1) initial cure within three months of treatment and 2) complete cure 
meaning initial cure plus no relapse within twelve months after treatment. 
Testing clinical isolates may be associated with methodological 
uncertainties. Patients may suffer from mixed infections with more than one 
strain present in the lesion. This is illustrated by the apparent change of parasite 
fingerprint during the course of treatment in one of our patients. Different 
strains may have different growth and macrophage infection rates, and these 
differences need not be the same in vivo (Le. in the lesion, where they may 
change during the course of treatment) and in the culture medium, which 
means we cannot be fully sure what strain predominates in the culture which 
was subpassaged more than once before testing, and whether the initially 
predominating strain (or the one that was more important in defining the 
clinical picture) was not lost altogether. A similar problem concerning isolating 
trypanosomatids from naturally infected wild insects was discussed in a recent 
review [Podlipaev, 2001]. 
It is possible to conceive that factors other than parasite sensitivity to drugs 
are more important in determining the clinical course of the disease. One of 
these factors could be host immune response, which was not tested in this 
study. 
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4.5. Tables 
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Table 4.1. Summary of articles reporting testing Leishmania sensitivity to Sbv • I~ 
Reference Location Species Form Host Ratio Duration of Concentration Counting EC50 values for 
range and amasti~otes 
steps (~g Sb /ml) 
infection treatment ofSbv 
Q 
[Berman et a/., Iran? ref: WR 401 major amastigotes PMC (human) 7.5:1 4h, 6 days; 2 - 251 !-Ig/ml, 1. number of [mean] 
I 1982; Berman (NIH 173) from mice diff. to Mq> in washing drugs 2x (?!) amastigotes 2.8 (1.6-3.6) 
and Gallalee, 6d. and refreshed on 2. scintillation (3H); 
I 1985] drugging day 3. of radiolabelled 4.1 (2.2-5.3) 
cultures 
I [Faraut- France infantum amastigotes Mouse -4:1 not stated 7 days; 7.5, 15, 30, 45, 1. number of [range for -35 
Gambarelli et peritoneal Mq> (30:8) drugs 60 !-Ig/ml MGA surviving samples] 17 -234 
a/., 1997] refreshed on Leishmania cells (?!) 
days 2 and in 100 Mq> 
I 5. 
[Lira et a/., India donovani amastigotes Mouse -3:1 1 h, then 3 days, Seven 1. % Mq> [mean] 
1999] peritoneal Mq> washed drugged concentrations, infected; responsive 
and once. 2-50 !-Ig/ml 2. rr/infected 2.4±2.6; 
incubated SSG Mq>; unresponsive 
72h before 3. % killing = 7.4±3.7. [Range] 
1st total rr/100Mq> 1-13.5 ED90s 
treatment (treated reported 
untreated) 
[Hadlghl et al., Iran tropica amastigotes Mouse Mq>, 41 2h, 6 days; drug not stated; 1. % Mq> 2.2-51 !-Ig/ml 
2006] THP washing refreshed on published EC50 infected; 
and day 3. values range 2. rr/infected drugging 2.2-51 !-Ig/ml Mq>; 
MGA 3. luciferase in THP 
[Rojas et al., Colombia panamensis, amastigotes U-937 201 2h, 72h; drug 2-128!-1g/ml %Mq> infected. 0.9 - >128 
2006] braziliensis, (human), diff. washing, refreshed MGA 
guayanensis to Mq> in 96h then 24h after 48h. 2x 
and 
drugging 
1 Not stated; inferred from graph. 
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Reference Location Species Form Host Ratio Duration of Concentration Counting EC", values for 
range and amasti~otes 
steps (~g Sb Iml) 
infection treatment ofSbv I 
[Azeredo- Brazil braziliensis, promastigotes, J774A.1 1: 1 4h, wash 72h, not stated; 1. 19-55 j.Jg/ml I 
Coutinho et al., guayanensis axenic mouse M<p and drug drugged reported ECso promastigot 
2007] (field); amastigotes in cell line every 24h; results: es: Coulter panamensis, M<p promastigotes, counter tropica, 0.8-60 mg/ml; 2. 
amazonensis, amastigotes, amastigotes 
mexicana 19-55 j.Jg/ml : number in 50 (WRAIR) (braziliensis random M<p/well 
only) (braziliensis only) 
[Robledo et SWColombia panamensis, amastigotes; U-937 20:1 2h, 3,4 and 6 standardization 1. % infected <5.3 - >170 
aI., 1999] braziliensis promastigotes washing; days, : 0.85-8500 M<p; 
24h, then renewing j.Jg/ml, 10x; 2. mean 
infecting drug every 2 assay: 5.3- number of 
days 170 j.Jg/ml, parasites per M<p 
prob. 2x steps, (for ECso) 
for 4 days 
[St George et unknown major, amastigotes, mouse M<p 6.251 not stated 3 days, 50 and 75 1. % infected not stated 
al., 2006] tarentolae promastigotes drugged j.Jg/ml M<p; 
once? 2. 
amastigotes 
/100 M<p 
[Yardley and unknown major amastigotes, mouse M<p 5:1 24h 5 days, not stated % of cells 30 and 35 
Croft, 1997] promastigotes renewed on infected (2 strains tested) 
day 3 
-------
M(l), milcrophilgc; 'IT, parasite; MeA, meglumine antimoniate; ECso, 50% effective concentration; ED90, 90')-'0 effective concentration. 
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Table 4.2. Comparison between ECso values for sodium 
stibogluconate obtained by counting the percentage of infected 
macrophages and those by counting the number of parasites within 
each macrophage. Confidence intervals (950 0) are given in 
parentheses. 
Strain ECso (macrophages) ECso (burden) 
K127/p 205 (107-325) 6.5 (3.3-13.0) 
Y132/p 197 (173-225) 55.3 (28.6-107) 
A 135/p 2405 (465-12k) 101 (50.9-202) 
A062/p' 260 (207 - 326) "Does not converge" 
Neal-P* 330 (281-387) 81.6 (30.9-215) 
* MRHO/SU/59/Neal-P is a reference strain of L. major. Passage 2 was used. 
Table 4.3. Comparison between ECso values for Glucantime 
obtained by counting the percentage of infected macro phages and 
those by counting the number of parasites within each macrophage. 
Confidence intervals (95%) are given in parentheses. 
Strain ECso (macrophages) ECso (burden) 
K127/p 318 (194-521) 17.06 (4.97-58) 
Y132/p 534 (313-909) 98.2 (too \,\,ide) 
A 135/p 496 (282-873) 86.7 (53-141) 
Table 4.4. Drug concentrations used in the experiments after 
calibration. 
Dose Unit : Max. : High : Low : Min. 
Dru 
SSG Ilg Sb/ml 500 100 
Glucantime [1g Sb/ml 2500 500 100 
.f 
20 
AmB 11M 500 167 55.6 18.5 
Sblll tlg Sb/ml 30 10 3.3 1.1 
Miltefosine [1M 30 10 3.3 1.1 
1M 50 : 16.7 5.56 1.85 
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Drug 
SSG 
Gme 
AmB 
Sb Ill 
Milt 
PM 
Table 4.5. Comparison of ECso values (J.lg Sbv/ml) obtained by 
counting the percentage of infected macrophages and by the 
number of parasites within each macrophage for three isolates. 
SSG Glucantime 
Isolate ID macropha:?e burden macropha:?e burden 
K127/p 205 6.5 318 17.1 
Y132/p 197 55.3 534 98.2 
A135/p 2405 101 496 86.7 
Table 4.6. Results of sensitivity testing of clinical isolates. 
n total % mean median interquart. range ran&e 
±SD 1 sl 3rd min. max. 
32 81 39.5 238±114 229 163 265 28.9 525.9 
15 16 93.8 748±552 547 407 1033 30.3 2288 
67 67 100 67.7±26.9 66.6 52.0 84.9 17.7 149.5 
1 13 7.7 5.4 5.4 5.4 5.4 5.4 5.4 
9 11 81.8 1O.4±4.5 9.7 7.9 14.0 2.6 17.5 
0 11 0 >50 >50 >50 >50 >50 >50 
SSG, sodium stibogluconate (Pentostam™); Gme, Glucantime™; AmB, amphotericin B; Sb rll, 
trivalent antimony; Milt, miltefosine; PM, paromomycin; n, number of results within the range 
of concentrations tested; total, total number of isolates for which an attempt has been made to 
determine ECso; %, (n/total)xlOO. 
Units for SSG and Gme are in f-Ig Sbv/ml; for AmB, nM; for Sbrll, f-Ig SbIII/ml; Milt and PM, mM. 
Table 4.7. Results of sensitivity testing of three isolates to AmB 
(ECso, nM) using two different drug dosage protocols, with a 
maximum 2 J.lM (high dose) and a maximum 500 nM (low dose). 
Strain ID Low dose High dose 
H020/p 22.3 144.5 
Y036/p 41.1 73.2 
KIOO/p 52.7 22.3 
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Table 4.8. Inter-experiment variability of sensitivity testing (AmB, , 
nM). 
Patient 10 isolation 1 isolation 2 isolation 3 range (-fold)" 
Y036 41.1 27.2 1.51 
A080 73.3 52.3 1.40 
A082 74.1 65.3 3~.3 1.93 
A092 34.7 65.3 60.4 1.88 
A094 53.2 52.7 1.01 
YlOS 63.7 94.4 1..t8 
K1l2 86.6 104.5 1.21 
.. The range IS the maxImum ECso result in a series divided by the minimum result in the 
same series. 
Table 4.9. Relationship between baseline parasite in vitro 
sensitivity to SSG (breakpoint at maximum testing concentration) 
and the number of injections (visits), treatment duration (weeks) 
and time to cure (weeks). 
up to SOO ~g Sbv/ml >SOO ~g Sbv/ml 
n mean (SO) median n mean (SO) median 
Visits 17 12.9 (4.3) 13 30 11.2 (4.3) 12 
Treatment 17 21.0 (6.4) 22 30 16.6 (9.0) 15.5 
duration 
Time to cure 11 21.9 (7.5) 23 23 22.7 (11.2) 
.. Mann-Whitney test. SO, standard deviation. 
Table 4.10. Relationship between baseline parasite in vitro 
sensitivity to SSG (breakpoint at the median sensitivity within 
testing concentrations) and the number of injections (visits), 
treatment duration (weeks) and time to cure (weeks). 
up to 229 I-lg Sbv/ml >229 I-lg SbY/ml 
23 
n mean (SO) median n mean (SO) median 
Visits 11 H.I (3.5) 15 36 11.0 (4.2) 10 
Treatment 11 22.7 (6.4) 2.t 36 16.8 (8.5) 1/ .5 
duration 
Time to cure 7 23.1 (7.9) 23 27 22.2 (10.7) 23 
.. Mann-Whitney test. SO, standard deviation. 
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p' 
0.171 
0.106 
0.868 
p' 
0.01 
O.O.t.t 
0.87 
4.6. Figures 
>40 days old 
Passage 0 
mould, 
yeast, 
bacteria 
mould, 
yeast, 
bacteria 
Re-examine until 
40 days old. 
No more 
subpassaging 
Within 3-7 days 
Within 3 -7 days 
no 
yes 
if not 
subpassaged 
previously 
Subpassage Passage 1 
L-________ ~--------~ 
Examined in the 
same way as 
Passage 0 
yes 
NOT in the same 
batch as 
Passage 0 
Figure 4.1. Flow chart showing the process of isolation of clinical 
samples until sending to LSHTM. 
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Figure 4.2. Schematic representation of a 16-well slide layout. For 
untreated controls only wells 1-4 were used. For drug assays the 
slides 1-4 contained the lowest concentration of a drug, slides 5-8, 
the next, 9-12 the next higher and 13-16 the maximum 
concentration. Each slide was marked (from left to right) with 
isolate ID, drug abbreviation, date of experiment and 
experimenter's initials. In experiments with more than one arm, 
additional information, such as parasite-to-macrophage ratio or days 
of exposure, was added. 
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Figure 4.3. Comparison of logarithms of ECso values of SSG and 
Glucantime The analysis includes the results of parasite burden 
testing. 
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Chapter 5. Knowledge, attitudes 
and practices 
5.1. Introduction 
Cutaneous leishmaniasis (CL) has been endemic in Aleppo, Syria for 
centuries, giving the disease one of its common names, Aleppo boil [Canaan, 
1929; Hovnanian et al., 1937]. Aleppo is also the site of the first recognisable 
modern description of CL [Russell, 1756], although the disease may have been 
described as early as in the ninth century under the name of Balkh sore [Elgood, 
1934]. 
Russell mentioned that the disease is known locally as habt il senne, 
translated by him as botch of a year. Peter Borovsky, the author of the first 
description of the Leishmania parasite that is in agreement with current 
knowledge about its morphology and relationship to host tissues, suggested 
that the aetiology of similar skin conditions, including those encountered in 
Aleppo and Biskra, should be investigated as there might be links to the same 
causative agent [Borovsky, 1898]. 
Russell's observations suggest that CL has been recognised by the lay 
population since at least the middle of eighteenth century. However, to our 
knowledge, no studies were published about the perceptions of the population 
of Aleppo concerning this common condition. Moreover, it seems there were no 
publications about popular perceptions of CL in the Old World until quite 
recently, although statements regarding the perceptions of local people of the 
disease occasionally appeared in articles dedicated to the epidemiology or 
treatment of leishmaniasis. However, these statements are probably based on 
authors' impressions, because no further references are given. Siage, working in 
Damascus where the causative agent was probably L. major, mentioned that the 
\"illagers tended to ignore the lesions because they are indolent, and "the scars 
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are not usually feared of" [Siage, 1964]. A similar statement was made about the 
perception of CL in the Arabian Peninsula, that this disease "was simply 
accepted as a fact of life" [Peters, 1988]. By contrast, in a report from Aleppo, 
Ashford et al. state: "Infection is most important as a public health problem in 
teenagers and young adults, for whom the cosmetic effects are often considered 
very serious" [Ashford et al., 1993]. These findings are echoed by studies 
performed in Afghanistan which often report that CL is considered 
stigmatising, and that people with the disease may face social ostracism. In 
Kabul girls with scars are considered unsuitable for marriage, and it is 
considered inappropriate for women with active lesions to raise children, cook 
or wash for the family [Reithinger et al., 2003; Reyburn et al., 2003]. A later 
Reithinger et al. involved a series of focus-group discussions which confirmed 
their previous observations of popular perceptions of CL in Kabul [Reithinger, 
Aadil et al., 2005]. Recently, a more in-depth study was performed in Istalif 
district of Kabul province, located 50 km to the north of Kabul and inhabited by 
Tajiks, with anecdotal reports of more than 50% prevalence of 
leishmaniasis [Stewart and Brieger, 2009]. The authors reported that the local 
name of the disease, saldana, means "one-year sore" (similar in meaning to habt 
il senne in Aleppo, salek in Iran and godovik in Russia) and confirmed its 
stigmatising perceptions among the local population. 
In Turkey, one study examined the psychological impact of CL in Sanliurfa, 
a region adjacent to Aleppo governorate [Yamk et al., 2004]. The authors 
compared active CL patients with healthy controls and healed leishmaniasis 
patients, and found that active and healed patients showed higher anxiety and 
depression scores and lower body image satisfaction scores compared to 
controls. They also speculated about possible stigrnatisation but did so in the 
context of established relationships between conspicuous skin conditions and 
psychological disorders, i.e. not specifically related to CL. This seems to be the 
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first and, to date, the only study that addressed the psychological impact of 
Old-World CL. 
An indirect indication of the dearth of published research about perceptions 
concerning CL in the Old World is the total absence of references to any social 
research publications about CL in the above-mentioned studies, and, moreover, 
none of these studies cross-referenced any other of the studies discussed abO\'e. 
It is worth mentioning that all these studies were performed in the areas 
where the causative organism is believed to be L. tropica and the cycle of 
transmission is anthroponotic. 
5.2. Materials and methods 
To provide information on the perception about CL held by the participants 
in this study a cross-sectional survey of the knowledge, attitudes and practices 
(KAP) with regard to cutaneous leishmaniasis in Aleppo was undertaken using 
structured questionnaires. 
The recruitment of the patients for the clinical study is described in detail in 
Chapter 3. Briefly, to be eligible, the patients who referred to one of the four 
primary health care (PHC) centres where this study was conducted should have 
leishmaniasis confirmed either by smear or culture, be resident in the PHC 
centre catchment area (hence likely to continue treatment in the same centre) 
and have no more than five active lesions. Informed consent to participate in 
the study was obtained from the patient or patient's caretakers when the 
patient's age was younger than 14 years. 
Each of these four PHC centres was visited on a fixed weekday by the same 
investigator to enable the follow-up of the patients who would turn up once a 
week to have their lesions evaluated and injected. 
A two-part structured questionnaire with open-ended questions was 
administered by the principal researcher to the patients or, when the patient 
was younger than 14 years, to an accompanying elder. The first part of the 
questionnaire was normally administered on the day of recruitment, frequently 
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before the eligibility for the clinical study was established. Because the formal 
establishment of the diagnosis is not likely to affect people's knowledge about 
and attitudes towards the disease, all the available questionnaires were 
analysed, regardless of whether or not the patient was actually included in the 
clinical study. The unit of this study is questionnaire, also referred to by the 
words "respondent" and" case". 
The questionnaire was custom-designed for the purposes of the current 
study. A copy and English translation is included in Appendixes 9 and 10. 
In addition to the data necessary to identify the patient, the questionnaire 
had two parts. The first part of the questionnaire was administered on 
recruitment while the second part was filled in at a second interview that took 
place near or at the end of the treatment course. The first interview consisted of 
several groups of questions (sections). In the first section, issues related to 
knowledge of disease name(s), aetiology, transmission, prevention, clinical 
course and acquired immunity (whether the disease can affect the same person 
more than once). The second section consisted of questions relating to disease 
recognition, treatment-seeking behaviour and access to treatment. The third 
section explored respondent's expectations regarding the treatment: the nature 
of treatment, how long it lasts and recognition of cure. The fourth section 
concerned the respondent's attitude to the possibility and necessity of 
prevention and treatment and what disease manifestations are perceived as the 
most distressing, while the last section in this part of the questionnaire was 
related to common practices: sleeping outdoors, using bednets, using 
insecticides. 
The second part of the questionnaire, administered at the second interview 
when the respondents had been through the treatment process, contained a 
series of questions related to perceptions of quality of care. Questions were 
asked about travel time and means to the PHC centre, waiting times within the 
centre and perceived quality of care at the PHC centre. The questions about 
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quality of care were administered in a location such that the health centre staff 
were unable to listen to the conversation. 
Open-ended questions were asked in a manner to avoid, as far as pOSSible, 
suggesting answers. For example, the questions were asked in the form "What 
is the cause of this disease?", "How do people contract this disease?" not "Can 
the disease be transmitted by water, insects, etc.?", i.e. without suggesting 
possible agents other than the ones mentioned by the respondent. 
When several children from one family presented together, one 
questionnaire was filled for them all based on the responses of the 
accompanying adult. If more than one patient from the same family were 
adults, we aimed to interview all the adults with a separate questionnaire for 
each. Thus, one questionnaire might correspond to one or more patients. 
It was not always possible to administer the questionnaires to new patients. 
In many instances the number of patients in the leishmaniasis clinic was high, 
and we had to follow up the patients recruited earlier without causing them 
unnecessary delays. The mean number of questionnaires administered in one 
day was 1.9, the median, 1.5, and it never exceeded five. The time necessary to 
administer the first part of a questionnaire was usually between ten and fifteen 
minutes. For the second part it would not exceed five minutes. 
While there were some refusals to participate in the clinical trial, of the 
people who consented to participate no one refused the KAP part of this study. 
Moreover, one patient who consented to participate in the study but withdrew 
after consulting her husband stated that her demographic, clinical and social 
questionnaire data collected on her first visit might still be used. 
The responses were coded and entered into Microsoft Excel spreadsheet 
(Microsoft Office Professional Edition 2003). The spreadsheet was imported into 
SPSS ver. 16 and analysed. 
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5.3. Results 
5.3.1. Sample description 
Seventy part one questionnaires (the component relating to knowledge, 
attitudes and practices) were available for analysis. Of the seventy respondents 
who completed the first part of the questionnaire, twenty-six were available for 
the follow-up interview and completed the second part (health care accessibility 
and quality assessment) of the questionnaire. The main reasons for drop-out 
were missing the respondent during the last visit, failure to turn up for post-
cure follow-up and drop-out from treatment before cure. 
The term respondents relates to the patients above 14 years (who answered 
the questionnaire themselves) and the caretakers of children under 14 years of 
age who were suffering from CL. That is, the demographic data relating to age 
and education, as well as the data on views and behaviour relate to the adults 
who responded to the questionnaire (patients and caretakers) and do not 
include demographic data about the children in their charge. In 31 cases the 
respondents were the caretakers of children with the disease whose age was 
less than 14 years. In 23 (32.9% of all respondents) of these cases the respondent 
was the patient's mother (nearly three-quarters of caretaker-respondents), in 
seven (10% of all respondents), the patient's father, and in one case, the patient's 
grandmother. 
The mean age of the seventy respondents (that is, the age of those who 
answered the questionnaire - not including the ages of the children for whom 
the caregivers were responding) was 32.3±12...l years, the median, 32 years, 
interquartile range, 22-40.25. Forty-eight (58.6%) of the respondents were 
female. In 39 cases (55.7%) the respondent was the patient while in 31 cases the 
respondents were the caretakers of children with the disease whose age was 
less than 14 years: in 23 (32.9% of all respondents) patient's mother (nearly 
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three-quarters of caretaker-respondents), in seven (10% of all respondents), 
patient's father, in one case, patient's grandmother. 
The respondents with cutaneous leishmaniasis (patient-respondents) tended 
to be younger (mean, 30.3, median, 28 years) than caretaker-respondents, i.e. the 
respondents who did not have cutaneous leishmaniasis themselves but were 
accompanying a minor patient (mean, 35.2, median, 33 years, Mann-Whitney 
test, 0.039). There was no difference in sex distribution, years in education, 
treatment seeking delay or responses related to knowledge or quality of care 
appraisal between these two groups. 
Data on education were available for sixty-seven respondents. Education 
was recorded as 'years in study', with the only qualitative value for encoding 
'university degree'. 
About one-third of the respondents, that is, either the patients themselves or 
the adult reporting on behalf of a child (22 respondents), reported six classes of 
education (mode, i.e. the most frequently occurring value). Six classes are 
termed primary education in Syria, and until recently this was the minimum 
obligatory education. A few years ago the minimum was raised to nine classes, 
formerly termed preparatory, now basic edllcation. The mean education level was 
6.4±4.4 years, median, six, interquartile range, 5-8. 
Thirteen respondents (19%) were illiterate, sixteen (2.J %) had nine years' 
education or higher, nine finished secondary school (twelve classes) and three 
obtained a university degree. The remaining six respondents were either 
university students or had post-school education below university degree. 
5.3.2. Knowledge 
5.3.2.1. Disease name 
The various names given to the condition by the respondents in the survey 
are presented in Table 5.1. The majority of respondents reported "one-year 
sore" as the onl" name for the disease. Two very close variants were 
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encountered: habt es-saneh and habbayet es-saneh. Three respondents reported 
Leishmania as the only name, and six said it was a "common pimple", i.e. they 
did not regard it as a specific condition and sought treatment for a pimple that 
persists too long. Four respondents reported more than one name: one gave the 
answers one-year sore and Aleppo sore, one Aleppo sore and Leishmania, one one-
year sore and Leishmania and one all three names. The respondent who reported 
three names had a university degree, and the two other respondents who 
mentioned Aleppo sore had fourteen years of education. This suggests that the 
name Aleppo sore may only be used in Aleppo by more educated people. 
However, the differences by sex or educational level (up to six classes vs. 
seven years or more) were minor. The only statistically significant difference 
was for the name one-year sore by educational level when responses were 
categorised to one-year sore and other (Pearson's X2=O.042). 
5.3.2.2. Contagiousness, sources and mode of transmission 
Responses about disease contagiousness, i.e. direct person-to-person 
transmission were available from fifty-seven respondents. Of these, thirty-nine 
(68%) replied it was not contagious, ten (18%) replied it was, and eight (14%) 
said they did not know. 
In reply to the question about the sources of the disease, many of the 
respondents mentioned more than one source. 
Insects were the most common source mentioned (fifty-five respondents). 
Forty-eight of these respondents suggested insect bites as the mechanism of 
causing the disease. The insects mentioned were baqq or barghash (the local 
names usually applied to tiny biting flying insects, such as sandflies) in thirty-
one cases, five of which also mentioned flies as the causative agent; mosquitoes 
were implicated by thirteen respondents, four of these also implicated flies and 
one sandflies; five respondents named unspecified insects and four, flies only. 
Forty-eight respondents said the disease was caused by insect bites and six said 
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the insects transmitted the disease from polluted sources, such as polluted 
water or wells (three responses) and "dirt" (two respondents). 
The next reported source of disease was man (twelve responses). Of these 
twelve respondents seven believed the disease could be transmitted by direct 
contact (three respondents) or indirect transmission by fomites, i.e. sharing 
objects such as towels (two respondents). One respondent believed the disease 
can be transmitted by contact with an infected person or via fomites or 
transmitted mechanically by unspecified insects. Four respondents who did not 
believe the disease was contagious said it was vector-transmitted: one 
implicated sandflies, one mosquitoes, one mosquitoes and flies, and one 
mosquitoes, flies and sandflies. 
Twelve respondents reported microbes as cause of the disease, and one of 
them named Leishmania as the causative agent. Four respondents said the 
microbe was transmitted by an insect bite, two (including the above-mentioned 
who knew the name of Leishmania) believed the transmission is mechanical, one 
said the sandfly injects microbes into blood, one suggested air-borne 
transmission, and one named contact with dirt. 
Eight respondents said the disease comes from dirt or dust, either by insects 
(three respondents) or direct contact (two respondents). The rest did not explain 
the transmission mode. 
Water as the cause/source of disease was mentioned by seven respondents. 
Three believed the disease resulted from drinking water, two said it was 
transmitted by insects. The other two respondents suggested swimming or 
washing, i.e. direct contact. 
Three respondents believed the disease resulted from a trauma (a splinter, 
any skin trauma or scratching an itch, one response each) and one believed it 
was related to psychological distress. 
The responses were ranked by frequency and differences were analysed by 
sex and education. Education was categorised as primary (up to six classes in 
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school, inclusive) and more than six classes. The first four ranks are presented 
in Table 5.3. In all groups baqq (i.e. sand flies) were mentioned most frequently 
as the cause of the disease. 
No significant differences were noted between patient-respondents (CL 
patients themselves) and caretaker-respondents (who accompanied CL 
patients). 
5.3.2.3. Prevention, recurrence and time to healing 
Forty-one of sixty-six respondents (62%) believed the disease could be 
prevented, nine (14%) believed it could not and sixteen (24%) said thev did not 
know. Of sixty-five respondents, forty-two (65%) believed the disease might 
affect the same individual more than once, twelve (18%) believed the disease 
never recurred and eleven (17%) did not know. 
The respondents suggested several prevention modes. Each respondent 
might give more than one reply to this question. The replies were available 
from 44 respondents (11 males, 33 females; 18 with education of up to six years, 
16 with education of more than six years). The most common modes of 
prevention are ranked in Table 5.4. Bednets, followed by insecticides, personal 
hygiene and waste evacuation were the most common responses in the whole 
sample, among females and those with more than six years in education. 
Respondents with up to six years in education differed from the complete 
sample in placing the insecticides in the first rank and the bed nets in the 
second. Among males, the bednets did not fall among the first four choices, and 
this difference in choosing bed nets was the only one that had a marginal 
statistical significance between sexes (p=O.049, Pearson's X2). 
Eight respondents suggested both bed nets and insecticides, while all the 
other combinations of more than one response were unique. 
Responses about time to healing were available from fifty-eight 
respondents. The mean time to healing from the forty-two respondents who 
gan' finite periods was 11.25±6.3 months, the median, 12 months, interquartile 
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range, 6-12.75 months. The responses ranged between one month and two 
years, and twenty respondents (48%) said the lesion needed one year to heal. 
Thirteen respondents said they did not know. Three respondents stated the 
disease does not heal unless treated. 
5.3.3. Disease recognition and treatment seeking 
The respondents were asked who had first noticed the appearance of a 
lesion. The lesions were noted by the patient in 37 cases (53%), followed by the 
patient's mother in 25 cases (36%), for a total of 89%. The other responses were 
parents and relatives (three cases each) and daughters and father (in one case 
each). 
In the patient-respondent group the lesion was noted by the patients 
themselves in 85% of cases, whereas in the caretaker-respondent group they 
were noticed by others in 87%. 
The most common descriptions given to the eruption were a small red 
papule. The word used was habba, literally "a grain", commonly used to 
describe well-delineated raised closed skin eruptions. The eruption was 
described as papule by fifty respondents, followed by insect bite by ten. 
Fourteen respondents described its colour as red (of the twenty-one who 
mentioned the colour). Nine said it was small, seven noticed slow growth and 
six said it did not change. 
Responses about measures taken after the lesion was noted were using an 
antiseptic (described as spirto, a common reference to ethanol) in nineteen cases, 
doing nothing about the lesion in sixteen and applying a cream or ointment in 
thirteen cases. 
Forty-three respondents did not report receiving any advice for home 
management of their lesions. Of those who received any advice, the most 
common, in seven cases, was to refer to a primary health care centre. All the 
other responses were unique. 
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Advice to seek treatment ("Who told you that your condition requires 
treatment?") was given by mothers in 21 case, decided by the patient without 
advice from others in 14 cases, family in 12 cases, fathers in six cases and 
neighbours in four cases. 
Treatment-seeking delay ranged between immediate to one year. The mean 
delay was 2.4±2.1 months, the median, 2 months, interquartile range, 
1-3 months. 
The patients were referred to the health centre ("Who told you to go to this 
health centre?") by mothers in 23 cases, knew the centre themselves in 20 cases, 
or by fathers or relatives in six cases each. 
In thirty cases the decision to treat the disease was taken by the patient, in 
24 cases by mothers and in twelve cases by fathers. 
In thirty cases the patients were accompanied on their first visit by their 
mothers, in 26 cases they came alone and in six cases accompanied by fathers. 
This was reflected by the differences in replies between the cases where the 
respondents were patients themselves (patient respondents) and caretaker 
respondents: the patient respondents were more likely to come unaccompanied 
(in two-thirds of cases) whereas the caretakers, usually mothers, were 
accompanying younger patients in all cases. The decision to seek treatment and 
referral to health centre was by the patient in the patient-respondent group (in 
three-quarters and half of the cases, respectively) and by mothers in most cases 
in caretaker-respondent group. 
5.3.4. Expectations 
Replies about what the respondents knew about and expected from the 
treatment were available from 67 respondents. 
5.3.4.1. Nature of treatment 
Four respondents did not know what the nature of treatment was. The rest 
said it was injections. Of these, 54 said the injections are made into the lesions, 
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three, that the disease can be treated with intralesional or intramuscular 
injections, and six only knew it was injections, but not the mode of 
administration. 
5.3.4.2. Treatment duration 
The expectations, as reported by the forty-nine respondents who gave 
quantitative responses, ranged between three weeks and one year. The mean 
expected treatment duration was 3.2±3.3 months, the median, two months, 
interquartile range, 1-4.5 months. Ten respondents reported having no idea 
about the length of treatment duration, and eight replied it could not be 
predicted because it depended on the clinical course of the disease. 
5.3.4.3. Cure 
The question asked was "How do you know you are cured?" Most 
respondents replied the lesions would disappear (29 replies) or diminish (15 
replies). Twenty-one respondents said the cure is determined by health centre 
staff, and two replied they did not know. However, the proportion of those who 
continued their treatment until formal dismissal was the same among those 
who said cure was to be determined by the health centre staff and those who 
suggested their own criteria (31 % VS. 32%, p=O.936, Pearson's X~). 
5.3.5. Attitudes 
5.3.5.1. Prevention 
The respondents were asked "Should the people try to prevent this 
disease?" "What needs to be done to prevent the spread of the disease?". Sixty-
seven responses were available for the first and fifty for the second question. 
Fifty-four respondents believed people should try to prevent the disease, 
ten replied these attempts were worthless and two did not know how to 
answer. 
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The suggested modes of prevention were insecticides (25 responses), 
bednets (14 responses), public waste evacuation (13 responses), personal 
hygiene (10 responses), safe water supply (7 responses) and window mesh 
(6 responses). The same trend was observed in both education level groups and 
in both sexes with one exception: males placed window mesh, rather than 
bednets, in the second rank. 
The respondents might give more than one reply. The most common 
combinations were bednets and insecticides (5 cases) and window mesh and 
insecticides (3 cases). 
5.3.5.2. Treatment 
All the respondents believed one must seek treatment for the disease. This 
unanimity is natural as all the respondents were interviewed when they 
actually sought treatment. 
The most frequent reason for seeking treatment was to prevent mutilation 
(23 cases) or the development of a deep ulcer (6 cases), for a total of 29 replies. 
The next most frequent reply was to speed cure and avoid multiplication of 
lesions (9 replies for each), or avoid lesion growth (8 cases). 
To the question what happens if the disease is not treated, eighteen 
respondents replied the lesion would ulcerate, thirteen said it would grow and 
eleven that it would spread (multiply in number and appear in other locations) 
or leave permanent marks. 
When naming the most unpleasant manifestations of the disease, most 
respondents mentioned the appearance of the lesion (48 cases), followed by the 
permanent mark it is known to leave (23 cases). Both these points were 
mentioned together in nine cases. Other replies were encountered in three or 
less cases each and included itch, pain, oozing or the feeling the lesion is 
unclean. 
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5.3.6. Practices 
Questions about sleeping outdoors and using bednets and insecticides were 
asked to elucidate the common practices. The replies were available from 68 
respondents. 
Forty-two respondents reported sleeping outdoors during the summer. 
Twenty-two reported using bed nets, plus seven said they used them 
"sometimes". Twenty-four respondents reported using insecticides, one, insect 
repellent tabs and nine occasional use of insecticides. 
5.3.7. Quality of care appraisal 
Towards the end of the therapy process a second questionnaire was 
administered to ascertain the participants' views on the ease of accessing 
treatment and the quality of care provided. These interviews took place, on 
average, seven months after the first questionnaire has been administered. The 
questions about the quality of care included travel time to the health centre and 
the mode of transport, waiting time within the health centre, the perceived 
attitudes of the health centre staff and an overall qualitative evaluation of 
service as very bad, bad, acceptable, good, very good, encoded with numbers 1 
through 5. These questions were asked near or after the end of therapy, 
preferably in such a way that the staff were not able to listen to the 
conversation. The patients who dropped out and could be contacted were also 
asked about the reasons of interruption of treatment. 
The major limiting factor in the interpretation the results from the second 
round of questionnaires is that only 26 respondents were available to fill the 
exit part of the questionnaire. 
Replies about travel time were available from 26 respondents. ~ineteen of 
these (79%) reported travel time of fifteen minutes or shorter, and nine of them 
estimated travel time to be ten minutes. Another two respondents failed to 
pnwide an estimate, just characterised the travel time as "short". 
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The replies about mode of transportation were available from eighteen 
respondents. Nine of these arrived on foot and three in a public minivan. A taxi 
or a private car was used by two respondents each, and a bicycle or a 
motorcycle, one respondent each. 
The replies about waiting time within the health centre were available from 
26 respondents, and ten of these replied only with qualitative estimates: long 
(3 cases), medium (one case) or short (6 cases). Among the remaining sixteen 
respondents who gave quantitative replies, the median waiting time was ten 
minutes. Four respondents said they did not have to wait at all but waiting 
times ranging between 45 minutes and up to 21/2 hours were also reported in 
five cases. These prolonged waiting times (and two of three reports of "long" 
waiting times) were associated with one urban and one rural health centre. In 
the former large crowds formed after the reinforcement of health district system 
when all the corning patients needed to formally register in the health centre 
(see Structure of relevant health services in Chapter 1). In the latter centre 
cutaneous leishmaniasis was treated on one weekday only, and on that 
weekday during the peak season more than one hundred patients had to be 
treated. 
The quality of service was appraised by 25 respondents, eleven of them 
were from one urban centre, and the rest distributed evenly between the other 
three centres (4 or 5 cases each). Thirteen of the respondents estimated the 
quality of care as good, four as very good and three as acceptable. Bad and very bad 
responses were received in two and three cases, respectively. Two of lower-
than-acceptable appraisals were associated with the crowds at one of the urban 
health centres due to health district policy (and lead to drop-out) and the other 
three related to perceived staff arrogance and lack of care in the other urban 
and one rural centre. 
When we compared the respondents who did not complete follow-up until 
complete cure to those who were followed up until cure was documented 
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(Table 5.5), the responses of the former (ten respondents) distributed more or 
less evenly between very bad and good, but none characterised the services as 
very good. On the other hand, all the fifteen respondents with completed follow 
up characterised the services as good or very good. The median scores, with 1 
corresponding to very bad and 5 to very good, were 2.5 in the former group and -l 
in the latter, and this difference was statistically significant (p<O.OOl, \lann-
Whitney U test). 
Only six drop-outs of the forty-three people not known to have achieved 
cure in this sample could be contacted. Two of them (mentioned above, 
siblings) left because the service was perceived as awful, one reported lack of 
response, one considered the lesion improved enough (and was afraid of 
injections), one of them was a university student and could not visit the health 
centre during its opening hours, and one moved away from Aleppo for work 
(as reported by his mother on the telephone). These people also replied to the 
questions from the second part of the questionnaire. 
5.4. Discussion 
To our knowledge, this is the first attempt to describe knowledge, attitudes, 
expectations and practices of people in Aleppo, Syria, with regard to cutaneous 
leishmaniasis, a common condition in that area. 
We show that the disease is widely recognised by the participants in this 
study and is referred to by its traditional name, lzabbt il senne, or "one-year 
pimple", first documented more than 250 years ago [Russell, 1856]. This name is 
almost identical to the one reported from Afghanistan, saldana [Stewart and 
Brieger, 2009], salek in Iran [Elgood, 1934] and from Russia, godovik [Borovsky, 
1898], all of which incorporate year in their meaning. 
Most respondents mentioned insects as factors of the disease: either direct 
cause or vector. Forty-four percent of the respondents implicated sand flies as 
the C,1l\se of the disease, and nearly one-quarter implicated mosquitoes. Sheikh 
~tlkct, or "silent old man", that was used in a health education brochure as the 
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popular name for sand flies in Aleppo, was not mentioned by any of our 
respondents. However, we did not ask the respondents to describe the insect 
they mentioned. The next common response for disease source was man, 
followed by "dirt" and water. This corresponds well with the results of the 
Afghan study where the insects, sandflies and mosquitoes, were perceived as 
the most common cause, followed by contagion, then environmental factors. In 
that same study, about half of the respondents implicated sandflies but only ten 
of the participants mentioned the bites as the mode of transmission [Stewart 
and Brieger, 2009], compared with 47 of 52 in our sample. The authors did not 
mention the exact number of their respondents, only mentioning they recruited 
"eight groups < ... > of six to nine individuals each", which is more or less 
comparable to our sample size. 
In the study of Stewart and Brieger (2009) several options of horne treatment 
for cutaneous leishmaniasis are described. This cannot be compared to our 
study because in Aleppo the horne treatments tended to be used prior to disease 
recognition, while the patients still believed the lesion was a "common pimple", 
and after leishmaniasis was suspected the treatment was usually sought in the 
local primary health care centre. This may be due to better accessibility of 
medical care in Aleppo than in Istalif, where the clinic was not easily accessible 
for the majority of the local population and did not offer free diagnosis and 
treatment, better knowledge of the people in Aleppo about the disease and, 
probably, the effectiveness of health education in Aleppo. However, the sample 
of this study were people who were already accessing to PHC and therefore, 
their perceptions and reported actions may not be representative of the total 
population of leishmaniasis sufferers. 
With regard to prevention measures, our respondents placed standard 
bednets in the first place, insecticide spraying in the second and personal 
hygiene in the third. The people with a lower educational level placed 
insecticides before bednets, and males had a completely different ranking with 
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personal hygiene in the first place (Table 5.4). In the study by Stewart and 
Brieger (2009) the bednets and insecticides were also the first two options, with 
the former preferred by females and the latter by males. However, in our study 
the responses related to the way the question was posed. When a similar 
question was asked in the Attitudes section, phrased as "What needs to be done 
to prevent the spread of the disease?" rather than "How can one prevent this 
disease" in the Knowledge section, the insecticides came first, followed by 
bed nets and public waste evacuation. This is because in the Attitudes section 
the replies contained not only personal measures but also those that should be 
taken by public authorities. 
The most unpleasant reported manifestation of cutaneous leishmaniasis in 
our sample was the appearance of the lesion and fear of permanent mark. 
We show that health centres in Aleppo are easily accessible to most patients 
in our sample, with travel time of less than fifteen minutes in about 80% of 
cases. Half of the respondents arrived on foot. Waiting time was also short in 
most cases. 
Twenty of 25 respondents rated the quality of care as "acceptable" or better. 
Our data show that for the respondents in our sample the barriers to 
treatment seeking are generally low. The disease was recognised by the patients 
or their relatives in most cases, health centre locations are known, and free 
diagnosis and treatment is offered. 
Our study has several limitations. First, our respondents were recruited in 
the health centres where they came to seek diagnosis and treatment of 
leishmaniasis. For this reason, it is not surprising they all believed leishmaniasis 
should be treated, since those who believed it should not were far less likely to 
be encountered by us. Thus, our sample is not representative of the entire 
population at least in this point. 
We did not ask the respondents to describe the insects that cause or transmit 
the disease but only recorded the reported insect designation. We also did not 
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ask specific questions about possible marginalisation, although, most probably, 
if any significant social oppression existed, it would have been mentioned in 
one way or another. We also did not explore the signs or symptoms which 
necessitate treatment seeking. 
The data on travel and waiting time, and on perceived quality of care in our 
sample may be further biased due to high drop-out rate. The drop-outs could 
be contacted in a minority of cases only so the conclusions from their responses 
can only be regarded as provisional but it can be inferred with some confidence 
that patient compliance is probably related to perceived quality of service, 
given the fact that none of the patients who did not complete the treatment 
rated the services as very good and, on the other hand, all the patients who did 
complete the treatment rated them as good or very good (Table 5.5). Only one of 
our six respondents explicitly stated he was afraid of injections, and one could 
not corne during working hours of the PHC centre. It also seems that the 
attitude of our respondents relating to cure recognition (by health-centre staff 
vs. improvement of the lesion as assessed by the patient) was not predictive of 
treatment completion until cure. 
Two of lower-than-acceptable appraisals were related to disruptions in 
health centre operations because of sudden enforcement of a new policy and a 
three-week measles vaccination campaign when little or no other services were 
provided. 
It cannot be inferred from our PHC-based sample how accessible CL 
diagnosis and treatment services are for the entire population in terms of travel 
time. The knowledge, attitudes and practices reported may also differ 
considerably from those of the general population. Additional studies are 
needed to clarify these points. These studies should not be restricted to people 
who actively seek treatment preferably employing more in-depth interviewing 
techniques. 
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5.5. Tables 
Table 5.1. Name of the disease, total respondents and respondents 
by sex and education level. The percentages for each group are 
given in parentheses and rounded to nearest integer. The four 
combinations of multiple names are unique (see text), three of them 
included Aleppo sore which occurred in combinations only. 
Total Sex Education, years 
Name of the disease M F up to 6 
one-year sore 55 (79%) 17 (77%) 38 (79%) 37 (90%) 
Leishmania 3 (4%) 1 (5%) 2 (4%) 0 
common pimJ!!e 6 (9%) 2 (9%) 4 (8%) 4 (10%) 
multiple names 4 (6%) 1 (5%) 3 (6%) 0 
* Missing educatIonal level for one respondent. 
Table 5.2. Causes/sources of leishmaniasis. Respondents might 
name more than one cause/source. 
Source/cause n 
Insect 55 
sandf/ies 31 
mosquito 13 
flies 13 
unspecified 5 
Man 12 
Microbes 12 
Leishmania 1 
Dirt 8 
---
--
Water 7 
Other .f 
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16 (62°;,) 
2 (8°c»)* 
2 (80 ,,) 
.f (1 S",,) 
Table 5.3. Causes/sources of leishmaniasis, ordered by rank of 
mentioning by the respondents divided by sex and education. Data 
on the level of education were available for 67 respondents. The 
respondents could give more than one answer in this category. For 
this reason the sums of numbers of answers may total to more than 
the number of respondents. 
Sex Education 
Rank (number of M (n=22) F (n=48) up to 6 years 7 years or more 
1 
2 
3 
4 
responses) (n=41) (11=26) 
Rank" 
1 
2 
3 
4 
sand fly (8) sand fly (25) sand fly (22) sandflv (10) 
mosquito (5) mosquito (10) flies (10) mosquito (8) 
water (4) man (10) man (7) microbes (6) 
microbes (4) flies (10) microbes (6) man (4) 
Table 5.4. Knowledge: the most commonly mentioned cutaneous 
leishmaniasis prevention options, ordered by rank of mentioning, 
for the complete sample, males and in persons with educational 
level up to six years. The responses of females and those with more 
than six years in education had exactly the same order as in the 
complete sample. 
Complete sample Males ll£to 6 years education 
bednets (17) personal hygiene (3) insecticides (10) 
insecticides (14) window mesh (3) bednets (9) 
personal hygiene (9) sterilise water (2) personal hygiene (6) 
waste evacuation (St waste evacuation (2) waste evacuation (3) 
.. The ranks of responses of females and persons with more than six \'eilrS of education 
was similar to that in the whole sample. 
** There were two responses for waste evacuation from persons with more than six years 
of education. This group also gave two responses for each of window mesh and wash 
fruits. 
Table 5.5. Service quality assessment by the respondents for 
patients who were followed up until cure was documented and 
those whose cure was not documented. Number of responses for 
every mark is given: 1, very bad; 2, bad; 3, acceptable; 4, good; 5, 
very good. 
Service quality assessment 1 2 3 4 5 
Followed up until cure 0 0 0 11 
Cure not recorded 3 2 3 2 
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.f 15 
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Chapter 6. Discussion 
In the current study several aspects of cutaneous leishmaniasis (CL) in 
Aleppo, Syria were studied. The clinical and epidemiological characteristics of 
the patients who attended primary health care (PHC) centres in Aleppo during 
2005 were retrospectively analysed using the available routinely collected data 
and the course of treatment was explored in a subset of patients from PHC 
centre treatment registers and patient cards. 
The clinical course of the disease was studied. Biological material was 
obtained from the lesions of patients before and in the course of treatment from 
which Leishmania parasites isolated. Isolates were tested in amastigote-
macrophage system for sensitivity to antimonial drugs, amphotericin B, 
miltefosine and paromomycin. 
Interviews were held with patients or accompanying adults to explore their 
knowledge about the disease, treatment-seeking behaviour and attitudes and 
practices regarding prevention, diagnosis and treatment. 
A typical patient with CL is a child or adolescent who presents with one 
non-ulcerated lesion with reported duration of two months. Typically the 
patient undergoes one course of six injections and not infrequently stops 
treatment before the health centre staff tell them they are cured. 
Lesion duration of two months was associated with the highest yield of 
smear positivity. On the other hand, patients with lesion duration of two 
months or longer received fewer injections and had shorter treatment duration. 
This suggests that active immunity to the parasite develops around two months 
from lesion appearance and contributes to faster cure. A similar notice was 
made in a study of the clinical course of cutaneous leishmaniasis in Peru, 
caused mostly by species of the Vial1nia subgenus (L. penn'imza, L. braziTiensis 
and L. guayal1ellsis) [Llanos-Cuentas et aT., 2008], where disease duration of less 
than fin> weeks was associated with higher risk of treatment failure. Giwn this, 
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earlier diagnosis and start of treatment may worsen the prognosis for 
individual patients. On the other hand, if the risk for the sandfly acquiring 
infection from a lesion is correlated with smear positivity, which in tum is 
probably correlated with local parasite load, delaying the start of treatment may 
increase the risk of infection for the sand flies and, consequently, of disease 
transmission between humans. 
More research is needed to better understand the human immune response 
to CL, possible non-human reservoirs of infection, the lifestyle of the known 
vector, Ph. sergenti, and possible other vectors of cutaneous leishmaniasis in 
Aleppo. 
Given that only about half of our patients could be followed up until cure 
despite attempts to contact them, it can be concluded that a significant 
proportion of patients are not treated until cure, thus representing a potential 
reservoir for parasites that are primary-resistant in the clinical sense. This is 
probably related to the indolent nature of the disease itself and, in contrast, to 
painful and lengthy treatment. Since we avoided to select the PHC centres for 
this study where a proportion of population are likely to leave for harvest 
seasons, and tried to contact the patients who missed their appointments, it can 
be expected that patient compliance in Aleppo as a whole is even lower. 
The leishmaniasis control strategy based on early detection, treatment until 
cure and vector control seems to fail in reducing the incidence of CL in 
Aleppo [Jalouk et ai., 2007], and the weak link is the treatment until cure. The 
other two components are probably also suboptimal. The results of treatment 
course analysis and in vitro assays in this study suggest that the real effect of 
intralesional pentavalent antimonial treatment of CL in Aleppo may be due 
mostly to physical local destruction of the tissues. 
Jalouk et al. (2007) reported the results of insecticide-treated nets (ITNs) 
study in Aleppo governorate which were encouraging and suggested 
incorporating ITNs in the leishmaniasis control programme. But this 
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intervention requires substantial funds, and providing the nets on commercial 
basis by the MoH is hampered by imperfections in the legislation, according to 
which the PHC centres do not sell materials or medicines. In addition to IT"\:s, a 
relatively simple and inexpensive option deserves to be explored, covering any 
skin lesions that persist for longer than two weeks, at least during nights, to 
prevent the sandflies reaching them [Dr. Lama Jalouk, personal 
communication] . 
Less painful, shorter and more efficient treatment and/or prevention (e.g. 
vaccine) options are urgently needed but none are available to date. 
Any treatment to be proposed should also be free of serious potential long-
term side effects because most patients are young (75% are 25 years old or 
younger) and the disease is not life-threatening. This makes, for example, oral 
miltefosine not suitable for its treatment because of its teratogenic potential. 
However, for the rare cases of chronic mutilating disseminated disease that 
does not respond to systemic antimonials, drugs with potential efficacy may 
worth trying. This may include miltefosine or amphotericin B. A recent study 
reported the efficacy of a novel oral formulation or amphotericin B in 
mice [Wasan et al., 2009]. This formulation had low toxicity in earlier studies, 
and if its efficacy and safety is confirmed in humans it can be an acceptable 
alternative to the current intralesional treatment. However, the cost may prove 
prohibitive. A novel topical aminoglycoside formulation was tested against 
L. major infection in Tunisia with significant efficacy [Ben Salah et al., 2009], 
although about two-thirds of placebo patients also achieved cure. Paromomycin 
in Aleppo is not likely to be successful, given our in vitro results for 
paromomycin. 
Our in vitro sensitivity data suggest that the parasites isolated from Aleppo 
are remarkably insensitive to pentavalent antimonials (mean and median ECso 
values greater than 200 flg Sbv/ml). All the isolates that were tested for 
sensitivity to paromomycin had ECso values higher than the maximum test 
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concentration of 50 flM but all the isolates were highly sensitive to 
amphotericin B (mean and median ECso values of about 67 nM). No meaningful 
association was found between in vitro parasite sensitivity and clinical outcome. 
This disagrees with a study of L. tropica in Iran [Hadighi et al., 2006] but is in 
agreement with another study from Peru [Yardley et al., 2006] that found no 
correlation between in vitro parasite sensitivity and outcome of infection with 
Latin American strains. 
More than half of our isolates had ECso values for Sbv higher than the 
maximum assay concentration. This might be partly attributed to promastigotes 
that obscured the vision and probably affected the results. Ways to minimise 
this effect, either by modifying the assay protocol to get rid of promastigotes or 
using automated counting that is able to tell amastigotes from promastigotes, 
are needed. The promastigotes in our assay might corne from the proportion of 
non-meta cyclic dividing parasites that continued to multiply while the assay 
was being conducted. Metacyclics can be selected to improve infectivity by 
using lectin peanut agglutinin [da Silva and Sacks, 1987] or by pre-conditioning 
of the promastigotes by culturing in low pH [Inocencio da Luz et al., 2009]. Both 
these studies were performed on parasites other than L. tropica. 
Epidemiological cycles and clinical characteristics of CL in the adjacent 
governorates of Idlib, Lattakia and Tartous, where the disease is believed to 
have emerged recently, should be investigated, with typing of the causative 
organisms and potential vectors. 
The social study showed that a significant proportion of CL patients held 
views about disease causes, transmission and prevention that contradict 
contemporary scientific data. This shows there is room for improvement in 
health education delivery in Aleppo. 
The disease was well recognised by our respondents but this may not be 
representative of the general population because the study was health-facility, 
rather than community based. This fact significantly limits the generalisability 
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of our results, and more systematic, community-based, studies are needed. 
Most respondents rated health services as good, and this response was 
associated with increased probability of treatment compliance. 
212 
Appendices 
Appendix 1. Reporting health centres 
Dataset 
Health centre Main Treatment Patient Cards 
Abtin* NA 49 SA 
Abzmu* NA 37 NA 
Anadan* NA 46 NA 
Ashrafiyyeh 1281 NA 90 
Atareb* 1169 240 2 
Ayadat Shamileh 207 NA 19 
Bab* 635 324 73 
Batbu* NA 39 NA 
Efrin* 96 46 NA 
Halab al-Jadidah 237 168 23 
Hamadaniyyeh 1170 NA 22 
Haydariyyeh 55 NA NA 
Hritan* 681 152 9 
Jamal Abd aI-Naser 337 NA NA 
Khalid ibn Walid 1435 NA 37 
Khalidiyyeh NA 478 NA 
LCC 3051 391 62 
Nayrab 314 90 28 
Nizar al-Homsi 1619 NA 37 
Salah aI-Din 296 85 41 
Sheikh Said 652 NA 22 
Shuhadaa 148 NA NA 
Yousef al-Azmeh 545 NA 3 
al-Jalaa 440 NA 30 
Total 14368 2145 498 
* Rural health centre. NA, no cases available in correspondmg dataset. 
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Appendix 2. The health centres that report leishmaniasis cases in Aleppo 
No. Centre type Centre name borough/village (coverage) population, ACL2003 Incid. 
2003 rate, °0 
I. Main centre LCC Aleppo governorate 2,103 
2. Nizar Homsi Sheikh Maqsud 108,601 649 0.6 r---3. Khaled ibn Walid Khalidiyyeh 21.685 882 ... 1 r---4. Ashrafiyyeh Ashrafjyyeh 84,174 501 0.6 r---5. Jamal abdul-Naser Hulluk 18,151 285 1.6 r---6. Haydariyyeh Masaken Hananu 118,138 323 0.3 r---
7. Centre Yousef al-Azmeh Tariq al-Bab 67,411 406 0.6 -
8. names in the Jalaa Qadi Askar 25,243 579 2.3 -
9. city MukhClJYam Nayrab Mukhayyam Nayrab 14,254 265 1.9 -
10. Sheikh Said Sheikh Said 8,114 492 6.1 -
II. Shuhada Sukkari 43,473 236 0.5 r---
12. Salah ai-Din Salah ai-Din 36,364 32 .. 0.9 r---
13. Ayadat Shamileh Hamadaniyyeh 38,651 703 1.8 r---
14. Halab al-Jadidah Halab al-Jadidah 21,963 197 0.9 
15. Health Mukhayyam Handarat Mukhayyam Handarat 4,628 662 1 .. r--u; posts,* city BaniZayd BaniZayd 7,462 720 9.1> 
City subtotal 618,312 9,327 1.5 
17. 
f---
Efrin Efrin 38,977 34 0.08 
18. Hritan Hritan 15,901 775 4.9 
-
Bab Bab 61,629 135 0.2 19. r--
Hader Hader 8,728 (h) 20. r--
~ Atareb Atareb 18,260 638 3.5 
22. Abzmu Abzmu 5,369 7 0.1 r-- Centre 
Kafr Dael Kafr Dael 3,416 [b) ~ names in the 
Hayyan Hayyan 8,225 (h) ~ countryside 
~ Anadan Anadan 11,807 [b) 
26. 
r--
Batbu Batbu 4,031 (h) 
27. 
r--
Ais Ais 4,519 (h) 
Abtin Abtin 1,684 (h) ~ 
29. Bias Bias 1,476 [b) 
r--
30. Aynjara Aynjara 4,069 (h) 
~ Health Kafr Karmin Kafr Karmin 1,165 [b) 
~ posts,· Tqad Tqad 2,681 (h) 
~ countryside Dhahabiyyeh Dhahabiyyeh 891 (h) 
~ KafrAmma Kafr Amma 1,165 (h) 
35. Shqaydleh Shqaydleh 660 (h) 
Countryside subtotal 194,653 2,025 1.0 
Total 11,352 
14 health centres in city 
14 health centres in countryside 
7 health posts in city and countryside 
• Health posts work one day a week when they are visited by a qualified team from Leishmaniasis Control 
Centre or from a nearby PHC centre for diagnosis and treatment. . 
[hi Newly opened centres without lab diagnostic facilities; patients are sent to lab-eqUipped centres for 
confirmations and then treated in these new centres. No records for new patients are Instituted. 
21-+ 
Appendix 3. Consent form (original) 
DD 
~..,;..JI ~I"", :; j~1 
(XXX XX XX XX :....4» .:..;jj)y . .l :JJ.;-JI ~'..Jl 
:~~I~~ 
~ y}hJI.JA L.. ~..!.ll \..iI J ,~I Cy::J1 ~) ,~I I~ ...... b.ll -:"L...,h-JI ~ :.::ci.J ~ • 
~~I I~ .,.! .,:,S)_":: U ~~ IJL..J 
~~I 14; ~I ~i .jc ....,~ y,-, ~jL,i )y . .l /-.3 • 
uJ..illJ 01) ,..illJ yL;.....1 fiJ...J! ~I 01 ':)J.:J ~ ~ ;i....1..!.l!1 jA ,-:-,~'ll ~i ~i --iy:.i \..il • 
~.:Jla....\1 .J:!-!.ulIJ ~\&.)I ..,Ie jS....:: -jL J y 
.~IIiA. .,.! ;..s.JL.:..J1 .)to. :::..asl) ~ • 
:~~ ,.)\c i .J~I I.lc. J 
~ ~\.:i.JI ~I 0-0...r. J\....Ai)\j ~1.A i!..!J ~Ijlc J>", -:"L...,h-JI ~LJI ::;:';".s:i.....; j ..,Ie j!IJi • 
'l 0 ~ 0 ".JJ~I 
~ :P ...... ~ '1 )~, ~~ i:J\ ~ ~.~ '.J."...JI .iA. ('I~I ~ )J ,-:"I.!'jl .J;l"""':; ~ j .)to. j!IJi • 
'lO ~O 
'lO ~O 
'l 0 ~D 
'l 0 ~D 
'lO ~O 
.' ·':11 
............... :~.".... ......... :~Ii!.J 
. 'WI ~L.l1 
...................... <..r 
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f' 2007/ .... ../. .... ::::·d~l 
Appendix 4. Consent form (translation) 
Tolerance of L. tropica to 
antimonials in Aleppo 
Patient consent form 
Researcher: Dr. Nizar Abazid (phone XXX XX XX XX) 
Patient's declaration 
DD 
• I read the information page, or understood oral explanation, and I understand what is 
required from me, and what happens if I decide to participate in this study; 
• Dr. Nizar Abazid replied to my questions; 
• I am aware I can withdraw from the study whenever I wish, and that I am not obliged to 
explain the reasons, and that my decision to withdraw will not affect in any way the usual 
health care and management I receive; 
• I have agreed to participate in this study. 
In addition to the above, I: 
• agree that the study team use my contact details to contact me for follow up if necessary 
Dyes 0 no 
• agree to have my lesions photographed, and the images used, provided they do not 
allow to identify me, for the following purposes: 
my medical record 0 yes 0 no 
research purposes 0 yes 0 no 
teaching purposes 0 yes 0 no 
publication in health and medical literature 0 yes 0 no 
publication on medical or health internet sites 0 yes ::J no 
Patient name: ..................... . patient 10: signed: ... 
or (if the patient is illiterate): 
First witness ........... . Second witness ... 
Date: ..... ..!. .... .. .1200 .. 
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Appendix 5. Study questionnaire 
DO 
..r-ll jS yJI,....1 I 
: .... 1,......1 I :0..:;1,...1 I :~I :~yJI,...1 
--'pi .-iJ 
~I .. ji-ll :~I ~I&:...fl 
:y')U ~I .. ji-ll :JW,')U I I 
:,.')U :~I 
i 
:,.':il~ :' ... /il~ ~II ..!..Lc~ 
c$~ I ...A .",.;I~\ 
:~WI ,...1 :~UJlI ~ 20071 1 
:(~I) ~lyJl J.< Jj':ll .>-= 200 1 
..:..~ (~) l+il....\,!i \.f.W.,. lfh.W 'J'il 
x I 
x 2 
x 3 
x 4 
x 5 
~lrlll 
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I~I ~'11 
------
I - -
1 
1 
I 
('""'11 
-
w\.k.)l. 4j"iI~ 
.)-.ill .:..=.yJl w.J 
5 4 3 2 I / / .,Ii~l~"'" 
/ / / / 2 
/ / / / 3 
/ / / / 4 
/ / / / 5 
/ / / / 6 
/ / / / 7 
/ / / / 8 
/ / / / 9 
/ / / / 10 
/ / / / II 
/ / / / 12 
/ / / / 11 
/ / / / 14 
/ / / / 15 
/ / / / 16 
/ / / / 17 
/ / / / 18 
/ / / / 19 
/ / / / 20 
/ / / / 21 
/ / / / 22 
/ I / / 23 
/ I / / 24 
,2007/ / : 4.tJWI .2007/ / : ~WI .2007/ / : j/JI.:"l!':I1 .l,W tul;; 
2007/ / : ~~I jS.r j! 6Jl> ~I ~)I;; Ji ,2007/ / : ~WI .2007/ / • ",,-!I}I 
~~I rW! ~ ~llll ~I):!j 
..:,l.l;,.".)L. :<";'11 ".lh ..)..ill .><..,.JI i ;i.!)i 
5 4 3 2 I 
I I / / '))'11 
/ I / I ~I 
I I I I ~I 
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Data sheet DO Appendix 6. Study questionnaire (translation) 
For leishmaniasis patients 
I Patient No.: Lab. Treat. I I Health centre: 
Patient data 
mother 1 father 1 Surname 1 Name ID 
Education Age DOB 
For children: father's 
Sex / / 
mother's 
mother father occupation ! 
mobile 1 tel. address l 
Clinical data 
I No. lesions 
ex. by: I smear res: I smear date: 
lesion duration: I date first noted: 
I Referred: 
Lesion description (baseline) 
Notes Dimensions Location Type Les. 
(mm) 
x I 1 
x I 2 
x 3 
x 4 
x 5 
I Culture I Social I Consent 
Notes 
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Course of treatment 
score name notes lesion size actual sched. I \"lS. 
5 4 3 2 1 / / first dose 
x x X / / / / / / "') 
-
X / / X / / / / / " I -' 
/ / X / / / / / / 4 
x X / / / / / / / i 5 
/ X X / X / / / / 6 
x / / X x / / / / 7 
x x X / X / / / / 8 
x x x x x / / / / 9 
x x x x x / / / / 10 
x x x x x / / / / 11 
x x x x x / / / / 12 
x / x X x / / / / 13 
x x x x x / / / / 14 
x x x X y / / / / 15 
x x x x x / / / / 16 
x x x x , / / / / 17 
x x x x x / / / / 18 
x x x x . / / / / 19 
x x x x . / / / / 20 
x x x x x / / / I 21 
x x x , , / / / I "')"') 
--
x X X X x / / / I 23 
x x x x x / / / / 24 
Lesions cured - first: / 
fourth: / /200 fifth: / 
1200 : second: / /200: third: /200 
/200 1200 : or date of referral to Lee. / 
F 11 0 ow-up VISItS a ft 1 . er comp.etlOn 0 [t t rea men t 
name notes lesion status actual sched. visit 
5 4 3 ::: 1 
/ / I / first 
/ / / / second 
/ / / I third 
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Appendix 7. Medium M199 
(for Leishmania spp. promastigotes 
for 1 litre : 
ddH20 
M199 powder (+ HEPES + I-glutamine) 
NaHC03 
Adenosine 
Hemin* 
Pen/strep** 
1 litre 
Sigma M2520 1 litre units 
2.2g 
13.35mg 
1ml - defrost 
2ml - defrost 
In a clean f1ask/beaker add the M199 powder to - 800ml ddH20. r'\lix well 
Add 2.2g NaHC03. Allow to mix well. 
In a clean bijoux, dissolve the adenosine in 5mll0mM NaOH. Add to medium and allow 
to mix well. 
Add the pen/strep and hemin aliquots. Mix well. 
Adjust to pH7.3 - 7.4 (use 5M HCI or 5M NaOH) 
Filter sterilise into 2 x 500ml. Store at 4"C. 
* 1M Hemin stocks are prepared: 25mg in 100ml 10mM NaOH. Freeze lml aliquots at -
20QC. 
**2ml aliquots of penicillin/streptomycin are stored at -20"C. 
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Appendix 8. Protocol o/fingerprinting 
I-DNA 
EXTRACTION 
(PHENOU 
CHLOROFORM) 
Calilbrated 
micropipettes. 
sterile barrier tiPS 
and tubes. 
sterile/molecular 
biology grade 
reagents in all 
steps. 
DNA extraction 
bl anks used every 
22 samples: 24 
samples batch 
processed. bl anks 
at 
positions 1 and 24 
1- Leishmania 
promastigotes 
pellet washing 
1.1- Centrifugue 
original tubes : 3000 
rpm 10 min 4'C 
1.2- Transfer pellet 
and supernatant to 
1.5 ml eppendorf 
trubes (screw cap) 
1.3- Additional 
centrifugation 
(bench top 
microfugue): 6000 
rpm 10 min RT 
1.4- Disca rd 
supernatant (by 
pipeting ) 
1.5- Add 1 mL PBS 
1X to remove 
ethanol trace 
1 6- Centrifugatton 
6000 rpm 10 min 
RT 
1 7- Discard 
supernatant (by 
pipeting) 
1 8- Store pellet at 
4 'c 
2- Pellet Lysis 
2 1- Add to each 
pellet 400 IlL 
NET10 buffer, 40 
IlL 10%SDS, 2 ilL 
ProtK (20 mg/mL) 
I- DNA 
EXTRACTION 
(PHENOU 
CHLOROFORM) 
Call ibrated 
m,crop'pettes, 
sterile barrier tiPS 
and tubes, 
sterile/molecular 
biology grade 
reagents in all 
steps. 
DNA extraction 
blanks used every 
22 samples: 24 
samples batch 
processed, blanks 
at 
positions 1 and 25 
1- Leishmania 
promastigotes 
pellet washing 
1.1- Centrifugue 
origi nal tubes: 3000 
rpm 10 min 4 'C 
1.2- Tran sfer pellet 
and supernatant to 
1.5 ml eppendorf 
trubes (screw cap) 
1 3- Additional 
centrifugation 
(bench top 
microfugue): 6000 
rpm 10 min RT 
1 4- Discard 
supernatant (by 
pipeting) 
1 5- Add 1 mL PBS 
1X to remove 
ethanol trace 
1 6- Cenlr~ugatlon 
6000 rpm 10 min 
RT 
1 7- Discard 
supernalant (by 
plpeting) 
1 8- Store pellet al 
4 'c 
2- Pellet Lysis 
2 1- Add to each 
pellet 400 IlL 
NET10 buffer, 40 
ilL 10%SDS, 211L 
ProtK (20 mg/mL) 
I-DNA 
EXTRACTION 
(PHENOU 
CHLOROFORM) 
Cailibrated 
mlcroplpettes, 
sterile barner tiPS 
and lubes, 
stenle/molecular 
biology grade 
reagents In all 
steps 
DNA extrac~on 
blanks used every 
22 samples ' 24 
samples batch 
processed , blanks 
at 
positions 1 and 26 
1- Leishmania 
proma stigotes 
pellet washing 
1.1- Centrifugue 
original tubes 3000 
rpm 10 min 4 'C 
1.2- Transfer pellet 
and supernatant to 
1 5 ml eppendorf 
trubes (screw cap) 
1 3- Additional 
centnfugatlon 
(bench top 
mlcrofugue) 6000 
rpm 10 min RT 
1.4- Discard 
supemalant (by 
pipeting ) 
1 5- Add 1 mL PBS 
1X to remove 
ethanol trace 
1 6- Centr~ugatlon 
6000 rpm 10 min 
RT 
1 7- Discard 
supematant (by 
pipeting) 
1 8- Siore pellet at 
4 'c 
2- Pellet Lysis 
2 1- Add to each 
pellet 400 ilL 
NET10 buffer, 40 
ilL 10%SDS , 2 ilL 
ProtK (20 mglmL) 
I- DNA 
EXTRACTION 
(PHENOU 
CHLOROFORM) 
Calilbrated 
mlcrOplpettes , 
stenle barner ~ps 
and tubes, 
stenle/molecular 
biology grade 
reagents In all 
steps 
DNA extra~on 
blanks used every 
22 samples 24 
samples batch 
processed , blanks 
at 
posI~ons 1 and 27 
1- Leishmania 
promastigotes 
pell et washing 
1 1- Centnfugue 
onglnal tubes 3000 
rpm 10 min 4 'C 
1 2- Transfer pellet 
and supernalant 10 
1 5 ml eppendorf 
trubes (screw cap) 
1 3- Additional 
centnfugatlOn 
(bench top 
mlcrofugue) 6000 
rpm 10 min RT 
1 4- Discard 
supematant (by 
plpetlng) 
1 5- Add 1 mL PBS 
1X to remove 
elhanol lrace 
1 6- Centnfugatlon 
6000 rpm 10 min 
RT 
1 7- Discard 
supematant (by 
plpellng ) 
1 8- Store pellet at 
4 'c 
2- Pellet Lysis 
21- Add 10 each 
pellet 400 ilL 
NET10 buffer 40 
ilL 10%SDS 2 ilL 
ProlK (20 mg ·mL) 
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I- DNA 
EXTRACnON 
(PHENOU 
CHLOROFORM) 
Cali lbrated 
mlcrOplpettes 
slenle bamer bps 
and tubes 
stenle/molecular 
biology grade 
reagents In all 
steps 
DNA extractJon 
blanks used every 
22 samples 24 
samples batch 
processed , blanks 
al 
poslbons 1 and 28 
1- Leishmania 
promastigotes 
pellet was hing 
1 1- Cenlr~ugue 
onglnal tubes 3000 
rpm 10 min 4 'C 
1 2- Transfer pellel 
and supernatanl to 
1 5 ml eppendorf 
lrubes (screw cap) 
1 3- Addilional 
centrifugation 
(bench lOp 
mlcrofugue) 6000 
rpm 10 min RT 
1 4- Discard 
supematanl (by 
p'pellng) 
1 5- Add 1 mL PBS 
1X to remove 
elhanol brace 
1 6- Centnfugatlon 
6000 rpm 10 min 
RT 
1 7- Discard 
supematant (by 
plpellng ) 
1 8- Siore pellet at 
4'C 
2- Pell et Lysis 
21- Add 10 each 
pellet 400 uL 
ET10 buffer 40 
ilL 10%SDS 2 IlL 
ProlK (20 mg mL) 
I· DNA 
EXTRACnON 
(PHENOU 
CHLOROFORM) 
Calilbraled 
mlCfop lpe es 
s enle bamer bpS 
and tubes 
stenle/molecular 
biology grade 
reagents In all 
steps 
DNA extracbOn 
blanks used every 
22 samples 24 
samples batch 
processed blanks 
al 
posttJons 1 and 29 
1- Leishmania 
promasligotes 
pellet wash ing 
1 1- Centnfugue 
onglnal lubes 3000 
rpm 10 min 4 'C 
1 2- Transfer pellel 
and supernatant to 
1 5 ml eppendorf 
lrubes (screw cap) 
1 3- Addl~onal 
centrifugation 
(bench lop 
mlcrofugue) 6000 
rpm 10 min RT 
1 4- Discard 
supematanl (by 
plpettng) 
1 5- Add 1 mL PBS 
1X to remove 
ethanol brace 
1 6- Centnfugabon 
6000 rpm 10 min 
RT 
1 7- Discard 
supematant (by 
pl pe~ng ) 
1 8- Siore pellet al 
4 'C 
2- Pellet Lys is 
2 1- Add to each 
pellet 400 uL 
ET 10 buffer 40 
ilL 10%SDS 2 uL 
ProtK (20 Illg mL) 
I-ONA 
EXTRACTION 
(PHENOU 
CHLOROFORM) 
2 2- M,x by vortex 
2.3- O/N incubation 
at 56 ·C. shaking 
3- DNA 
purification 
3 1- Bnefly spin the 
tubes 
3.2- Add of 500 IlL 
Phenoll 
Chloroforml 
Isoamyl alcohol 
(25 :24 :1) 
3.3- Mix by 
inversion 10 times 
3.4- Centrifugue: 
13000 rpm 6 min 
3.5- Transfer 
aqueous phase to 
1.5 mL tubes 
containing 500 IlL 
Chloroforml 
Isoamyla lcohol 
(24 :1) 
3.6- Discard the 
tubes containing 
the dirty-phenol 
phase 
3.7- Centrifugue the 
tubes containing 
Cil iA-Aqueous 
phase: 13000 rpm 6 
min 
3.8- Tran sfer 
aqueous phase to 
1.5 mL tubes 
containing: 
3.9- Mix by 
inversion 10 times 
3.10- Keep the 
tubes at -7 0 ·C for 
20 min (or -20 ·C 
O/N) 
3.11 - Centrifugue' 
13000 rpm 6 min 
3.12- Discard 
supernatant 
313- Add 1 mL 
70% EtOH 
31 4- M,x by 
inverSion 10 times 
3 15- Centnfugue 
13000 rpm 6 min 
I- ONA 
EXTRACnON 
(PHENOU 
CHLOROFORM) 
2 2- M,x by vortex 
2 3- O/N Incubation 
at 56 ·C. shaking 
3- DNA 
purification 
3 1- Bnefly Spin the 
tubes 
3 2- Add of 500 IlL 
Phenoll 
Chloroforml 
Isoamylalcohol 
(25 :24:1) 
3.3- Mix by 
inversion 10 times 
3.4- Centrifugue: 
13000 rpm 6 min 
35- Tran sfer 
aq ueous phase to 
1.5 mL tubes 
containing 500 ilL 
Chloroforml 
I soamylalcohol 
(24:1) 
3.6- Discard the 
tubes conta ining 
the dirty-phenol 
pha se 
3.7- Centrifugue the 
tubes containing 
Cil iA-Aqueous 
phase: 13000 rpm 6 
min 
3.8- Transfer 
aqueous phase to 
1.5 mL tubes 
containing: 
3.9- Mix by 
inverSion 10 times 
3.10- Keep the 
tubes at -7 0 ·C for 
20 min (or -20 ·C 
O/N) 
3.11 - Centrifugue. 
13000 rpm 6 min 
3 12- Discard 
supernatant 
313- Add 1 mL 
70% EtOH 
31 4- M,x by 
inverSion 10 times 
3 15- Centnfugue 
13000 rpm 6 min 
I-DNA 
EXTRACTION 
(PHENOU 
CHLOROFORM) 
2 2- M,x by vortex 
2 3- O/N Incubation 
at 56 ·C. shaking 
3- DNA 
purification 
3 1- Bnefly spin the 
tubes 
3.2- Add of 500 ilL 
Phenoll 
Chloroforml 
Isoamylalcohol 
(25241) 
3.3- M,x by 
inversion 10 times 
3 4- Centnfugue 
13000 rpm 6 min 
35- Tran sfer 
aqueous phase to 
1 5 mL tubes 
containing 500 pL 
Chloroforml 
Isoamyl alcohol 
(24 :1) 
3.6- Discard the 
tubes containing 
the dirty-phenol 
phase 
37- Centnfugue the 
tubes containing 
CiliA-Aqueous 
phase 13000 rpm 6 
min 
3.8- Tran sfer 
aqueous phase to 
1.5 mL tubes 
conta ining: 
3.9- Mix by 
InverSion 10 times 
3 10- Keep the 
tubes at -70·C for 
20 min (or -20 ·C 
O/N) 
3.11- Centrifugue 
13000 rpm 6 min 
3 12- Discard 
supernatant 
313-Add 1 mL 
70% EtOH 
31 4- M,x by 
inverSion 10 times 
3 15- Centnfugue 
13000 rpm 6 min 
I-DNA 
EXTRACTION 
(PHENOU 
CHLOROFORM) 
2 2- M,x by vortex 
2 3- O/N Incubation 
at 56 ·C . shaking 
3- DNA 
purification 
3 1- Bnefly spin the 
tubes 
3 2- Add of 500 ilL 
Phenoll 
Chloroform! 
Isoamylalcohol 
(25241) 
33- M,x by 
inverSion 10 times 
3 4- Centnfugue 
13000 rpm 6 min 
35- Transfer 
aqueous pha se to 
1 5 mL tubes 
conta ining 500 ilL 
Chloroform! 
Isoamylalcohol 
(24 1) 
3 6- Discard the 
tubes containing 
the dirty-phenol 
pha se 
37- Centnfugue the 
tubes containing 
CiliA-Aqueous 
phase 13000 rpm 6 
3 8- Transfer 
aqueous phase to 
1.5 mL tubes 
containing 
39- M,x by 
InverSion 10 times 
3 10- Keep the 
tubes at -70 ·C for 
20 min (or -20 ·C 
O/N) 
3 11- Centnfugue 
13000 rpm 6 min 
3 12- Discard 
supernatant 
313- Add 1 mL 
70% EtOH 
314- M,x by 
Inversion 10 bmes 
3 15- Centnfugue 
13000 rpm 6 min 
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1- DNA 
EXTRACnON 
(PHENOU 
CHLOROFORM) 
2 2- M,x by vortex 
2 3- 0 1 Incubation 
at 56·C shaking 
3- DNA 
purification 
3 1- Bnefly spin the 
tubes 
3 2- Add of 500 ilL 
Phenoll 
Chloroform! 
Isoamylalcohol 
(25241) 
33- M,x by 
inverSion 10 times 
3 4- Centnfugue 
13000 rpm 6 min 
35- Transfer 
aqueous phase to 
1 5 mL tubes 
containing 500 pL 
Chloroforml 
Isoamyl alcohol 
(24 1) 
3 6- Discard the 
tubes containing 
the dirty-phenol 
phase 
3 7- Centnfugue the 
tubes containing 
Cil iA-Aqueous 
phase 13000 rpm 6 
min 
3 8- Transfer 
aqueous phase to 
1 5 mL tubes 
containing 
39- M,x by 
inverSion 10 bmes 
3 10- Keep the 
tubes at -70·C for 
20 min (or -20 ·C 
O/N) 
3 11- Centnfugue 
13000 rpm 6 min 
3 12- Discard 
supematant 
313- Add 1 mL 
70% EtOH 
314- M,x by 
Inversion 10 times 
3 15- Centnfugue 
13000 rpm 6 min 
I- DNA 
EXTRACn ON 
(PHENOU 
CHLOROFORM) 
2 2- M,x by vortex 
2 3- OIN IncubatIOn 
at 56 · C shaking 
3- DNA 
purification 
3 1- Bne y spin the 
tubes 
3 2- Add of 500 ilL 
Phenoll 
Chloroform! 
Isoamylalcohol 
(25241 ) 
33- M,x by 
InverSion 10 times 
3 4- Centnfugue 
13000 rpm 6 min 
3 5- Transfer 
aqueous phase to 
15 mL tubes 
containing 500 ilL 
Chloroform! 
Isoamyl alcohol 
(241 ) 
3 6- Discard the 
tubes containing 
the dirty-phenol 
phase 
37- Centnfugue the 
tubes containing 
Cil iA-Aqueous 
phase 13000 rpm 6 
min 
38- Transfer 
aqueous phase to 
1 5 mL tubes 
39- MIX by 
inverSion 10 bmes 
3 10- Keep the 
tubes at -70·C for 
20 min (or -20 ·C 
OIN ) 
3 11- Centnfugue 
13000 rpm 6 min 
3 12- Discard 
supematant 
313-Add 1 mL 
70% EtOH 
314- M,x by 
inversion 10 times 
3 15- Centnfugue 
13000 rpm 6 min 
I-DNA 
EXTRACTION 
(PHENOU 
CHLOROFORM) 
3.16- Discard 
supernatant 
317- Let the tubes 
to air dry RT 
4- DNA elution 
41 - Add 50 ~IL 
sterile distilled 
water to each tube 
4.2- Store at 4 ·C 
for 24h before use 
11- REAGENTS 
USED FOR DNA 
EXTRACTION 
1- NET 10 Buffer 
10mM NaCl, 
10mMEDTA, 10mM 
Tris HCI 
Autoclave and store 
at 4 ·C 
2- 10%SDS 
Dilute SDS on 
sterile distilled 
water and store at 
RT 
3- PHENOL / 
CHLOROFORM / 
ISOAMYL 
ALCOHOL 
(25 :24:1) 
Mix 25 parts of 
Phenol with 25 
parts of 
Chloroform : Isoamyl 
alcohol (24: I ) 
previously prepared 
Let two phases to 
appear, wrap with 
aluminum paper 
and store at 4 ·C 
4- CHLOROFORM 
/ISOAMYL 
ALCOHOL (24:1) 
M,x 24 parts of 
Chloroform With 1 
part of Isoamyl 
alcohol 
I-DNA 
EXTRACTION 
(PHENOU 
CHLOROFORM) 
3.16- Discard 
supernatant 
317- Let the tu bes 
to air dry RT 
4- DNA elution 
4.1- Add 50 ~L 
sterile disti lled 
water to each tu be 
4.2- Store at 4 ·C 
for 24h before use 
II-REAGENTS 
USED FOR DNA 
EXTRACTION 
1- NET 10 Buffer 
10mM NaCl, 
10mMEDTA, 10mM 
Tris HCI 
Autoclave and store 
at 4 ·C 
2-10%SDS 
Dilute SDS on 
sterile distilled 
water and store at 
RT 
3- PHENOL / 
CHLOROFORM / 
ISOAMYL 
ALCOHOL 
(25 :24:1) 
Mix 25 parts of 
Phenol wi th 25 
parts of 
Chloroform:lsoamyl 
alcohol (24 : 1 ) 
previously prepared 
Let two phases to 
appear, wrap with 
aluminum paper 
and store at 4 ·C 
4- CHLOROFORM 
/ISOAMYL 
ALCOHOL (24 :1) 
Mix 24 parts of 
Chloroform With 1 
part of Isoamyl 
alcohol 
I- DNA 
EXTRACTION 
(PHENOU 
CHLOROFORM) 
3 16- Discard 
supernatant 
317- Let the tubes 
to air dry RT 
4- DNA elution 
4 I-Add 50 ~L 
stenle dis~lled 
water to each tube 
4.2- Store at 4 ·C 
for 24h before use 
II-REAGENTS 
USED FOR DNA 
EXTRACTION 
1- NET 10 Buffer 
10mM NaCl, 
10mMEDTA.l0mM 
Tris HCI 
Autoclave and store 
at 4 ·C 
2-10%SDS 
Dilute SDS on 
sterile distilled 
water and store at 
RT 
3- PHENOL / 
CHLOROFORM / 
ISOAMYL 
ALCOHOL 
(25 :24:1) 
Mix 25 parts of 
Phenol with 25 
parts of 
Chloroform :lsoamyl 
alcohol (24 : 1) 
previously prepared 
Let two phases to 
appear, wrap with 
aluminum paper 
and store at 4 ·C 
4- CHLOROFORM 
/ISOAMYL 
ALCOHOL (24 :1) 
M,x 24 parts of 
Chloroform With 1 
part of Isoamyl 
alcohol 
I-DNA 
EXTRACTION 
(PHENOU 
CHLOROFORM) 
3 16- Discard 
supernatant 
317-Letthetubes 
to air dry RT 
4- DNA elution 
41-Add 50~L 
stenle dls~l1ed 
water to each tube 
4 2- Store at 4 ·C 
for 24h before use 
11 - REAGENTS 
USED FOR DNA 
EXTRACTION 
1- NET 10 Buffer 
10mM NaCl , 
10mMEDTA. l0mM 
Tns HCI 
Autoclave and store 
at 4·C 
2- 10%SDS 
Dilute SDS on 
stenle distilled 
water and store at 
RT 
3- PHENOL / 
CHLOROFORM / 
ISOAMYL 
ALCOHOL 
(25 :24:1) 
Mix 25 parts of 
Phenol Wi th 25 
parts of 
Chloroform. Isoamyl 
alcohol (24 I) 
previously prepared 
Let two phases to 
appear, wrap With 
aluminum paper 
and store at 4 ·C 
4- CHLOROFORM 
/ISOAMYL 
ALCOHOL (24 :1) 
M,x 24 parts of 
Chloroform With 1 
part of Isoamyl 
alcohol 
22-! 
I- DNA 
EXTRACnON 
(PHENOU 
CHLOROFORM) 
3 16- Discard 
supernatant 
317- Let the tubes 
to air dry RT 
4- DNA elution 
4 1- Add 50 ~ L 
stenle dls~lled 
water to each tube 
4 2- Store at 4 ·C 
for 24h before use 
11- REAGENTS 
USED FOR DNA 
EXTRACTION 
1- NET 10 Buffer 
10mM NaCI, 
10mMEDTA, 10mM 
Tns HCI 
Autoclave and store 
at 4·C 
2- 10%SDS 
Dilute SDS on 
stenle dlsblled 
water and store at 
RT 
3- PHENOL / 
CHLOROFORM / 
ISOAMYL 
ALCOHOL 
(25 :24:1) 
M,x 25 parts of 
Phenol With 25 
parts of 
Chloroform Isoamyl 
alcohol (24 I) 
previously prepared 
Let two phases to 
appear, wrap With 
aluminum paper 
and store at 4 ·C 
4- CHLOROFORM 
/ISOAMYL 
ALCOHOL (24:1) 
M,x 24 parts of 
Chloroform With 1 
part of Isoamyl 
alcohol 
I- DNA 
EXTRACnON 
(PHENOU 
CHLOROFORM) 
3 16- Discard 
supernatant 
3 17- Let the tubes 
to air dry RT 
4- DNA elution 
41- Add 50 ~L 
stenle d,sblled 
water to each tube 
4 2- Store at 4 ·C 
for 24h before use 
11 - REAGENTS 
USED FOR DNA 
EXTRACnON 
1- NET 10 Buffer 
10mM NaCI 
10mMEDTA. l0mM 
Tns HCI 
Autoclave and store 
at 4 ·C 
2- 10%SDS 
Dilute SDS on 
stenle dlSblled 
water and store at 
RT 
3- PHENOL / 
CHLOROFORM / 
ISOAMYL 
ALCOHOL 
(25 :24:1) 
MIX 25 parts of 
Phenol With 25 
parts of 
Chloroform Isoamyl 
alcohol (24 1) 
preViously prepared 
Let two phases to 
appear, wrap with 
aluminum paper 
and store at 4 ·C 
4- CHLOROFORM 
/I SOAMYL 
ALCOHOL (24 :1) 
M,x 24 parts of 
Chloroform With 1 
part of Isoamyl 
alcohol 
11- REAGENTS 
USED FOR DNA 
EXTRACTION 
Wrap with 
aluminum paper 
and store at 4 'C 
5- ETHANOL 
ABSOLUTE & 
ETHANOL 70% 
Store at -20 'C 
6- 3M Na-Acetate 
pH 6.0 
pH adjusted with 
Acetic Acid 
Autoclave and store 
atRT 
III-DNA 
QUANTIFICATION 
System NO-1000 
Spectrophotometer 
(NanoOrop ) 
Volume of sample 
assayed 2 ~. L . in 
duplicate 
Records of cc (ngl 
I'L) and A260 1 
A280 ratio were 
taken 
IV- PCR METHOD 
PCR method: 
based on Aransay 
et al Appl 
Enviroment 
Microbiol 
2000.66.1933-38 
Reference strain : 
Leishmania tropica 
K27 
PCR MIX 
Reagents B,otools 
B&M LABS 
(www b.otools eu) 
> Buffer 10X (20 
mM Mg C12) 
> dNTP m.x (10 mM 
each) 
11- REAGENTS 
USED FOR DNA 
EXTRACTION 
Wrapw.th 
aluminum paper 
and store at 4 'C 
5- ETHANOL 
ABSOLUTE & 
ETHANOL 70% 
Store at -20 'C 
6- 3M Na-Aceta te 
pH 6.1 
pH adjusted with 
Acetic Acid 
Autoclave and store 
at RT 
III-DNA 
QUANTIFICA TION 
System NO-1000 
Spectrophotometer 
(NanoOrop· ) 
Volume of sample 
assayed 2 ~.L . in 
duplicate 
Records of cc (ngl 
~.L) and A260 I 
A280 ratio were 
taken 
IV- PCR METHOD 
PCR method : 
ba sed on Aransay 
at al Appl 
Enviroment 
Microbiol 
2000;66 '1933-3 9 
Refe rence strain : 
Leishmania tropica 
K28 
PCR MIX 
Reagents Blotools 
B&M LABS 
(www b.otools eu) 
> Buffer 10X (20 
mM Mg C12) 
> dNTP m.x (10 mM 
each ) 
11- REAGENTS 
USED FOR DNA 
EXTRACTION 
Wrapw.th 
aluminum paper 
and store at 4 'C 
5- ETHANOL 
ABSOLUTE & 
ETHANOL 70% 
Store at -20 'C 
6- 3M Na-Acetate 
pH 6.2 
pH adjusted w.th 
AcetiC Ac.d 
Autoclave and store 
at RT 
III- DNA 
QUANTIFICATION 
System NO-1000 
Spectrophotomete r 
(NanoOrop·) 
Volume of sample 
assayed 2 pL . • n 
duplicate 
Records 0/ cc (n gl 
~.L) and A260 1 
A280 rat.o were 
taken 
IV- PCR METHOD 
PCR method: 
ba sed on Aransay 
et al Appl 
Enviroment 
Microbiol 
2000;661933-40 
Referenc e strain : 
Leishmania tropica 
K29 
PCR MIX 
Reagents B.otools 
B&M LABS 
(www b.otools eu) 
> Buffer 10X (20 
mM Mg C12) 
> dNTP m.x (10 mM 
each) 
11- REAGENTS 
USED FOR DNA 
EXTRACTION 
Wrap With 
aluminum paper 
and store at 4 'C 
5- ETHANOL 
ABSOLUTE & 
ETHANOL 70% 
Store at -20 'C 
6- 3M Na-Acetate 
pH 6.3 
pH adjusted w.th 
AcetiC Ac.d 
Autoclave and store 
at RT 
III-DNA 
QUANTIFICATtON 
System NO-1000 
Spectrophotometer 
(NanoOrop·) 
Volume 0/ sample 
assayed 2 pL. In 
duplicate 
Records 0/ cc (ngl 
I'L) and A260 1 
A280 ralto were 
taken 
IV- PCR METHOD 
PCR method : 
based on Aransay 
et al Appl 
Envlromenl 
Microblol 
2000.66 1933-41 
Refe rence strain : 
Leishmania troplca 
K30 
PCR MIX 
Reagents B,otools 
B&M LABS 
(www b.otools eu) 
> Buffer lOX (20 
mM Mg C12) 
> dNTP miX (1 0 mM 
each) 
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11 - REAGENTS 
USED FOR DNA 
EXTRACnON 
Wrapw 
aluminum paper 
and store at 4 'C 
5- ETHANOL 
ABSOLUTE & 
ETHANOL 70% 
Store at -20 'C 
6- 3M Na-Acetate 
pH 6.4 
pH adjusted With 
AcetiC ACid 
Autoclave and store 
at RT 
III-DNA 
QUANTIFICATION 
System NO-1000 
Spectrophotometer 
(NanoOrop·) 
Volume 0/ sample 
assayed 2 pL .• n 
duplicate 
Records 0/ cc (ng l 
pL) and A260 1 
A2S0 ratio were 
taken 
IV- PCR METHOD 
PCR method: 
based on Aransay 
et al Appl 
Envlroment 
Mlcroblol 
2000.66 1933-42 
Reference strain : 
Leishmania troplca 
K31 
PCR MIX 
Reagents B.otools 
B&M LABS 
(www b,otools eu) 
> Buffer lOX (20 
mM Mg C12) 
> d TP mlx(10 mM 
each) 
11- REAGENTS 
USED FOR DNA 
EXTRACnON 
Wrapw 
aluminum paper 
and store at 4 °C 
5- ETHANOL 
ABSOLUTE & 
ETHANOL 70% 
Store at -20 ·C 
6- 3M Na-Acetate 
pH 6.5 
pH adjusted w,th 
AcetiC ACid 
Autoclave and store 
atRT 
III - DNA 
QUANTIFICA nON 
System NO-l000 
Spectrophotometer 
(NanoOrop·) 
Volume 0/ sample 
assayed 2 pL In 
duplicate 
Records 0/ cc (ngl 
I'L) and A260 I 
A2S0 ratio were 
taken 
IV- PCR METHOD 
PCR method : 
based on Aransay 
et al Appl 
Envlroment 
Mlcroblol 
2000.66 1933-43 
Reference stra in: 
Lelshmama troplca 
K32 
PCR MIX 
Reagents Blotools 
B&M LABS 
(www blotools eu) 
> Buffer lOX (20 
mM Mg C12) 
> d TP mix (10 
mM each) 
IV- peR METHOD IV- peR METHOD IV- peR METHOD IV- peR METH OD IV- peR METHOD IV- peR METHOD 
> pemers LIN R4 > pemers LIN R4 > pemers LI N R4 > pemers LIN R4 > pnme rs LIN R4 > pnme rs LIN R4 
and LIN 19 and LIN 19 and LIN 19 and LIN 19 and II 19 and II 19 
synthesIZed by synthesized by synthesized by synthesized by synthesIZed by syn eSlZed by 
SIGMA Genosys SIGMA Genosys SIGMA Genosys SIGMA Genosys SIGMA Genosys SIGMA Genosys 
> Tth DNA pol (1 UI > Tth DNA pol (1U1 > Tth DNA pol (1 UI > Tth DNA pol (1U1 > Tth DNA pol (1 U > Tth D A pol 1UI 
~L ) ~L ) ~L ) ~ L ) ~ L ) ~L ) 
PCR MIX PCR MI X PCR MIX PCR MIX PCR MIX PCR MIX 
REAGENT REAGENT REAGENT REAGENT REAGENT REAGE T 
H2O H2O H2O H2O H2O H2O 
Buffer10X Buffer10X Buffer10X Buffer10X Buffer 10X Buffer10X 
dNTP mix dNTP mix dNTP mix dNTP mIX dNTP mIX d TP mIX 
LlNR4 (10 pmoll~L) LlNR4 (1 0 pmoll~L) LlNR4 (10 pmoll~ L) LlNR4 (10 pmoll~ L ) lIN R4 (1 0 pmoll~ L) LI R4 (1 0 pmoll~ L ) 
LlN19 (10 pmoll~L) LlN19 (10 pmollllL) LlN19 (10 pmollllL) LlN19 (10 pmoll~L) LlN19 (10 pmoU~ L ) LlN19 (10 pmoU~ L ) 
Tth Dna pol Tth Dna pol Tth Dna pol Tth Dna pol Tth Dna pol Tth Dna pol 
DNA template DN A template DNA template DNA template DNA template DNA template 
V- RFLP V- RFLP V- RFLP V-RFLP V- RFLP V-RFLP 
17 pL PCR product 18 pL PCR product 19 ~L PCR product 20 ~ L PCR product 21 ~L PCR product 22 ~ L PCR product 
2 ~ L Buffer 10X 3 ilL Buffer 10X 4 ~L Buffer 10X 5 ~L Buffer 10X 6 ~I L Buffer 10X 7 ~L Buffer 10X 
1 ilL enzyme 2 ilL enzyme 3 ~L enzyme 4 ~I L enzyme 5 ilL enzyme 6 ~L enzyme 
(Hael il l Rsa l) (Hael il l Rsa l) (Haelil l Rsal) (Haelil l Rsal) (Hael il l Rsal) (Haelil l Rsal ) 
37'C O/N 37'C O/N 37'C OIN 37'C O/N 37'C OIN 37' C O/N 
Electrophoresis 2% Electropho resis 2% ElectrophoreSIS 2% ElectrophoresIs 2% ElectrophoresIs 2% ElectrophoreSIS 2% 
agarose agarose agarose agarose agarose agarose 
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Appendix 9. Social study questionnaire 
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Appendix 10. Social study questionnaire (translation) 
Leishmaniasis in Aleppo, Syria 
Social study questionnaire 
PID JSex JAge J Respondent 
Knowledge 
I. What do you name this problem:' 
2. What is the cause of this problem? 
JAge JEdu jIntcn le\\ed 
J. How do people get the disease (is it contagious, can it be contracted by simple contact, transmitted b"lI,es. 
etef' 
I 
mo.\qulfoes. 
4. Can the disease be prevented? /fyes, how? (avoiding affected persons. insecticides. sleeping indoors/outdoors. hed flets) 
5. How long it takes to cure' 
6. How often the does the disease affect the same person again' 
Treatment seeking and access 
I. Who no(iced the problem first, was it you or someone else? 
, Wha( did you/irst notice? 
3. W/,," did you first do? 
4. What advice were you given? 
5. Who advised the patient to seek treatment? Who parlicrpa(ed in dCClS/()JHuk,ng) 
6. How long did it take Fom disease recognition and seeking treatment) 
7. Who referred the patient to this centre? 
8. Did the patient himse/fmake the decision to seek treatment/whose permission was required:' An .. other prohlcms 1\ IIh 
access to the clinic? 
9. Who accompanies the patient? 
Expectations 
I. What is the nature o.ftreatment? 
, How long does the treatment (ake:' 
3. How do you knoH' .1'011 are cured? 
Attitudes 
I, Should people tIT to prevent the disease? HOI,.:' Whose responsibility is this (government.indmduals):' 
, Is it necessal)' to treat the disease:' I(,'es. ,,./'.1':' What happens i(Iesions are I~(t untreated? Wh .. treating the disease is 
beller/worse? 
3. H'Iw/ are most distressing manUL'srations and consequences of the disease? 
Practices 
a) do ,1'011 sleep outdoors:' 
b) do you use bed nets? 
c) do you sp,.ay insecticides? 
Perceived quality of care 
Travel time 
Waiting time 
Perceived staff attitude 
Patients prematurely stopping their treatment 
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